0001932393-26-000007 | 10-K | XBRL Viewer | GE Healthcare Technologies INC

Print Document

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 4,492	$ 2,874
Short-term restricted cash	20	16
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Financial Position	4,512	2,889
Long-term restricted cash	3	3
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Cash Flows	$ 4,515	$ 2,893	$ 2,506	$ 1,451

SHARE-BASED COMPENSATION - Summary of Other Share-Based Compensation Data (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Cash received from stock options exercised	$ 37	$ 33	$ 34
Intrinsic value of stock options exercised and RSUs/PSUs vested	$ 141	$ 251	$ 106

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (2)	$ (2)
Current financing receivables – net	95	90
Allowance for credit losses, noncurrent	(3)	(4)
Non-current financing receivables – net	190	183
Loans receivable, at amortized cost
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	21	23
Non-current financing receivables, gross	44	35
Investment in finance leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	76	69
Non-current financing receivables, gross	$ 149	$ 152

RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	12 Months Ended
RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	Dec. 31, 2025
Related Party Transactions [Abstract]
RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	RELATED PARTIES AND TRANSITION SERVICES AGREEMENT On January 3, 2023, GE completed the Spin-Off of GE HealthCare through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE’s common stock as of the close of business on December 16, 2022 (the “Distribution”). On April 2, 2024, GE completed the separation of its GE Vernova business into an independent publicly traded company. As of December 31, 2024, GE had sold the rest of its remaining ownership of the Company’s outstanding common stock. Following the share sell-down, GE continues to be considered a related party due to board member affiliation. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility, and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,849 million for the year ended December 31, 2023. These items substantially consisted of the transfer of certain pension plan liabilities and assets, certain deferred income taxes, deferred compensation liabilities, and employee termination obligations. Also in connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. •Separation and Distribution Agreement – sets forth the principal actions to be taken in connection with the Spin-Off, including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters. •Transition Services Agreement – governed all matters relating to the provision of shared services between the Company and GE on a transitional basis. The services the Company received included support for information technology, human resources, supply chain, finance, and facilities services, among others. The services generally commenced on the date of the Spin-Off and terminated in the 24 months following the Distribution Date depending upon the related transitional service. Net costs incurred were not significant for the year ended December 31, 2025, and we incurred $172 million, net, and $372 million, net, for the years ended December 31, 2024 and 2023, respectively, under this agreement. These amounts represent fees charged from GE and GE Vernova to the Company, the majority of which are related to information technology, and are net of fees charged from the Company to GE and GE Vernova for facilities and other shared services. •Tax Matters Agreement – governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibited us from taking or failing to take any action in the two-year period following the Distribution that would have prevented the Distribution from qualifying as tax-free for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The Tax Matters Agreement specifies the portion of tax liability, including certain pre-Spin-Off tax obligations attributable to the Company that may result from audit or other tax proceedings, for which the Company will bear contractual responsibility, and the Company and GE each agree to indemnify each other against any amounts for which such indemnified party is not responsible. The resolution of pre-Spin-Off tax obligations may result in changes to our unrecognized tax benefits and indemnity obligations.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2025
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Estimates are used for, but are not limited to, determining the following: revenue from contracts with customers; recoverability of long-lived assets and inventory; valuation of goodwill and intangible assets; useful lives used in depreciation and amortization; asset retirement obligations; income taxes and related valuation allowances; accruals for contingencies including legal and product warranties; actuarial assumptions used to determine costs of pension and other postretirement benefits; valuation of pension assets; valuation and recoverability of receivables; valuation of derivatives; and valuation of assets acquired, liabilities assumed, and contingent consideration as a result of acquisitions. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. REVENUE RECOGNITION. Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. The Company recognizes a contract with a customer when there is a legally enforceable agreement between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives, discounts, returns, chargebacks, group purchasing organization fees, rebates, or credits, as well as taxes collected from customers that are remitted to government authorities. Our estimates for these deductions, which are accounted for as variable consideration, are based on historical experience and consider current and forecasted market trends. We record these estimated amounts as a reduction to revenue when we recognize the related product or service sales. Payment terms are generally within 12 months. Payment terms within 12 months are not treated as significant financing components. Contracts for the sale of products and services often include multiple distinct performance obligations, usually involving an upfront deliverable of equipment and future performance obligations such as installation, training, or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors. Revenue is recognized in the period in which the customer obtains control of the underlying products or services, allowing them the ability to direct the use of, and obtain substantially all of, the remaining benefits of such product or service. This may occur at a point in time or over time. Shipping and handling costs to deliver products to customers are expensed as incurred and recognized within Cost of products or Cost of services in our Consolidated Statements of Income. For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time the revenue is recognized. The provision recorded reflects the estimated costs of replacement and free-of-charge services that will be incurred related to the products sold. Service-type warranties or extended warranties sold with products are considered separate performance obligations. As such, a portion of the overall transaction price is allocated to these performance obligations and recognized in revenue over time, as the performance obligations are satisfied. The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified within Contract and other deferred assets or All other non-current assets in the Consolidated Statements of Financial Position and are recognized within Selling, general, and administrative (“SG&A”) in the Consolidated Statements of Income based on the timing of when the Company expects to earn related revenues. Management assesses these costs for impairment based on periodic assessments of recoverability. Performance Obligations Satisfied at a Point in Time We primarily recognize revenue from sales of products at the point in time that the customer obtains control, which is generally no earlier than when the customer has physical possession. Our billing terms for these point-in-time product contracts generally coincide with delivery to the customer and customer acceptance; however, periodically, we transfer control of products in advance of billing or we receive customer advances and deposits from customers in advance of transfer of control of products which are recognized as contract assets or contract liabilities, respectively, in the Consolidated Statements of Financial Position. Any differences between the timing of our revenue recognition and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. Performance Obligations Satisfied Over Time We recognize revenue from the sale of certain service contracts, including preventative maintenance, corrective services, and extended warranties over time on a ratable basis consistent with the nature, timing, and extent of our services, which primarily relate to routine maintenance and as-needed product repairs. Our billing terms for these contracts vary and can occur in advance of or following the period of service; however, we generally invoice periodically as services are provided. The differences between the timing of our revenue recognized and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. See Note 3, “Revenue Recognition” for further information. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH. Cash deposits, short-term investments, and high-liquidity mutual funds with original maturities of three months or less are included in Cash, cash equivalents, and restricted cash in the Consolidated Statements of Financial Position. Restricted cash primarily relates to funds restricted in connection with escrow accounts and other contractual and legal restrictions. See Note 18, “Supplemental Financial Information” for further information. INVESTMENT SECURITIES. Publicly traded equity securities for which we do not have the ability to exercise significant influence are recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated Statements of Income. Certain private equity securities for which we do have the ability to exercise significant influence are also recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated Statements of Income based on an election made. Privately held equity securities for which we do not have the ability to exercise significant influence are accounted for using the measurement alternative approach and are recorded at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes in the measurement recognized through Other (income) expense – net in the Consolidated Statements of Income. Equity investments without readily determinable fair value as of December 31, 2025 and 2024 were $217 million and $176 million, respectively. Investment securities are recognized within All other non-current assets in the Consolidated Statements of Financial Position. EQUITY METHOD INVESTMENTS. Investments in equity securities in which we do not have a controlling financial interest, but over which we have significant influence are accounted for using the equity method of accounting, or at fair value if we elect the fair value option. Equity method investments are assessed for other-than-temporary impairment when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. Equity method investments are recognized within All other non-current assets in the Consolidated Statements of Financial Position. Our share of the results of equity method investments is recognized within Other (income) expense – net in the Consolidated Statements of Income. See Note 18, “Supplemental Financial Information” for further information. RECEIVABLES. Amounts due from customers arising from the sales of products and services are recorded at the outstanding amount, less allowances for credit losses, chargebacks, and other credits. We regularly monitor the recoverability of our receivables. See Note 5, “Receivables” for further information. FINANCING RECEIVABLES. Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance, non-homogeneous loans and leases, and smaller-balance homogeneous loans and leases. Loans Loans represent term loans that are collateralized by equipment and other assets. Loans are classified as either held for sale or held for investment (“HFI”) based on management’s intent and ability to hold the loans for the foreseeable future. Loans where the Company does not have the ability and intent to hold for investment purposes and those where the Company intends to hold for sale in the foreseeable future are accounted for as loans held for sale. Loans held for sale are recorded at the lower of cost or current fair value with any fair value write-down (or change to the write-down) recorded as a valuation allowance through current period earnings in the period in which the change occurs. Loans classified as HFI are recorded at amortized cost. Investment in Finance Leases Finance leases include mostly sales-type leases of equipment and represent net unpaid rentals and estimated unguaranteed residual values of leased equipment, less related deferred income and the allowance for credit losses. See Note 7, “Leases” for further information on our finance leases and “Allowance for credit losses” below for the Company’s policy regarding allowances for credit losses on financing receivables. Credit Quality Indicators We manage our financing receivables portfolio using delinquency and nonaccrual data as key performance indicators. We assess the overall quality of the portfolio based on a potential risk of loss measure. The metric incorporates both the borrower’s credit quality along with any related collateral protection. Financing receivables are considered past due if default on a contractual principal or interest payment exists for a period of 30 days or more. We stop accruing interest on financing receivables at the earlier of when collection of an account becomes doubtful or the account becomes 90 days past due. Although we stop accruing interest in advance of payments, we recognize income within Other (income) expense – net in the Consolidated Statements of Income when we determine that the account is returned to accrual status, provided that the amount does not exceed that which would have been earned at the historical effective interest rate. See Note 6, “Financing Receivables” for further information. ALLOWANCE FOR CREDIT LOSSES. When we record customer receivables, contract assets, and financing receivables, we maintain an allowance for credit losses for the current expected credit losses. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. The credit losses are recognized within SG&A in the Consolidated Statements of Income. For financing receivables, expected credit losses are calculated based on the gross carrying amount of the financial asset, multiplied by a factor reflecting the probability of default and the loss in the event of default. We routinely evaluate our entire portfolio for potential specific credit or collection issues that might indicate an impairment. We estimate expected credit losses based on relevant information from past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses. INVENTORIES. Inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a first-in, first-out basis. Inventories are generally classified as current, however, based on consumption timelines, certain inventories are considered non-current and are recognized, net of related reserves, within All other non-current assets in the Consolidated Statements of Financial Position. As necessary, we record provisions and write-downs for excess, slow moving, and obsolete inventory. To determine these amounts, we regularly review inventory quantities on hand and compare them to historical utilization and estimates of future product demand, market conditions, and technological developments. See Note 18, “Supplemental Financial Information” for further information. PROPERTY, PLANT, AND EQUIPMENT. Property, plant, and equipment is stated at cost and is depreciated on a straight-line basis over its estimated useful life. Estimated useful lives generally range from 8 to 40 years for buildings, structures and related equipment, 3 to 20 years for machinery and equipment, and 1 to 16 years for leasehold improvements. Repair and maintenance costs are expensed as incurred. Property, plant and equipment is reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, assets are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values. See Note 18, “Supplemental Financial Information” for further information. LEASES. Lessee Arrangements At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. ROU assets are recognized within Property, plant, and equipment – net and lease liabilities are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. Options to extend a lease are included as part of the ROU lease asset and liability at commencement when it is reasonably certain the Company will exercise the option. We have elected to combine lease and non-lease components in determining our lease liability, primarily for real estate leases. Non-lease components are generally related to services that the lessor performs for the Company associated with the leased asset. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using our incremental collateralized borrowing rate at lease commencement for leases that commenced post-Spin-Off and GE’s incremental collateralized borrowing rate at lease commencement for leases that commenced pre-Spin-Off. For leases with an initial term of 12 months or less, an ROU asset and lease liability are not recognized, and lease expense is recognized on a straight-line basis over the lease term. Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations, and usage-based amounts. The Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. We review ROU assets for impairment annually or when events occur or circumstances change that indicate that the asset may be impaired. Lessor Arrangements Equipment leased to others under operating leases is recognized within Property, plant, and equipment – net in the Consolidated Statements of Financial Position. Leases classified as sales-type leases or direct finance leases are recognized within All other current assets and All other non-current assets, respectively, in the Consolidated Statements of Financial Position. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term or purchase the underlying asset, vary by customer. See Note 6, “Financing Receivables” and Note 7, “Leases” for further information. GOODWILL AND OTHER INTANGIBLE ASSETS. Goodwill and Acquired Intangibles Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We test goodwill for impairment at the reporting unit level annually in the fourth quarter of each year as of October 1st, or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. When testing goodwill for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of a reporting unit is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that goodwill is impaired, an impairment charge is recognized based on the difference between the reporting unit’s carrying value and its fair value. When performing a quantitative test, the market approach is typically used for estimating the fair values for our reporting units. Under the market approach, we estimate the fair value based on market multiples of earnings derived from comparable publicly traded companies with operating and investment characteristics similar to the reporting unit. Depending on the specific reporting unit circumstances, we may also consider performing a valuation based on an income approach. It is reasonably possible that the judgments and estimates used could change in future periods. In-process research and development (“IPR&D”) acquired as part of a business acquisition is capitalized at fair value when acquired and is considered an indefinite-lived intangible asset. We test indefinite-lived intangible assets for impairment annually in the third quarter of each year or when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. When testing IPR&D for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of the IPR&D is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that the IPR&D is impaired, an impairment charge is recognized based on the difference between the IPR&D’s carrying value and its fair value. When the IPR&D project is complete, the asset is considered a finite-lived intangible asset and subject to an impairment test at that date. Thereafter, the resulting asset is amortized over its estimated useful life and is subject to impairment assessments in the same manner as all amortizing intangible assets. For other intangible assets that are not deemed indefinite-lived, the cost of the intangible asset is amortized on a straight-line basis over the asset’s estimated useful life. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, they are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values. Internal-use Software Internal-use software is software that is developed, purchased, or modified to meet internal needs and for which no substantive plan exists to sell, lease, or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begins after both of the following occur: (1) the preliminary project development stage is completed and (2) management authorizes and commits to funding the software project and it is probable that the project will be completed and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are recognized within Other intangible assets – net in the Consolidated Statements of Financial Position and are amortized on a straight-line basis over the asset’s estimated useful life. Capitalized cloud computing arrangement implementation costs For cloud computing arrangements that are considered a service contract, our capitalization of implementation costs is aligned with the internal-use software requirements. Capitalized amounts are recognized within All other non-current assets in the Consolidated Statements of Financial Position and are amortized on a straight-line basis over the expected term of the related service contract. External-use Software External-use software relates to software that is (1) intended to be sold, licensed, or marketed to our customers or (2) embedded and integral to our tangible products for which research and development (“R&D”) has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset and recognized within Other intangible assets – net in the Consolidated Statements of Financial Position. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated useful life of the product. The Company performs regular reviews to assess whether unamortized capitalized external use software program costs remain recoverable through future revenue. See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” and Note 18, “Supplemental Financial Information” for further information. DERIVATIVES AND HEDGING. We use derivative contracts to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. Our policy is to use derivatives solely for managing risks and not for speculative purposes. We employ the following hedge types: (1) cash flow hedges of foreign currency risk associated with third-party and intercompany foreign currency-denominated forecasted transactions and firm commitments, (2) net investment hedges of foreign currency risk associated with investments in foreign operations, (3) fair value hedges of interest rate risk associated with long-term borrowings, and (4) economic hedges not designated as qualifying hedging relationships of foreign currency risk associated with monetary assets and liabilities, including intercompany balances and equity price risk. For net investment hedges, changes in the fair value of the components of the hedging derivatives excluded from the assessment of hedge effectiveness are deferred and amortized to earnings in the Consolidated Statements of Income using a systematic and rational method over the life of the derivative transaction. Contracts that do not in their entirety meet the definition of a derivative instrument and are not measured at fair value may contain embedded features affecting some or all of the cash flows or value of other exchanges that would otherwise be considered derivatives when assessed separately from the host contract. Such embedded features are separated from the host contract and accounted for as a derivative measured at fair value if their economic characteristics and risks are not clearly and closely related to those of the host contract. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. INCOME TAXES. Uncertain tax positions that meet the more likely than not recognition threshold are included in the financial statements. Such uncertain tax positions are measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Our policy is to adjust these reserves when facts and circumstances change, such as the change in the technical merit of a position, an uncertain tax position is effectively settled with the relevant taxing authority, or the statute of limitations has expired. Penalties and interest related to income tax matters are recognized within Benefit (provision) for income taxes in the Consolidated Statements of Income. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax basis, as well as net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and credits considering all available positive and negative evidence, including the impact of the Tax Matters Agreement with GE, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, taxable income in prior carryback years, if applicable, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established to reduce its carrying value to the amount that is more likely than not to be realized. Deferred taxes are provided for the outside basis difference of certain investments in non-U.S. affiliates and associated companies based upon our evaluation of the undistributed earnings of such entities if the permanently reinvested assumption cannot be made. See Note 11, “Income Taxes” and Note 19, “Related Parties and Transition Services Agreement” for further information. POSTRETIREMENT BENEFIT PLANS. We measure our plan assets at fair value and categorize plan assets for disclosure purposes in accordance with the fair value hierarchy. Certain assets for which the fair value is measured using the net asset value (“NAV”) per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The components of net periodic benefit costs, other than the service cost component, are recognized within Non-operating benefit (income) costs in the Consolidated Statements of Income for plans sponsored by the Company. We engage third-party actuaries to assist in the determination of benefit obligations and related net periodic benefit costs. We develop significant long-term assumptions, including discount rates and the expected rate of return on assets in connection with our pension accounting. In the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement, we recognize differences between expected long-term return on plan assets and actual returns, and net actuarial gains and losses for the pension plan liabilities within the Consolidated Statements of Comprehensive Income (Loss). We amortize gains and losses, as well as the effects of changes in actuarial assumptions and plan provisions, that exceed 10% of the greater of the market related value of plan assets or benefit obligations, determined as of the beginning of the year. The period over which gains and losses are amortized to earnings is generally over the average remaining life expectancy of plan participants. See Note 10, “Postretirement Benefit Plans” for further information. LOSS CONTINGENCIES. Loss contingencies are uncertain and unresolved matters that arise in the ordinary course of business and result from events that have the potential to result in a future loss. Such contingencies include, but are not limited to, product warranties, claims, litigation, environmental obligations, regulatory investigations and proceedings, product quality, and losses resulting from other events and developments. When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the loss. When there appears to be a range of possible losses with equal likelihood, liabilities are based on the low end of such range. Disclosure is provided for material loss contingencies when a loss is probable and a reasonable estimate can be made, when a loss is probable but a reasonable estimate cannot be made, and when it is reasonably possible that a loss will be incurred or the amount of a loss will exceed the recorded provision. We regularly review contingencies to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. Legal costs incurred in connection with loss contingencies are expensed as incurred. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information. ASSET RETIREMENT OBLIGATIONS. Our operations involve the use, disposal, and cleanup of substances regulated under nuclear decommissioning regulations that require asset retirement obligations. Liabilities for nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. We record asset retirement obligations associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information. SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables to borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements. See Note 18, “Supplemental Financial Information” for further information. FAIR VALUE MEASUREMENTS. The following sections describe the valuation methodologies we use to measure financial and non-financial instruments at fair value including certain assets within our postretirement benefit plans. Observable inputs for fair value measurements reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. These inputs establish the following fair value hierarchy: •Level 1 — Quoted prices for identical instruments in active markets. •Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. •Level 3 — Significant inputs to the valuation model are unobservable. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. RECURRING FAIR VALUE MEASUREMENTS. For financial assets and liabilities measured at fair value on a recurring basis, primarily money market funds, investment securities, derivatives, and contingent consideration, fair value is the price we would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Money Market Funds Money market funds are valued using pricing information from the fund managers, quoted on a daily basis, and are considered Level 2 inputs. Investment Securities Publicly traded equity securities are valued using Level 1 quoted price inputs. Non-publicly traded equity securities for which the fair value option was elected are classified within Level 3 and are valued using unobservable inputs, primarily by discounting expected future cash flows. Derivatives The majority of our derivatives are valued using model-derived offers received from financial institutions for similar over-the-counter instruments without an active market or internal models. The models maximize observable inputs including interest rates and both forward and spot prices for currencies. As of December 31, 2025 and 2024, foreign currency contracts, interest rate contracts, embedded derivatives, and equity-linked total return swaps were valued using Level 2 inputs. Contingent Consideration When an acquisition involves a contingent consideration arrangement, we record on the date of acquisition a liability for the fair value of the estimated additional consideration we may be obligated to pay in the future. The fair value is based upon estimates of future financial projections under various potential scenarios using a probability-weighted expected payment model discounted to present value. The estimates used to determine the fair value are subject to significant judgment and as such are considered Level 3 inputs. We subsequently remeasure such liabilities at the end of each reporting period and record changes in the fair value within SG&A in the Consolidated Statements of Income. Investments in Annuity Contracts, Private Equity, Real Estate and Collective Funds held within our Postretirement Benefit Plans Investments are generally valued using the NAV per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. Investments that are measured at fair value using the NAV practical expedient are not required to be classified in the fair value hierarchy. Investments classified within Level 3 primarily relate to an annuity contract, real estate, and private equities which are valued using unobservable inputs, primarily by discounting expected future cash flows, using comparative market multiples, third-party pricing sources, or a combination of these approaches as appropriate. See Note 10, “Postretirement Benefit Plans” for further information. Debt Securities held within our Postretirement Benefit Plans When available, we use quoted market prices to determine the fair value of debt securities which are Level 1 inputs. For our remaining debt securities, we obtain pricing information from an independent pricing vendor. The inputs and assumptions to the pricing vendor’s models are derived from market observable sources including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. These investments are classified within Level 2. See Note 10, “Postretirement Benefit Plans” for further information. There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended December 31, 2025, 2024, and 2023. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. NON-RECURRING FAIR VALUE MEASUREMENTS. Certain assets and liabilities are measured at fair value on a non-recurring basis. These items may include financing receivables and long-lived assets reduced to fair value upon classification as held for sale and impaired equity method investments and long-lived assets, which, when written down to fair value upon an impairment, are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Company uses to measure these assets not measured on a recurring fair value basis. Equity Method Investments Equity method investments for which the fair value option was not elected are initially recorded at cost and are adjusted in each period for the Company’s share of the investee’s income or loss and dividends paid. In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using either a discounted cash flow model, comparative market multiples, third-party pricing sources, or a combination of these approaches, as appropriate. These investments are generally valued using Level 3 inputs. Equity Investments Without Readily Determinable Fair Value Equity investments without readily determinable fair value, subject to a policy choice on a transaction-by-transaction basis, are accounted for under the measurement alternative at cost less impairment and adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. In the instance of impairment, if any, equity investments are adjusted to fair value using market observable data if available. If market observable data is not available, fair values are estimated using discounted cash flow models, comparative market multiples, or a combination of these approaches using Level 3 inputs. Financing Receivables We generally use market data, including pricing on recently closed market transactions, to value financing receivables that are held for sale. Such financing receivables are valued using Level 2 inputs. When data is unobservable, we use valuation methodologies based on current market interest rate data adjusted for inherent credit risk. Such financing receivables are valued using Level 3 inputs. Long-Lived Assets Fair values of long-lived assets are primarily developed internally and are corroborated by available external appraisal information, as applicable. These assets are generally valued using Level 3 inputs. FOREIGN CURRENCY. We have determined that the functional currency for many of our international operations is the local currency, and for other international operations the functional currency is the USD. The basis of this determination is the currency in which each of the international operations primarily generates and expends cash. When the functional currency is not the USD, asset and liability accounts are translated at period-end exchange rates. The Company translates functional currency income and expense amounts to their USD equivalents using average exchange rates for the period. These translation gains and losses are recognized within Accumulated other comprehensive income (loss) – net (“AOCI”) in the Consolidated Statements of Financial Position. Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the non-functional currency and those resulting from remeasurements of monetary items, are included in Cost of products, Cost of services, SG&A, and R&D in the Consolidated Statements of Income, depending on the underlying nature of the item. Net gains (losses) from foreign currency transactions were $(149) million, $16 million, and $16 million for the years ended December 31, 2025, 2024, and 2023, respectively. BUSINESS COMBINATIONS. Our financial statements include the operations of acquired businesses from the date of acquisition. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with U.S. GAAP, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. When we acquire the remaining equity ownership of a company in which we hold an equity interest, we remeasure our equity interest to fair value. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as Goodwill. Transaction costs are expensed as incurred. For those arrangements that involve potential future contingent consideration, on the date of acquisition we record a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” and Note 13, “Financial Instruments and Fair Value Measurements” for further information. DISCONTINUED OPERATIONS. Certain of our operations have been presented as discontinued. We present businesses whose disposal represents a strategic shift that has, or will have, a major effect on our operations and financial results as discontinued operations when the components meet the criteria for held for sale, are sold, or are spun-off. Presentation as discontinued operations is consistent for all periods presented. RESTRUCTURING COSTS. We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. See Note 15, “Restructuring Activities” for further information. RESEARCH AND DEVELOPMENT. The Company conducts R&D activities to create new products, develop new applications for existing products, and enhance existing products. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&D costs are expensed as incurred. In certain instances, R&D activities may be funded by third parties, including government entities. These R&D funding arrangements may include upfront payments, R&D cost sharing payments, and future milestone payments that may be based upon the occurrence of future R&D or commercialization events. Payments received as part of the R&D funding arrangements are generally presented as an offset to R&D expense. COLLABORATIVE ARRANGEMENTS. We enter into collaborative arrangements primarily related to development of new products. A collaborative arrangement is a contractual arrangement that involves two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. The assessment for a collaborative arrangement is performed throughout the life of the arrangement based on changes in the responsibilities of all parties. Amounts that are owed by collaboration partners related to R&D activities are generally presented as an offset to R&D expense. ACCOUNTING CHANGES. We evaluate Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not included in our disclosures were assessed and determined to either be not applicable or are not expected to have a significant impact on our financial statements. Recent Accounting Pronouncements Reflected in Our Consolidated Financial Statements In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the year ended December 31, 2025, prospectively applied to disclosures in our notes to the financial statements. See Note 11, “Income Taxes.” for further information. Other Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 addresses investor requests for more transparency about expense information through the disaggregation of relevant expense captions in the notes to the financial statements. The provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. We expect the adoption to increase disclosures in our notes to the financial statements. In September 2025, the FASB issued ASU No. 2025-06 (“ASU 2025-06”), Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. ASU 2025-06 updates the accounting for internal-use software by eliminating the concept of development stages. Under the updated guidance, software costs are capitalized once management has authorized and committed to funding the project, and it is probable the project will be completed and the software will be used to perform the function intended. The provisions of ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual periods. We are currently evaluating the effect that ASU 2025-06 will have on our financial statements.

SHARE-BASED COMPENSATION - Schedule of Stock Options Valuation Assumptions (Details) - Stock options	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free rate	4.00%	4.10%	3.60%
Dividend yield	0.16%	0.13%	0.01%
Expected volatility	26.70%	26.20%	26.20%
Expected term (in years)	6 years 2 months 12 days	6 years 2 months 12 days	6 years 2 months 12 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 20,625	$ 19,672	$ 19,552
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	9,168	8,617	8,228
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	2,031	2,135	2,560
All other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 9,427	$ 8,919	$ 8,764

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Cover - USD ($) $ in Billions	12 Months Ended
Cover - USD ($) $ in Billions	Dec. 31, 2025	Jan. 28, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 34
Entity Common Stock, Shares Outstanding		455,749,767
Documents Incorporated by Reference	The definitive proxy statement relating to the registrant’s Annual Meeting of Stockholders, to be held May 7, 2026, is incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025

POSTRETIREMENT BENEFIT PLANS - Assumptions (Details)	12 Months Ended
POSTRETIREMENT BENEFIT PLANS - Assumptions (Details)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Pension Plans \| U.S. Plans
Weighted-average benefit obligations assumptions
Discount rate	5.40%	5.70%	5.20%
Compensation increases	3.50%	3.50%	3.70%
Weighted-average benefit cost assumptions
Discount rate	5.70%	5.20%	5.50%
Expected rate of return on plan assets	7.00%	7.00%	7.00%
Pension Plans \| International Plans
Weighted-average benefit obligations assumptions
Discount rate	5.10%	4.90%	4.20%
Compensation increases	2.70%	2.80%	3.10%
Weighted-average benefit cost assumptions
Discount rate	4.90%	4.20%	4.60%
Expected rate of return on plan assets	4.70%	5.30%	5.20%
Other Postretirement Benefits Plan
Weighted-average benefit obligations assumptions
Discount rate	5.00%	5.50%	5.10%
Compensation increases	3.60%	3.60%	3.60%
Weighted-average benefit cost assumptions
Discount rate	5.50%	5.10%	5.40%
Expected rate of return on plan assets	0.00%	0.00%	0.00%

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Capitalized Cloud Computing Arrangement Implementation Costs (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capitalized implementation costs	$ 249	$ 114
Accumulated amortization	(49)	(30)
Total Capitalized cloud computing arrangement implementation costs, net	$ 200	$ 84

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax


Income From Continuing Operations Before Income Taxes
	For the years ended December 31
	2025		2024		2023
U.S. income	$	1,028	$	593	$	816
Non-U.S. income	1,740		1,988		1,545
Total	$	2,768	$	2,581	$	2,361

Schedule of Provision for Income Taxes


Provision for Income Taxes	For the years ended December 31
	2025		2024		2023
Current
U.S. Federal	$	4	$	62	$	171
Non-U.S.	317		412		345
U.S. State	8		8		42
Deferred
U.S. Federal	110		3		—
Non-U.S.	131		(12)		103
U.S. State	44		58		82
Total	$	614	$	531	$	743

Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate

The effective income tax rate for the year ended December 31, 2025 differs from the statutory federal income tax rate as follows.


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the year ended December 31, 2025
	Amount		Percent
Income from continuing operations before income taxes	$	2,768
Tax expected at 21%	581		21.0	%
State and local income taxes, net of federal income tax effect(1)	41		1.5	%
Foreign tax effects
China	30		1.1	%
Other foreign jurisdictions	54		2.0	%
Effect of cross-border tax laws

Foreign-derived deduction eligible income	(49)		(1.8)	%
Net CFC tested income	45		1.6	%
Other	5		0.2	%
Tax credits
R&D tax credits	(28)		(1.0)	%
Foreign tax credits	(81)		(2.9)	%
Changes in valuation allowances	9		0.3	%
Nontaxable or nondeductible items(2)	22		0.8	%
Changes in unrecognized tax benefits	(24)		(0.9)	%
Other adjustments	8		0.3	%
Effective tax rate	$	614	22.2	%

(1) In 2025, state and local income taxes in California, Illinois, New York, Florida, New Jersey, New York City, and Pennsylvania comprise more than 50% of state and local income taxes, net of federal income tax effect.

(2) The tax impact of any share-based compensation items are included in this category.

For the years ended December 31, 2024 and 2023, the effective income tax rate differs from the statutory federal income tax rate as follows.


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the years ended December 31
	2024		2023
Income from continuing operations before income taxes	$	2,581	$	2,361
Tax expected at 21%	542		496
Foreign operations	38		63
Withholding taxes	34		28
U.S. tax on foreign operations	(43)		(35)
Uncertain tax positions	170		11
R&D benefits	(51)		(33)
State and local income taxes, net of federal income tax effect	49		24
Valuation allowance	(281)		19
Spin-Off and separation costs	72		184
Other	—		(14)
Provision for income taxes	$	531	$	743
Effective income tax rate	20.6%		31.5%

Schedule of Unrecognized Tax Benefits Reconciliation

The balance of unrecognized tax benefits, the amount of related interest and penalties, and the portion that, if recognized, would reduce tax expense and effective tax rate are as follows.


	2025		2024		2023
Balance at beginning of period	$	551	$	409	$	465
Additions for tax positions of the current year	5		4		—
Additions for tax positions of prior years	43		181		156
Reductions for tax positions of prior years	(108)		(33)		(203)
Settlements with tax authorities	(7)		(4)		(6)
Expiration of the statute of limitations	(21)		(6)		(3)
Balance at end of period	$	463	$	551	$	409

Schedule of Unrecognized Tax Benefits


Unrecognized Tax Benefits	For the years ended December 31
	2025		2024		2023
Unrecognized tax benefits	$	463	$	551	$	409
Accrued interest on unrecognized tax benefits	65		81		72

Portion that, if recognized, would reduce tax expense and effective tax rate	158		182		157

Schedule of Deferred Tax Assets and Liabilities


	As of
	December 31, 2025		December 31, 2024
Total assets	$	4,491	$	4,474
Total liabilities	(193)		(56)
Net deferred income tax asset (liability)	$	4,298	$	4,418


Components of the Net Deferred Income Tax Asset (Liability)	As of
	December 31, 2025		December 31, 2024
Deferred tax assets:
Employee benefits	$	1,247	$	1,340
Reserves and accruals	481		413
Operating loss carryforwards	463		447
Lease liabilities	48		57
Tax credit carryforwards	119		80
U.S. interest restriction carryforwards	135		156
Goodwill and other intangible assets	1,184		1,355
Property, plant, and equipment	181		223
Capitalized R&D	834		689
Other deferred tax assets	100		55
Total deferred income tax asset	4,793		4,817
Valuation allowances	(251)		(231)
Total deferred income tax asset after valuation allowance	4,542		4,586
Deferred tax liabilities:
ROU assets	(47)		(42)
Other deferred tax liabilities	(198)		(126)
Total deferred income tax liability	(244)		(168)
Net deferred income tax asset (liability)	$	4,298	$	4,418

Summary of Valuation Allowance

Activity in the valuation allowance consists of the following:


Valuation Allowances	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	231	$	540	$	272
Provision for income taxes	4		(279)		(12)
Foreign currency exchange and other	16		(31)		280
Balance at end of period	$	251	$	231	$	540

Schedule of Income Taxes Paid

The amounts of cash paid for income taxes by GE HealthCare are as follows.


	For the year ended December 31, 2025
U.S. Federal	$	38
U.S. State	17
Foreign
Norway	69
China	66
India	41
Japan	23
United Kingdom	23
Other	151
Cash paid during the year for income taxes	$	429

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Depreciation and Amortization by Segment (Details) - Operating segments - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Imaging
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 227	$ 249	$ 274
AVS
Segment Reporting Information [Line Items]
Depreciation and amortization	70	78	90
PCS
Segment Reporting Information [Line Items]
Depreciation and amortization	53	55	69
PDx
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 66	$ 55	$ 45

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References + Details

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense (pre-tax)	$ 130	$ 125	$ 114
Income tax benefits	(24)	(23)	(23)
Share-based compensation expense (after-tax)	$ 106	$ 102	$ 91

POSTRETIREMENT BENEFIT PLANS - Amounts Recorded in Statements of Financial Position (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Amounts Recorded in Consolidated Statements of Financial Position
Non-current compensation and benefits	$ (5,453)	$ (5,583)
Pension Plans \| U.S. Plans
Amounts Recorded in Consolidated Statements of Financial Position
All other non-current assets	13	11
Current compensation and benefits	(178)	(172)
Non-current compensation and benefits	(3,673)	(3,702)
Net amount recorded	(3,838)	(3,863)
Pension Plans \| International Plans
Amounts Recorded in Consolidated Statements of Financial Position
All other non-current assets	723	642
Current compensation and benefits	(23)	(18)
Non-current compensation and benefits	(319)	(305)
Net amount recorded	380	319
Other Postretirement Benefits Plan
Amounts Recorded in Consolidated Statements of Financial Position
All other non-current assets	0	0
Current compensation and benefits	(118)	(135)
Non-current compensation and benefits	(790)	(881)
Net amount recorded	$ (908)	$ (1,016)

- Definition

Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.

+ References + Details

FINANCING RECEIVABLES - Narrative (Details)	Dec. 31, 2025	Dec. 31, 2024
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	1.00%	3.00%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	1.00%	4.00%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	1.00%	4.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-14

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-12

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 80
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479294/326-20-55-80

+ Details

POSTRETIREMENT BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

Schedule of Defined Benefit Plans Disclosures

The total assets and liabilities for all plans assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of plan assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

(1) Defined benefit plans are comprised of both U.S. Plans and International Plans, as described below.
(2) OPEB Plans are comprised of benefits, as described below.


Plan Obligations in Excess of Plan Assets	As of
	December 31, 2025		December 31, 2024
Accumulated benefit obligation	$	22,595	$	22,185
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	19,754	$	19,517
Fair value of plan assets	14,677		14,327
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	19,778	$	19,540
Fair value of plan assets	14,677		14,327


Pre-Tax Amounts Recorded in AOCI
	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
Net loss (gain)	$	(147)	$	(506)	$	909	$	849	$	(450)	$	(469)
Prior service cost (credit)	(40)		(51)		(15)		(16)		(367)		(447)
Total recorded in AOCI	$	(187)	$	(557)	$	893	$	833	$	(818)	$	(916)

Schedule of Net Funded Status


Plan Funded Status	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
Change in projected benefit obligations
Balance at January 1	$	18,241	$	19,363	$	2,957	$	3,385	$	1,016	$	1,133
Service cost	4		35		21		20		6		7
Interest cost	996		970		151		141		50		54
Participant contributions	—		4		1		—		14		16

Actuarial loss (gain) – net	591		(799)		(122)		(357)		(45)		(48)
Benefits paid	(1,266)		(1,332)		(136)		(131)		(134)		(146)

Settlements	—		—		(8)		(4)		—		—
Special termination cost	3		—		—		—		1		—
Acquisitions/Divestitures/Mergers	—		—		33		—		—		—
Exchange rate adjustments	—		—		252		(96)		—		—
Balance at December 31	$	18,569	$	18,241	$	3,148	$	2,957	$	908	$	1,016
Change in plan assets
Balance at January 1	$	14,378	$	15,485	$	3,276	$	3,733	$	—	$	—
Actual gain (loss) on plan assets	1,443		49		14		(263)		—		—
Employer contributions	176		172		41		30		120		130
Participant contributions	—		4		1		—		14		16
Benefits paid	(1,266)		(1,332)		(144)		(136)		(134)		(146)
Acquisitions/Divestitures/Mergers	—		—		72		—		—		—
Exchange rate adjustments	—		—		269		(89)		—		—
Balance at December 31	$	14,731	$	14,378	$	3,528	$	3,276	$	—	$	—
Funded status – surplus (deficit)	$	(3,838)	$	(3,863)	$	380	$	319	$	(908)	$	(1,016)

Schedule of Amounts Recognized in Balance Sheet


Amounts Recorded in Consolidated Statements of Financial Position
	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
All other non-current assets	$	13	$	11	$	723	$	642	$	—	$	—
Current compensation and benefits	(178)		(172)		(23)		(18)		(118)		(135)
Non-current compensation and benefits	(3,673)		(3,702)		(319)		(305)		(790)		(881)
Net amount recorded	$	(3,838)	$	(3,863)	$	380	$	319	$	(908)	$	(1,016)

Schedule of Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income


Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Cost (income) of postretirement benefit plans	$	(218)	$	(250)	$	(224)	$	37	$	(20)	$	(22)	$	(86)	$	(87)	$	(86)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	—		—		(1,791)		—		—		542		—		—		(1,216)
Plan amendments	—		—		53		—		(1)		—		—		—		—
Net loss (gain) – current year	294		348		695		16		98		198		(45)		(48)		50
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	—		—		(108)		1		—		—		—		—		—

Amortization of net (loss) gain	65		68		121		(21)		(14)		(6)		64		61		64
Amortization of prior service (cost) credit	11		(8)		(4)		2		2		3		80		87		87
Total changes in other comprehensive loss (income)	$	370	$	408	$	(1,034)	$	(2)	$	86	$	737	$	98	$	100	$	(1,015)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$	152	$	158	$	(1,258)	$	35	$	66	$	715	$	12	$	13	$	(1,101)

Components of Net Periodic Expense


Components of Expense (Income)
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Service cost – Operating	$	4	$	35	$	35	$	21	$	20	$	20	$	6	$	7	$	6
Interest cost	996		970		1,022		151		141		139		50		54		59
Expected return on plan assets	(1,145)		(1,196)		(1,242)		(152)		(193)		(184)		—		—		—
Amortization of net loss (gain)	(65)		(68)		(121)		21		14		6		(64)		(61)		(64)
Amortization of prior service cost (credit)	(11)		8		4		(2)		(2)		(3)		(80)		(87)		(87)
Curtailment loss (gain)	—		—		17		—		—		—		—		—		—
Settlement loss (gain)	—		—		61		(1)		—		—		—		—		—
Special termination cost	3		1		—		—		—		—		1		—		—
Non-operating	$	(222)	$	(285)	$	(259)	$	17	$	(40)	$	(42)	$	(92)	$	(94)	$	(92)
Net periodic expense (income)	$	(218)	$	(250)	$	(224)	$	37	$	(20)	$	(22)	$	(86)	$	(87)	$	(86)

Schedule of Assumptions


Assumptions
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Weighted-average benefit obligations assumptions
Discount rate	5.4	%	5.7	%	5.2	%	5.1	%	4.9	%	4.2	%	5.0	%	5.5	%	5.1	%
Compensation increases	3.5	%	3.5	%	3.7	%	2.7	%	2.8	%	3.1	%	3.6	%	3.6	%	3.6	%
Weighted-average benefit cost assumptions
Discount rate	5.7	%	5.2	%	5.5	%	4.9	%	4.2	%	4.6	%	5.5	%	5.1	%	5.4	%
Expected rate of return on plan assets	7.0	%	7.0	%	7.0	%	4.7	%	5.3	%	5.2	%	—	%	—	%	—	%

Schedule of Expected Benefit Payments


Expected Future Benefit Payments of Our Benefit Plans
	U.S. Plans		International Plans		OPEB Plans
2026	$	1,397	$	157	$	118
2027	1,403		158		116
2028	1,408		167		112
2029	1,409		172		110
2030	1,404		179		105
2031-2035	6,797		980		436

Schedule of Allocation of Plan Assets

The following tables summarize our pension plan assets that are measured at fair value on a recurring basis. There are no plan assets associated with our OPEB Plans. The inputs and valuation techniques used to measure the fair value of the assets are consistent with the valuation methodologies we use to measure financial assets at fair value on a recurring basis, as described in Note 2, “Summary of Significant Accounting Policies.”


Composition of Plan Assets			Basis of fair value measurement
	Balance as of December 31, 2025		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	4,832	$	2,292	$	108	$	—	$	2,432
Debt securities, cash, and cash equivalents	8,412		2,042		5,330		—		1,040
Real estate	793		—		—		299		494
Private equities and other investments	1,990		(75)		46		161		1,858
Annuity contract	2,104		—		—		2,104		—
Other	128		—		—		—		—
Fair value of plan assets	$	18,259	$	4,258	$	5,484	$	2,564	$	5,825

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


			Basis of fair value measurement
	Balance as of December 31, 2024		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	4,084	$	944	$	38	$	—	$	3,101
Debt securities, cash, and cash equivalents	10,593		1,307		8,000		—		1,285
Real estate	1,100		—		—		476		623
Private equities and other investments	1,877		7		53		216		1,602

Fair value of plan assets	$	17,654	$	2,258	$	8,091	$	692	$	6,612

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


Weighted Average Asset Allocation of Pension Plans	2025 Target		2025 Actual

Global equity securities	22	%	26	%
Debt securities, cash, and cash equivalents	49	%	46	%
Real estate	5	%	4	%
Private equities and other instruments	12	%	12	%
Annuity contract	12	%	12	%

SHARE-BASED COMPENSATION - Narrative (Details) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance \| shares	41
Unrecognized compensation \| $	$ 159
Weighted average period of recognition	2 years
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Stock options \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock options \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
RSUs \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
RSUs \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Cash flow hedge gain to be reclassified within 12 months	$ 7
Derivative, potential effect of rights of offset to assets and liabilities	107	$ 77
Cash, cash equivalents, and restricted cash	4,512	2,889
Estimated fair value
Derivative [Line Items]
Borrowings	10,545	9,374
Carrying value
Derivative [Line Items]
Borrowings	10,003	8,951
Money market funds \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	399	312
Other cash equivalents \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	$ 3,046	1,573
Cash flow hedges
Derivative [Line Items]
Derivative, contract term	5 years
Derivative, remaining maturity	51 months
Net investment hedges \| Cross-currency swaps \| Designated as hedging instrument
Derivative [Line Items]
Payment for settlement of hedge	$ 178	$ 94

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Numerator:
Net income from continuing operations	$ 2,154	$ 2,050	$ 1,618
Net (income) loss attributable to noncontrolling interests	(70)	(57)	(46)
Net income from continuing operations attributable to GE HealthCare	2,084	1,993	1,572
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)
Net income from continuing operations attributable to GE HealthCare common stockholders	2,084	1,993	1,389
Income (loss) from discontinued operations, net of taxes	0	0	(4)
Net income attributable to GE HealthCare common stockholders	$ 2,084	$ 1,993	$ 1,385
Denominator:
Basic weighted-average shares outstanding	456	456	455
Dilutive effect of common stock equivalents (in shares)	1	2	3
Diluted weighted-average shares outstanding	458	459	458
Basic Earnings Per Share:
Continuing operations (in dollars per share)	$ 4.56	$ 4.37	$ 3.06
Discontinued operations (in dollars per share)	0	0	(0.01)
Basic earnings per share (in dollars per share)	4.56	4.37	3.05
Diluted Earnings Per Share:
Continuing operations (in dollars per share)	4.55	4.34	3.04
Discontinued operations (in dollars per share)	0	0	(0.01)
Diluted earnings per share (in dollars per share)	$ 4.55	$ 4.34	$ 3.03
Antidilutive securities (in shares)	3	3	4

LEASES - Schedule of Lease, Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Long-term (fixed)	$ 136	$ 134	$ 121
Long-term (variable)	101	120	106
Short-term	12	4	2
Total operating lease expense	$ 249	$ 258	$ 229

RESTRUCTURING ACTIVITIES - Narrative (Details) $ in Millions	Dec. 31, 2025 USD ($)
Restructuring and Related Activities [Abstract]
Expected restructuring expense remaining	$ 53

SEGMENT AND GEOGRAPHICAL INFORMATION

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHICAL INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Advanced Visualization Solutions (“AVS”), Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in Item 1, “Business” of this Annual Report on Form 10-K.

The Company’s organizational structure is based upon the availability of separate financial information that is evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) for the purpose of assessing performance and allocating resources. The Company’s CODM is our Chief Executive Officer. The CODM assesses segment performance using Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as income before income taxes in our Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss). Segment EBIT is also used in the annual budget and periodic forecasting processes and informs the CODM in decision making regarding the allocation of resources to the segments.


Total Revenues by Segment	For the years ended December 31
		2025		2024		2023
Total Imaging		$	9,245	$	8,855	$	8,944
AVS:
Procedural Guidance		2,752		2,711		2,666
Specialized Ultrasound		2,601		2,420		2,428
Total AVS		5,354		5,131		5,094
PCS:
Monitoring Solutions		2,256		2,194		2,283
Life Support Solutions		831		931		859
Total PCS		3,086		3,125		3,142
Total PDx		2,900		2,508		2,306
Other(1)		40		52		66
Total revenues		$	20,625	$	19,672	$	19,552

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”) which does not meet the definition of an operating segment.

No single customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2025, 2024, or 2023. Additionally, no single customer accounted for more than 10% of accounts receivable as of December 31, 2025 or 2024.


Significant Expenses by Segment	For the years ended December 31
		2025		2024		2023
Imaging:
Cost of sales		$	6,099	$	5,623	$	5,901
Other segment items(1)		2,255		2,270		2,222
Total Imaging		$	8,353	$	7,893	$	8,123
AVS:
Cost of sales		$	2,629	$	2,485	$	2,485
Other segment items(1)		1,550		1,528		1,485
Total AVS		$	4,178	$	4,014	$	3,970
PCS:
Cost of sales		$	2,028	$	1,930	$	1,890
Other segment items(1)		849		848		869
Total PCS		$	2,877	$	2,778	$	2,759
PDx:
Cost of sales		$	1,450	$	1,236	$	1,192
Other segment items(1)		579		490		497
Total PDx		$	2,028	$	1,725	$	1,689

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.


Segment EBIT	For the years ended December 31
		2025		2024		2023
Segment EBIT
Imaging		$	891	$	962	$	821
AVS		1,175		1,118		1,124
PCS		209		347		383
PDx		872		783		617
Other(1)		7		2		11
		3,155		3,211		2,956
Restructuring costs		(120)		(120)		(54)
Acquisition and disposition-related benefits (charges)		(39)		(3)		15
Gain (loss) on business and asset dispositions		5		—		—
Spin-Off and separation costs		(38)		(251)		(270)
Amortization of acquisition-related intangible assets		(156)		(137)		(127)
Investment revaluation gain (loss)		112		(22)		1
Interest and other financial charges – net		(440)		(504)		(542)
Non-operating benefit income (costs)		288		406		382
Income before income taxes		$	2,768	$	2,581	$	2,361

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.

The following table represents the depreciation and amortization amounts reported within the Segment EBIT metric for our reportable segments. Depreciation and amortization expense related to shared property, plant, and equipment and intangibles, exclusive of acquisition-related intangible assets, has been fully allocated to our segments and those allocations are reflected in the amounts presented in the table below. These amounts are included within Cost of sales and Other segment items disclosed in the Significant Expenses by Segment table above.


Depreciation and Amortization by Segment	For the years ended December 31
		2025		2024		2023

Imaging		$	227	$	249	$	274
AVS		70		78		90
PCS		53		55		69
PDx		66		55		45

The Company does not report total assets by segment as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

GEOGRAPHIC INFORMATION.

Revenues are classified according to the country in which products and services are sold.


Total Revenues by Country	For the years ended December 31
	2025		2024		2023
United States	$	9,168	$	8,617	$	8,228
China	2,031		2,135		2,560
All other countries	9,427		8,919		8,764
Total revenues	$	20,625	$	19,672	$	19,552

Long-lived assets represent Property, plant, and equipment – net and are classified according to the country where the asset is located.


Long-Lived Assets – Net by Country	As of
	December 31, 2025		December 31, 2024
United States	$	962	$	908
China	439		392
Norway	368		296
Japan	296		62
All other countries	1,027		893
Total long-lived assets – net	$	3,092	$	2,550

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)					6 Months Ended	12 Months Ended
	Nov. 20, 2025	Nov. 07, 2025	Mar. 31, 2025	Apr. 01, 2024	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Combination [Line Items]
Cash consideration, net of cash acquired						$ 378,000,000	$ 313,000,000	$ 147,000,000
Goodwill						13,489,000,000	13,136,000,000	12,936,000,000
Gain on remeasurement of NMP equity method investment						97,000,000	0	0
Definite-lived intangible assets acquired						$ 280,000,000
Acquired finite-lived intangible assets, weighted average useful life						10 years
Goodwill impairment						$ 0	0
Impairment of intangible assets, indefinite-lived						0	0	0
Impairment of intangible assets, definite-lived						0	0	0
Amortization of acquisition-related intangible assets						$ 291,000,000	$ 312,000,000	$ 362,000,000
Nihon Medi-Physics
Business Combination [Line Items]
Defined benefit plan, asset			$ 71,000,000
Defined benefit plan, liability			33,000,000
Defined benefit plan, net asset			$ 38,000,000
icometrix NV
Business Combination [Line Items]
Percent of interest acquired		100.00%
Cash consideration, net of cash acquired		$ 98,000,000
Contingent consideration		$ 35,000,000
Contingent consideration, sales period		2 years
Goodwill		$ 74,000,000
Intangible assets		34,000,000
Deferred tax liabilities		$ 9,000,000
Nihon Medi-Physics
Business Combination [Line Items]
Percent of interest acquired			50.00%
Cash consideration, net of cash acquired			$ 271,000,000
Goodwill			220,000,000
Intangible assets			235,000,000
Deferred tax liabilities			$ 81,000,000
Equity interest in acquiree, existing percentage			50.00%
Fair value of previously held interest in NMP			$ 301,000,000
Equity interest in acquiree, carrying value			204,000,000
Gain on remeasurement of NMP equity method investment			97,000,000
Foreign currency translation gain, reclassification adjustment			63,000,000
Defined benefit pension plan loss, reclassification adjustment			8,000,000
Measurement period adjustment, increase in goodwill					$ 4,000,000
Definite-lived intangible assets acquired			$ 235,000,000
Acquired finite-lived intangible assets, weighted average useful life			13 years
Asset retirement obligations and decommissioning liabilities assumed			$ 124,000,000
Purchase price			$ 577,000,000
MIM Software
Business Combination [Line Items]
Percent of interest acquired				100.00%
Cash consideration, net of cash acquired				$ 259,000,000
Goodwill				189,000,000
Deferred tax liabilities				13,000,000
Cash acquired from acquisition				11,000,000
Purchase price				283,000,000
Other net assets				7,000,000
MIM Software \| Customer-related
Business Combination [Line Items]
Intangible assets				52,000,000
MIM Software \| Developed technology
Business Combination [Line Items]
Intangible assets				48,000,000
MIM Software \| Purchase price
Business Combination [Line Items]
Contingent consideration				13,000,000
MIM Software \| Service requirements
Business Combination [Line Items]
Contingent consideration				$ 23,000,000
Intelerad
Business Combination [Line Items]
Price of acquisition, expected	$ 2,300,000,000

LEASES

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

LEASES

OPERATING LEASES.

As a lessee, the Company leases certain logistics, office, and manufacturing facilities, as well as vehicles and other equipment. Certain of the Company’s leases may include options to extend. Our ROU operating lease assets are recognized within Property, plant, and equipment – net in the Consolidated Statements of Financial Position. Our operating lease liabilities are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position, as detailed below.


Operating Lease Assets and Liabilities	As of
	December 31, 2025		December 31, 2024
Operating lease ROU assets	$	410	$	364
Current operating lease liabilities	134		115
Non-current operating lease liabilities	284		270
Total operating lease liabilities	$	419	$	385


Operating Lease Expense	For the years ended December 31
	2025		2024		2023
Long-term (fixed)	$	136	$	134	$	121
Long-term (variable)	101		120		106
Short-term	12		4		2
Total operating lease expense	$	249	$	258	$	229


Maturity of Lease Liabilities
	2026		2027		2028		2029		2030		Thereafter		Total
Undiscounted lease payments	$	153	$	116	$	73	$	42	$	20	$	56	$	460
Less: imputed interest													41
Total lease liability as of December 31, 2025													$	419


Supplemental Information Related to Operating Leases	For the years ended December 31
	2025			2024			2023
Cash paid for amounts included in the measurement of operating lease liabilities	$	151		$	138		$	130
Right-of-use assets obtained in exchange for new lease liabilities	162			147			154
Weighted-average remaining lease term (in years)	4.6			4.4			4.7
Weighted-average discount rate	4.4		%	4.5		%	4.4		%

FINANCE LEASES.

The Company leases equipment manufactured or sold by the Company to customers through sales-type leases. Sales-type leases are included in financing receivables and are recognized within All other current assets and All other non-current assets in the Consolidated Statements of Financial Position.

Finance lease income was $14 million, $14 million, and $13 million for the years ended December 31, 2025, 2024, and 2023, respectively, and is recognized within Other (income) expense – net in the Consolidated Statements of Income.


Net Investment in Finance Leases	As of
	December 31, 2025		December 31, 2024
Minimum lease payments receivable	$	243	$	242
Less: deferred income	(30)		(31)
Discounted lease receivable	213		211
Estimated unguaranteed residual value of leased assets, net of deferred income	12		10
Investment in finance leases, net of deferred income	$	225	$	221


Contractual Maturities

Due In	2026		2027		2028		2029		2030		Thereafter		Total
Minimum lease payments receivable	$	86	$	56	$	39	$	26	$	16	$	19	$	243

We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

LEASES

OPERATING LEASES.


Operating Lease Assets and Liabilities	As of
	December 31, 2025		December 31, 2024
Operating lease ROU assets	$	410	$	364
Current operating lease liabilities	134		115
Non-current operating lease liabilities	284		270
Total operating lease liabilities	$	419	$	385


Operating Lease Expense	For the years ended December 31
	2025		2024		2023
Long-term (fixed)	$	136	$	134	$	121
Long-term (variable)	101		120		106
Short-term	12		4		2
Total operating lease expense	$	249	$	258	$	229


Maturity of Lease Liabilities
	2026		2027		2028		2029		2030		Thereafter		Total
Undiscounted lease payments	$	153	$	116	$	73	$	42	$	20	$	56	$	460
Less: imputed interest													41
Total lease liability as of December 31, 2025													$	419


Supplemental Information Related to Operating Leases	For the years ended December 31
	2025			2024			2023
Cash paid for amounts included in the measurement of operating lease liabilities	$	151		$	138		$	130
Right-of-use assets obtained in exchange for new lease liabilities	162			147			154
Weighted-average remaining lease term (in years)	4.6			4.4			4.7
Weighted-average discount rate	4.4		%	4.5		%	4.4		%

FINANCE LEASES.


Net Investment in Finance Leases	As of
	December 31, 2025		December 31, 2024
Minimum lease payments receivable	$	243	$	242
Less: deferred income	(30)		(31)
Discounted lease receivable	213		211
Estimated unguaranteed residual value of leased assets, net of deferred income	12		10
Investment in finance leases, net of deferred income	$	225	$	221


Contractual Maturities

Due In	2026		2027		2028		2029		2030		Thereafter		Total
Minimum lease payments receivable	$	86	$	56	$	39	$	26	$	16	$	19	$	243

We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

ORGANIZATION AND BASIS OF PRESENTATION	12 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION GE HealthCare Technologies Inc. is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions. The consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for annual financial information and in accordance with the instructions to Form 10-K. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. On January 3, 2023, General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). Following this transaction, GE continues to be considered a related party due to board member affiliation. Refer to Note 19, “Related Parties and Transition Services Agreement” for further information. Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation. Amounts due from related parties and due to related parties, which were previously shown on separate lines on the Consolidated Statements of Financial Position and Consolidated Statements of Cash Flows, were reclassified to Receivables, All other current assets, Accounts Payable, All other current liabilities, and All other operating activities – net as applicable. Additionally, gain on fair value remeasurement of contingent consideration amounts, which was previously shown on a separate line on the Consolidated Statements of Cash Flows, was reclassified to All other operating activities – net.

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 9, “Borrowings” for further information.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.



	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	168	$	192	$	193
Current-year provisions	208		202		216
Expenditures	(214)		(220)		(218)
Foreign currency exchange and other	6		(6)		1
Balance at end of period	$	169	$	168	$	192

Product warranties are recognized within All other current liabilities in the Consolidated Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matter described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matter described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On June 24, 2024, the Supreme Court vacated the D.C. Circuit’s decision and remanded the case to the D.C. Circuit for further consideration. On January 23, 2026, the D.C. Circuit reversed the District Court’s decision to dismiss the complaint and remanded the case for further proceedings.

ENVIRONMENTAL AND ASSET RETIREMENT OBLIGATIONS.

Our environmental remediation liabilities, which are measured on an undiscounted basis, were $15 million and $16 million as of December 31, 2025 and 2024, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position.

Our asset retirement obligations were $409 million and $292 million as of December 31, 2025 and 2024, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. The increase is primarily driven by $124 million in asset retirement obligations and decommissioning liabilities assumed as part of the NMP acquisition. Refer to Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for further information.

OTHER UNRECOGNIZED CONTRACTUAL OBLIGATIONS.

In the normal course of business, we enter into purchase commitments that are legally binding and specify minimum purchase quantities or spending amounts for items such as inventory, contractual services, and capital expenditures. As of December 31, 2025, these future purchase obligations are as follows.


	2026		2027		2028		2029		2030		Thereafter		Total
Other Unrecognized Contractual Obligations	$	468	$	188	$	171	$	155	$	77	$	89	$	1,149

POSTRETIREMENT BENEFIT PLANS - Pre-Tax Amounts Recorded in AOCI (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Net loss (gain)	$ (147)	$ (506)
Prior service cost (credit)	(40)	(51)
Total recorded in AOCI	(187)	(557)
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Net loss (gain)	909	849
Prior service cost (credit)	(15)	(16)
Total recorded in AOCI	893	833
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Net loss (gain)	(450)	(469)
Prior service cost (credit)	(367)	(447)
Total recorded in AOCI	$ (818)	$ (916)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

+ Details

SUBSEQUENT EVENTS (Details) - Floating rate Term Loan Facility due January 2, 2026 - Line of credit - USD ($) $ in Millions		3 Months Ended
	Jan. 02, 2026	Mar. 31, 2025
Subsequent Event [Line Items]
Debt repayments		$ 250
Subsequent event
Subsequent Event [Line Items]
Debt repayments	$ 500

RESTRUCTURING ACTIVITIES - Schedule of Restructuring Activities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 100	$ 85	$ 38
Facility and other exit costs	8	18	3
Asset write-downs	12	17	13
Total restructuring activities – net	$ 120	$ 120	$ 54

SHARE-BASED COMPENSATION - Summary of Weighted Average Grant Date Fair Value (Details) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options (in dollars per share)	$ 30	$ 32	$ 25
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	83	89	73
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 85	$ 96	$ 85

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 168	$ 192	$ 193
Current-year provisions	208	202	216
Expenditures	(214)	(220)	(218)
Foreign currency exchange and other	6	(6)	1
Balance at end of period	$ 169	$ 168	$ 192

SEGMENT AND GEOGRAPHICAL INFORMATION - Narrative (Details)	12 Months Ended
	Dec. 31, 2025 segment
Segment Reporting [Abstract]
Number of reportable segments	4
Number of operating segments	4

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Business Acquisitions

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	271
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	577

The preliminary fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Preliminary allocation
Receivables	$	53
Inventories	9
All other current assets(1)	35
Property, plant, and equipment	240
Goodwill	220
Other intangible assets	235
All other non-current assets	39
Deferred income taxes	(81)
All other non-current liabilities	(145)
Other(2)	(28)
Total net assets post acquisition	$	577

(1) All other current assets includes $35 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

Schedule of Goodwill


	Imaging		AVS		PCS		PDx		Total
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936
Reallocation	(1,031)		1,031		—		—		—
Acquisitions(1)	194		42		—		—		236
Foreign currency exchange and other	(13)		(19)		(3)		(1)		(36)
Balance at December 31, 2024	3,581		4,987		2,035		2,533		13,136
Acquisitions(2)	81		—		—		220		301
Foreign currency exchange and other	20		33		6		(8)		51
Balance at December 31, 2025	$	3,682	$	5,020	$	2,041	$	2,745	$	13,489

(1) Includes the purchase of MIM Software recorded within our Imaging segment, as described above, and Intelligent Ultrasound Group PLC in our AVS segment.

(2) Includes the purchase of icometrix, as described above, and Spectronic Medical AB, both recorded within our Imaging segment. Also included is the purchase of NMP, as described above, recorded within our PDx segment.

Schedule of Finite-Lived Intangible Assets



	As of December 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	279	$	(43)	$	236	$	112	$	(24)	$	88
Patents and technology	2,698		(2,128)		570		2,593		(1,987)		606
Capitalized software	1,703		(1,470)		233		1,743		(1,437)		306
Trademarks and other	47		(31)		15		33		(29)		4
Total definite-lived assets	4,727		(3,672)		1,055		4,481		(3,477)		1,004
Indefinite-lived assets(1)	75		—		75		74		—		74
Total other intangible assets	$	4,802	$	(3,672)	$	1,130	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Schedule of Indefinite-Lived Intangible Assets



	As of December 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	279	$	(43)	$	236	$	112	$	(24)	$	88
Patents and technology	2,698		(2,128)		570		2,593		(1,987)		606
Capitalized software	1,703		(1,470)		233		1,743		(1,437)		306
Trademarks and other	47		(31)		15		33		(29)		4
Total definite-lived assets	4,727		(3,672)		1,055		4,481		(3,477)		1,004
Indefinite-lived assets(1)	75		—		75		74		—		74
Total other intangible assets	$	4,802	$	(3,672)	$	1,130	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Schedule of Pre-tax Amortization Expense for Intangible Assets

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2025 over the next five calendar years is as follows.


	2026		2027		2028		2029		2030
Estimated annual pre-tax amortization	$	259	$	178	$	127	$	108	$	93

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Receivables [Abstract]
Long-term customer receivables	$ 73	$ 59
Non-income based tax receivables	24	20
Other sundry receivables	100	68
Long-term sundry receivables	124	88
Allowance for credit losses	(7)	(5)
Total long-term receivables – net	$ 190	$ 142

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation of property, plant, and equipment	$ 287	$ 268	$ 248
Capitalized cloud computing arrangement implementation costs, amortization expense	19	10	$ 7
Equity method investments, fair value	$ 32	$ 6

Consolidated Statements of Financial Position - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Cash, cash equivalents, and restricted cash	$ 4,512	$ 2,889
Receivables – net of allowances of $103 and $103	3,955	3,566
Inventories	2,234	1,939
Contract and other deferred assets	1,073	974
All other current assets	726	532
Current assets	12,501	9,901
Property, plant, and equipment – net	3,092	2,550
Goodwill	13,489	13,136
Other intangible assets – net	1,130	1,078
Deferred income taxes	4,491	4,474
All other non-current assets	2,205	1,950
Total assets	36,906	33,089
Short-term borrowings	508	1,502
Accounts payable	3,250	3,035
Contract liabilities	2,095	1,943
Current compensation and benefits	1,666	1,521
All other current liabilities	1,587	1,552
Current liabilities	9,105	9,553
Long-term borrowings	9,495	7,449
Non-current compensation and benefits	5,453	5,583
Deferred income taxes	193	56
All other non-current liabilities	2,061	1,796
Total liabilities	26,307	24,437
Commitments and contingencies
Redeemable noncontrolling interests	209	188
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 458,844,209 shares issued as of December 31, 2025; 457,246,971 shares issued as of December 31, 2024	5	5
Treasury stock, at cost, 3,107,626 shares as of December 31, 2025 and 291,053 shares as of December 31, 2024	(225)	(25)
Additional paid-in capital	6,707	6,583
Retained earnings	5,281	3,262
Accumulated other comprehensive income (loss) – net	(1,388)	(1,379)
Total equity attributable to GE HealthCare	10,379	8,446
Noncontrolling interests	11	18
Total equity	10,390	8,464
Total liabilities, redeemable noncontrolling interests, and equity	$ 36,906	$ 33,089

INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current
U.S. Federal	$ 4	$ 62	$ 171
Non-U.S.	317	412	345
U.S. State	8	8	42
Deferred
U.S. Federal	110	3	0
Non-U.S.	131	(12)	103
U.S. State	44	58	82
Total	$ 614	$ 531	$ 743

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

RESTRUCTURING ACTIVITIES - Schedule of Restructuring Liability Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]
Restructuring liabilities	$ 92	$ 86	$ 68
Charges	$ 102	$ 93
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales, Selling, general, and administrative	Cost of sales, Selling, general, and administrative
Payments and other adjustments	$ (96)	$ (75)
Employee termination costs
Restructuring Reserve [Roll Forward]
Restructuring liabilities	82	67	43
Charges	95	85
Payments and other adjustments	(81)	(60)
Facility and other exit costs
Restructuring Reserve [Roll Forward]
Restructuring liabilities	11	18	$ 25
Charges	7	8
Payments and other adjustments	$ (15)	$ (15)

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References + Details

SHAREHOLDERS' EQUITY - Narrative (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Apr. 30, 2025
Equity [Abstract]
Share repurchase program, authorized amount		$ 1,000
Common stock repurchased (in shares)	2.8
Common stock repurchased	$ 200

RELATED PARTIES AND TRANSITION SERVICES AGREEMENT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
All other non-current assets	$ 2,205	$ 1,950
All other non-current liabilities	2,061	1,796
TSA \| Related party
Related Party Transaction [Line Items]
Transaction amount	$ 0	$ 172	$ 372

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	CYBERSECURITY RISK MANAGEMENT. GE HealthCare employs practices, processes, and procedures to proactively and comprehensively manage risks, including risks related to cybersecurity, through its enterprise risk management (“ERM”) program. We aim to identify material cybersecurity risks via multiple strategies, including user and external reporting, audit and assessment activities, and technology programs. We utilize risk identification and risk mitigation strategies. •Risk identification begins with understanding the devices and equipment in use across the company, including laptops, servers, and other data devices, industrial equipment and machinery, and associated risks related to the use of those devices and equipment. •Risk mitigation entails protecting our data and operational systems via a system of controls. We monitor and collect data about the devices and users that touch our network resources, reviewing this data for anomalies. When we identify anomalies, we investigate to determine if the anomaly represents a threat. We have a process to contain and remediate identified threats. As discussed further below, we have incident response processes in place to utilize in case of threats or incidents. We conduct regular crisis simulations. Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including those in our supply chain or who have access to our customer and employee data or our systems. Third-party risks are included within our ERM assessment program as well as our cybersecurity-specific risk identification program, as discussed above. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data, or facilities that house such systems or data, and monitor cybersecurity threat risks identified through such diligence. We have a dedicated team of cyber professionals who report to our Chief Information Security Officer (“CISO”). This team publishes information technology and security policies, measures compliance, trains the workforce on cyber risks and protections, and operates a program to identify and mitigate risks and threats. Our risk mitigation activities include workforce awareness, vulnerability management, network segmentation, cyber protection and containment, detection, response and recovery. This team operates to decrease the risk of cyber incidents having a material impact. We measure our programs against the National Institute of Standards and Technology Cyber Security Framework and regularly test our controls and incident response plans. We maintain incident response plans that guide our activities in preparing for, detecting, responding to, and recovering from cybersecurity incidents. These plans cover the range of activities we undertake in connection with responding to cybersecurity incidents, including assessment, investigation, containment, remediation, and mitigation, as well as compliance with legal obligations including any necessary regulatory reporting. As part of these processes, we regularly engage with assessors, consultants, auditors, and other third parties to review our cybersecurity program to help identify areas for continued focus, improvement, and compliance. To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company, including its business strategy, or financial results. However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. We describe whether and how cybersecurity-related risks could materially affect our business in Item 1A, “Risk Factors” under the heading “Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted cybercrimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our business.”
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	GE HealthCare employs practices, processes, and procedures to proactively and comprehensively manage risks, including risks related to cybersecurity, through its enterprise risk management (“ERM”) program. We aim to identify material cybersecurity risks via multiple strategies, including user and external reporting, audit and assessment activities, and technology programs. We utilize risk identification and risk mitigation strategies.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. The Audit Committee of our Board is responsible for the oversight of cybersecurity-related risks. The Audit Committee regularly receives reports from management on our cybersecurity threat risk management and strategy processes, including on topics such as our data security posture, results from third-party assessments, progress towards pre-determined risk-mitigation-related goals, incident response plans, and cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to these risks. The Audit Committee received reports from our Chief Information Officer (“CIO”) and/or CISO four times in 2025.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee of our Board is responsible for the oversight of cybersecurity-related risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee regularly receives reports from management on our cybersecurity threat risk management and strategy processes, including on topics such as our data security posture, results from third-party assessments, progress towards pre-determined risk-mitigation-related goals, incident response plans, and cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to these risks.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our CISO. The CISO works closely with the CIO, Chief Privacy Officer (“CPO”), and other members of the legal team who report to the General Counsel, to review the cybersecurity program while monitoring global data protection regulations and cyber security laws. The CISO, CIO, and CPO, collectively, have over 35 years of work experience in various roles involving managing information security, developing cybersecurity strategy, and implementing effective information and cybersecurity programs. Our CISO is currently a board member for the National Technology Security Coalition, a non-profit, non-partisan trade association serving as the voice of CISOs to help improve national cybersecurity and has served on the board of advisors of many security technology companies.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The CISO works closely with the CIO, Chief Privacy Officer (“CPO”), and other members of the legal team who report to the General Counsel, to review the cybersecurity program while monitoring global data protection regulations and cyber security laws.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The CISO, CIO, and CPO, collectively, have over 35 years of work experience in various roles involving managing information security, developing cybersecurity strategy, and implementing effective information and cybersecurity programs. Our CISO is currently a board member for the National Technology Security Coalition, a non-profit, non-partisan trade association serving as the voice of CISOs to help improve national cybersecurity and has served on the board of advisors of many security technology companies.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The CISO works closely with the CIO, Chief Privacy Officer (“CPO”), and other members of the legal team who report to the General Counsel, to review the cybersecurity program while monitoring global data protection regulations and cyber security laws.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

RELATED PARTIES AND TRANSITION SERVICES AGREEMENT (Details) - USD ($) $ in Millions		12 Months Ended
	Jan. 03, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Sale of stock, percent of stock distributed	80.10%
Net transfers from GE, including Spin-Off-related adjustments				$ 2,849
TSA \| Related party
Related Party Transaction [Line Items]
Agreement term		24 months
Transaction amount		$ 0	$ 172	$ 372
Tax Matters Agreement \| Related party
Related Party Transaction [Line Items]
Period following distribution date		2 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

INCOME TAXES - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of period	$ 551	$ 409	$ 465
Additions for tax positions of the current year	5	4	0
Additions for tax positions of prior years	43	181	156
Reductions for tax positions of prior years	(108)	(33)	(203)
Settlements with tax authorities	(7)	(4)	(6)
Expiration of the statute of limitations	(21)	(6)	(3)
Balance at end of period	463	551	409
Unrecognized tax benefits	463	551	409
Accrued interest on unrecognized tax benefits	65	81	72
Portion that, if recognized, would reduce tax expense and effective tax rate	$ 158	$ 182	$ 157

BORROWINGS (Tables)

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Schedule of Long-Term Borrowings


Borrowings Composition	As of
	December 31, 2025		December 31, 2024
5.600% senior notes due November 15, 2025	$	—	$	1,500
5.650% senior notes due November 15, 2027	1,750		1,750
4.150% senior notes due December 15, 2028	600		—
4.800% senior notes due August 14, 2029	1,000		1,000
5.857% senior notes due March 15, 2030	1,250		1,250
4.800% senior notes due January 15, 2031	650		—
5.905% senior notes due November 22, 2032	1,750		1,750
5.500% senior notes due June 15, 2035	850		—
4.950% senior notes due December 15, 2035	650		—
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	500		750
Other	24		36
Total principal debt issued	10,024		9,036
Less: Unamortized debt issuance costs and discounts	49		33
Add: Cumulative basis adjustment for fair value hedges	27		(51)
Total borrowings	10,003		8,951
Less: Short-term borrowings(1)	508		1,502
Long-term borrowings	$	9,495	$	7,449

(1) Short-term borrowings as of December 31, 2025 and 2024 includes $502 million and $1,500 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

Schedule of Maturities of Long-Term Debt

Scheduled maturities of borrowings, excluding amortization of discounts and debt issuance costs, are as follows.



2026		2027		2028		2029		2030		Thereafter		Total
$	508	$	1,767	$	600	$	1,000	$	1,250	$	4,900	$	10,024

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

POSTRETIREMENT BENEFIT PLANS - Composition of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			$ 18,908
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			$ 18,908
Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 18,259	$ 17,654
Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,258	2,258
Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,484	8,091
Level 3 \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,564	692
Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,564	692
Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,825	6,612
Global equity securities \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,832	4,084
Global equity securities \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,292	944
Global equity securities \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	108	38
Global equity securities \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Global equity securities \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,432	3,101
Debt securities, cash, and cash equivalents \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8,412	10,593
Debt securities, cash, and cash equivalents \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,042	1,307
Debt securities, cash, and cash equivalents \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,330	8,000
Debt securities, cash, and cash equivalents \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Debt securities, cash, and cash equivalents \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,040	1,285
Real estate \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	793	1,100
Real estate \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Real estate \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Real estate \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	299	476
Real estate \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	494	623
Private equities and other investments \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,990	1,877
Private equities and other investments \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(75)	7
Private equities and other investments \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	53
Private equities and other investments \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	161	216
Private equities and other investments \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,858	$ 1,602
Annuity contract \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104
Annuity contract \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Annuity contract \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Annuity contract \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,104
Annuity contract \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Other \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	128
Other \| Level 1 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Other \| Level 2 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Other \| Level 3 \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Other \| Net Asset Value \| Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Noncurrent Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract liabilities	$ 803	$ 686
Operating lease liabilities	284	270
Environmental and asset retirement obligations	413	291
Income and indirect tax liabilities including uncertain tax positions	156	237
Derivative instruments	160	64
Finance lease obligations	$ 42	$ 40
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Sales allowances and related liabilities	$ 23	$ 23
Other	178	184
All other non-current liabilities	$ 2,061	$ 1,796

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Pre-tax Amortization Expense for Intangible Assets (Details) $ in Millions	Dec. 31, 2025 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2026	$ 259
2027	178
2028	127
2029	108
2030	$ 93

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Unrecognized Contractual Obligations (Details) $ in Millions	Dec. 31, 2025 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026	$ 468
2027	188
2028	171
2029	155
2030	77
Thereafter	89
Total	$ 1,149

EARNINGS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Schedule of Earnings per Share


Earnings Per Share	For the years ended December 31
(In millions, except per share amounts)		2025		2024		2023
Numerator:
Net income from continuing operations		$	2,154	$	2,050	$	1,618
Net (income) loss attributable to noncontrolling interests		(70)		(57)		(46)
Net income from continuing operations attributable to GE HealthCare		2,084		1,993		1,572
Deemed preferred stock dividend of redeemable noncontrolling interest		—		—		(183)
Net income from continuing operations attributable to GE HealthCare common stockholders		2,084		1,993		1,389
Income (loss) from discontinued operations, net of taxes		—		—		(4)
Net income attributable to GE HealthCare common stockholders		$	2,084	$	1,993	$	1,385
Denominator:
Basic weighted-average shares outstanding		456		456		455
Dilutive effect of common stock equivalents		1		2		3
Diluted weighted-average shares outstanding		458		459		458
Basic Earnings Per Share:
Continuing operations		$	4.56	$	4.37	$	3.06
Discontinued operations		—		—		(0.01)
Attributable to GE HealthCare common stockholders		4.56		4.37		3.05
Diluted Earnings Per Share:
Continuing operations		$	4.55	$	4.34	$	3.04
Discontinued operations		—		—		(0.01)
Attributable to GE HealthCare common stockholders		4.55		4.34		3.03
Antidilutive securities(1)		3		3		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SHARE-BASED COMPENSATION - Summary of RSU and PSU Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
RSUs
Shares
Outstanding at beginning of period (in shares)	2,860
Granted (in shares)	1,478
Vested (in shares)	(1,484)
Forfeited (in shares)	(313)
Expired (in shares)	0
Outstanding at end of period (in shares)	2,542	2,860
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share)	$ 78
Granted (in dollars per share)	83	$ 89	$ 73
Vested (in dollars per share)	75
Forfeited (in dollars per share)	81
Expired (in dollars per share)	0
Outstanding at end of period (in dollars per share)	$ 82	$ 78
RSU and PSU, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding	2 years
RSU and PSU, intrinsic value
Intrinsic value, outstanding	$ 208
PSUs
Shares
Outstanding at beginning of period (in shares)	778
Granted (in shares)	492
Vested (in shares)	(72)
Forfeited (in shares)	(122)
Expired (in shares)	0
Outstanding at end of period (in shares)	1,076	778
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share)	$ 91
Granted (in dollars per share)	85	$ 96	$ 85
Vested (in dollars per share)	70
Forfeited (in dollars per share)	89
Expired (in dollars per share)	0
Outstanding at end of period (in dollars per share)	$ 88	$ 91
RSU and PSU, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding	2 years
RSU and PSU, intrinsic value
Intrinsic value, outstanding	$ 88

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Gross Notional	$ 15,986	$ 11,930
Fair Value – Assets	256	145
Fair Value – Liabilities	207	155
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,508	1,210
Fair Value – Assets	52	43
Fair Value – Liabilities	23	11
Designated as hedging instrument \| Cash flow hedges \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	1,508	1,210
Fair Value – Assets	52	43
Fair Value – Liabilities	23	11
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	6,697	3,726
Fair Value – Assets	101	45
Fair Value – Liabilities	172	64
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	4,115	1,995
Fair Value – Assets	51	15
Fair Value – Liabilities	135	46
Designated as hedging instrument \| Net investment hedges \| Foreign currency forward and options contracts
Derivative [Line Items]
Gross Notional	2,581	1,731
Fair Value – Assets	50	30
Fair Value – Liabilities	37	18
Designated as hedging instrument \| Fair value hedges
Derivative [Line Items]
Gross Notional	2,700	2,700
Fair Value – Assets	28	0
Fair Value – Liabilities	0	51
Designated as hedging instrument \| Fair value hedges \| Interest rate swaps
Derivative [Line Items]
Gross Notional	2,700	2,700
Fair Value – Assets	28	0
Fair Value – Liabilities	0	51
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	5,081	4,294
Fair Value – Assets	76	57
Fair Value – Liabilities	12	29
Not designated as hedging instrument \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	4,761	3,925
Fair Value – Assets	20	11
Fair Value – Liabilities	7	29
Not designated as hedging instrument \| Other derivatives
Derivative [Line Items]
Gross Notional	320	370
Fair Value – Assets	56	47
Fair Value – Liabilities	$ 5	$ 0

LEASES - Schedule of Maturity of Finance Leases (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
2026	$ 86
2027	56
2028	39
2029	26
2030	16
Thereafter	19
Total	$ 243	$ 242

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Noncurrent Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid pension asset	$ 742	$ 657
Equity method and other investments	351	373
Financing receivables – net	190	183
Derivative instruments	88	22
Long-term receivables – net	190	142
Inventories	121	139
Contract and other deferred assets	211	208
Capitalized cloud computing arrangement implementation costs	200	84
Other	112	142
All other non-current assets	$ 2,205	$ 1,950

Consolidated Statements of Changes in Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.14	$ 0.125	$ 0.12

REVENUE RECOGNITION - Schedule of Remaining Performance Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	$ 15,729	$ 14,491
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	5,001	4,755
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	$ 10,728	$ 9,737

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses and deferred costs	$ 228	$ 188
Financing receivables – net	95	90
Derivative instruments	169	123
Tax receivables	154	115
Other	81	16
All other current assets	$ 726	$ 532

BORROWINGS

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

BORROWINGS

The Company’s borrowings include the senior unsecured notes and credit agreements detailed below.

Senior Unsecured Notes

In the second quarter of 2025, the Company issued $650 million of 4.800% senior unsecured notes due in 2031 and $850 million of 5.500% senior unsecured notes due in 2035. In the fourth quarter of 2025, the Company issued $600 million of 4.150% senior unsecured notes due in 2028 and $650 million of 4.950% senior unsecured notes due in 2035. The senior unsecured notes issued in the fourth quarter of 2025 are subject to a special mandatory redemption at a price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest thereon, if the acquisition of Intelerad is not consummated on or prior to November 20, 2026, or if prior to such date the agreement to acquire Intelerad is terminated. Otherwise, the non-economic terms of the newly issued senior unsecured notes are substantially similar to the terms of the Company’s existing senior unsecured notes. For additional information on the proposed Intelerad acquisition, see Note 8, “Acquisitions, Goodwill, and Other Intangible Assets.”

In the fourth quarter of 2025, the Company repaid $1,500 million aggregate principal amount of 5.600% senior unsecured notes due November 2025. As of December 31, 2025, the Company’s borrowings include $9,500 million aggregate principal amount of senior unsecured notes in nine series with maturity dates ranging from 2027 through 2052 (collectively, the “Notes”).

Interest payments on the Notes are due semi-annually until maturity. In the event of a change in control and a related downgrade of the ratings of the Notes below investment grade, the indenture governing the Notes requires that the Company make an offer to each holder of the Notes to repurchase all or any part of that holder’s notes at a repurchase price equal to 101% of the aggregate principal amount of the Notes repurchased, plus any accrued and unpaid interest. The indenture also includes a limitation on liens incurred by the Company and its wholly owned U.S. subsidiaries. The indenture does not restrict the Company or its subsidiaries from incurring indebtedness, nor does it contain any financial covenants. All covenants are subject to a number of exceptions, limitations, and qualifications. Refer to the table below for further information about the Notes.

Credit Facilities

In the first quarter of 2025, the Company terminated its existing five-year and 364-day senior unsecured revolving credit facilities. These were replaced with new five-year and 364-day senior unsecured revolving credit facilities in aggregate committed amounts of $3,000 million and $500 million, respectively. The terms of these new facilities are substantially similar to those of the terminated facilities. In the fourth quarter of 2025, the Company entered into a delayed draw term loan facility in an aggregate committed amount of $750 million.

The Company has credit agreements providing for:

•a five-year senior unsecured revolving credit facility in an aggregate committed amount of $3,000 million, maturing on March 27, 2030;

•a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $500 million, maturing on March 26, 2026;

•a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million, maturing on January 2, 2026 (the “Term Loan Facility”), and

•a three-year senior unsecured delayed draw term loan credit facility in an aggregate principal amount of $750 million, maturing on the third anniversary of the date on which the term loan is made to the Company (the “Delayed Draw Term Loan Facility” and, together with the five-year revolving credit facility, the 364-day revolving credit facility, and the Term Loan Facility, the “Credit Facilities”).

There were no outstanding amounts under the Delayed Draw Term Loan Facility, the five-year revolving credit facility, or the 364-day revolving credit facility, and there was $500 million and $750 million outstanding on the Term Loan Facility as of December 31, 2025 and 2024, respectively. In the first quarter of 2025, we repaid $250 million of the Term Loan Facility. The Company expects to use borrowings under the Delayed Draw Term Facility to partially fund the expected acquisition of Intelerad.

The Company pays a facility fee to each lender, which accrues at a rate equal to an applicable margin specified in the revolving credit facility agreements on the daily commitments of the lenders. The borrowings under each of the Credit Facilities will bear interest at variable interest rates equal to: (1) the alternate base rate or (2) the Secured Overnight Financing Rate, in each case plus an applicable margin specified in the respective credit agreement. The Credit Facilities contain affirmative and negative covenants customary to financings of this type that limit, among other things, the Company’s ability to incur additional liens and to enter into certain fundamental change transactions and the incurrence of indebtedness by the Company’s subsidiaries. In addition, the Credit Facilities contain a financial covenant that requires the Company to not exceed a maximum consolidated net leverage ratio. The Company was in compliance with the financial covenant at each reporting period during 2025. The revolving credit facilities will be used for general corporate purposes.


Borrowings Composition	As of
	December 31, 2025		December 31, 2024
5.600% senior notes due November 15, 2025	$	—	$	1,500
5.650% senior notes due November 15, 2027	1,750		1,750
4.150% senior notes due December 15, 2028	600		—
4.800% senior notes due August 14, 2029	1,000		1,000
5.857% senior notes due March 15, 2030	1,250		1,250
4.800% senior notes due January 15, 2031	650		—
5.905% senior notes due November 22, 2032	1,750		1,750
5.500% senior notes due June 15, 2035	850		—
4.950% senior notes due December 15, 2035	650		—
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	500		750
Other	24		36
Total principal debt issued	10,024		9,036
Less: Unamortized debt issuance costs and discounts	49		33
Add: Cumulative basis adjustment for fair value hedges	27		(51)
Total borrowings	10,003		8,951
Less: Short-term borrowings(1)	508		1,502
Long-term borrowings	$	9,495	$	7,449

Interest expense associated with long-term debt was $540 million, $580 million, and $616 million for the years ended December 31, 2025, 2024, and 2023, respectively, and is included in Interest and other financial charges – net in the Consolidated Statements of Income.

Scheduled maturities of borrowings, excluding amortization of discounts and debt issuance costs, are as follows.



2026		2027		2028		2029		2030		Thereafter		Total
$	508	$	1,767	$	600	$	1,000	$	1,250	$	4,900	$	10,024

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of December 31, 2025 and 2024, the Company had bank guarantees and surety bonds of approximately $1,149 million and $784 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $22 million and $25 million of guarantees as of December 31, 2025 and 2024, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $3 million as of both December 31, 2025 and 2024 related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 2,084	$ 1,993	$ 1,568
Net income (loss) attributable to noncontrolling interests	70	57	46
Net income	2,154	2,050	1,614
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	418	(271)	74
Pension and Other Postretirement Plans – net of taxes	(422)	(456)	(897)
Cash flow hedges – net of taxes	(16)	36	(27)
Other comprehensive income (loss)	(19)	(691)	(850)
Comprehensive income (loss)	2,134	1,359	764
Less: Comprehensive income (loss) attributable to noncontrolling interests	60	53	9
Comprehensive income attributable to GE HealthCare	$ 2,074	$ 1,306	$ 755

SEGMENT AND GEOGRAPHICAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information


Total Revenues by Segment	For the years ended December 31
		2025		2024		2023
Total Imaging		$	9,245	$	8,855	$	8,944
AVS:
Procedural Guidance		2,752		2,711		2,666
Specialized Ultrasound		2,601		2,420		2,428
Total AVS		5,354		5,131		5,094
PCS:
Monitoring Solutions		2,256		2,194		2,283
Life Support Solutions		831		931		859
Total PCS		3,086		3,125		3,142
Total PDx		2,900		2,508		2,306
Other(1)		40		52		66
Total revenues		$	20,625	$	19,672	$	19,552


Significant Expenses by Segment	For the years ended December 31
		2025		2024		2023
Imaging:
Cost of sales		$	6,099	$	5,623	$	5,901
Other segment items(1)		2,255		2,270		2,222
Total Imaging		$	8,353	$	7,893	$	8,123
AVS:
Cost of sales		$	2,629	$	2,485	$	2,485
Other segment items(1)		1,550		1,528		1,485
Total AVS		$	4,178	$	4,014	$	3,970
PCS:
Cost of sales		$	2,028	$	1,930	$	1,890
Other segment items(1)		849		848		869
Total PCS		$	2,877	$	2,778	$	2,759
PDx:
Cost of sales		$	1,450	$	1,236	$	1,192
Other segment items(1)		579		490		497
Total PDx		$	2,028	$	1,725	$	1,689

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.


Segment EBIT	For the years ended December 31
		2025		2024		2023
Segment EBIT
Imaging		$	891	$	962	$	821
AVS		1,175		1,118		1,124
PCS		209		347		383
PDx		872		783		617
Other(1)		7		2		11
		3,155		3,211		2,956
Restructuring costs		(120)		(120)		(54)
Acquisition and disposition-related benefits (charges)		(39)		(3)		15
Gain (loss) on business and asset dispositions		5		—		—
Spin-Off and separation costs		(38)		(251)		(270)
Amortization of acquisition-related intangible assets		(156)		(137)		(127)
Investment revaluation gain (loss)		112		(22)		1
Interest and other financial charges – net		(440)		(504)		(542)
Non-operating benefit income (costs)		288		406		382
Income before income taxes		$	2,768	$	2,581	$	2,361

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.


Depreciation and Amortization by Segment	For the years ended December 31
		2025		2024		2023

Imaging		$	227	$	249	$	274
AVS		70		78		90
PCS		53		55		69
PDx		66		55		45

Schedule of Revenues by Geographic Region

Revenues are classified according to the country in which products and services are sold.


Total Revenues by Country	For the years ended December 31
	2025		2024		2023
United States	$	9,168	$	8,617	$	8,228
China	2,031		2,135		2,560
All other countries	9,427		8,919		8,764
Total revenues	$	20,625	$	19,672	$	19,552

Schedule of Long-Lived Assets by Geographic Areas

Long-lived assets represent Property, plant, and equipment – net and are classified according to the country where the asset is located.


Long-Lived Assets – Net by Country	As of
	December 31, 2025		December 31, 2024
United States	$	962	$	908
China	439		392
Norway	368		296
Japan	296		62
All other countries	1,027		893
Total long-lived assets – net	$	3,092	$	2,550

RECEIVABLES

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

RECEIVABLES


Current Receivables	As of
	December 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,719	$	3,382
Non-income based tax receivables	159		155
Other sundry receivables	180		133
Current sundry receivables	339		287
Allowance for credit losses	(103)		(103)
Total current receivables – net	$	3,955	$	3,566

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to Current customer receivables. Balances related to chargebacks were $148 million and $153 million as of December 31, 2025 and 2024, respectively.

Activity in the allowance for credit losses related to current receivables consisted of the following:


	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	103	$	98	$	91
Additions charged to costs and expenses	10		20		16
Write-offs	(15)		(12)		(11)
Foreign currency exchange and other	4		(2)		2
Balance at end of period	$	103	$	103	$	98


Long-Term Receivables	As of
	December 31, 2025		December 31, 2024
Long-term customer receivables	$	73	$	59
Non-income based tax receivables	24		20
Other sundry receivables	100		68
Long-term sundry receivables	124		88

Allowance for credit losses	(7)		(5)
Total long-term receivables – net	$	190	$	142

Long-term receivables are recognized within All other non-current assets in the Consolidated Statements of Financial Position.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

PROPOSED ACQUISITION.

On November 20, 2025, we announced an agreement to acquire Intelerad for a purchase price of $2,300 million to be paid in cash. The proceeds of senior unsecured notes issued in the fourth quarter of 2025, together with borrowings under a new delayed draw term loan facility and cash on hand, are expected to be used to fund the purchase price of the acquisition. See Note 9, “Borrowings” for additional information on the borrowings. Intelerad is a leading medical imaging software and digital enterprise workflow solutions company with a significant presence in outpatient ambulatory care settings. Its cloud-first products are designed for radiology and cardiology and extend across both inpatient and outpatient care settings. Intelerad’s outpatient footprint complements GE HealthCare’s footprint in hospital-based imaging. Together, these combined capabilities are expected to create a more comprehensive, cloud-first and AI-enabled imaging offering spanning diverse care settings—from large academic medical centers to rapidly expanding ambulatory networks. The transaction is expected to close in the first half of 2026, subject to customary closing conditions, including regulatory approvals.

ACQUISITIONS.

icometrix

On November 7, 2025, the Company acquired 100% of the stock of icometrix NV (“icometrix”) for approximately $98 million of upfront payment, net of cash acquired and potential earn-out payments up to $35 million based on sales targets over two years. icometrix is focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer’s disease. Through this acquisition, we expect to integrate the icometrix platform with our MRI systems. icometrix is included in the Company’s Imaging segment.

This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $74 million, intangible assets of $34 million, and deferred tax liabilities of $9 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes.

Nihon Medi-Physics

On March 31, 2025, the Company acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (“NMP”) from joint venture partner Sumitomo Chemical for net cash consideration of $271 million. NMP is a leading pharmaceutical manufacturer in Japan, focused on radiopharmaceuticals, which are used to enable clinical images across neurology, cardiology, and oncology procedures, as well as nonclinical and clinical development of radiotracers and theranostics research. Their product portfolio includes several GE HealthCare radiopharmaceuticals. NMP is included in the Company’s PDx segment.

On March 31, 2025, the fair value of the Company’s existing 50% interest in NMP was determined to be $301 million based on the cash consideration exchanged for acquiring the remaining 50% equity interest. The carrying value of our 50% interest was $204 million. The Company recognized a net gain of $97 million resulting from this remeasurement to fair value. This gain included the reclassification of certain amounts related to the Company’s 50% interest out of AOCI including foreign currency translation gains of $63 million and losses related to a defined benefit pension plan of $8 million. The net gain from this remeasurement was recorded in Other (income) expense – net in the Company’s Consolidated Statements of Income for the year ended December 31, 2025.

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	271
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	577

The preliminary fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Preliminary allocation
Receivables	$	53
Inventories	9
All other current assets(1)	35
Property, plant, and equipment	240
Goodwill	220
Other intangible assets	235
All other non-current assets	39
Deferred income taxes	(81)
All other non-current liabilities	(145)
Other(2)	(28)
Total net assets post acquisition	$	577

(1) All other current assets includes $35 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

The allocation of purchase price of NMP to the tangible and intangible assets acquired and liabilities assumed, as reflected in the table above, is based on the Company’s preliminary allocations of their fair values. As of December 31, 2025, measurement period adjustments included changes to the purchase price allocation, resulting in a net increase of approximately $4 million to goodwill. The measurement period adjustments resulted primarily from adjustments to acquired intangibles and decommissioning liabilities based on facts and circumstances that existed as of the acquisition date. While all amounts remain subject to adjustments, the areas potentially subject to the most significant adjustments are decommissioning liabilities and deferred income taxes. The Company’s management believes the fair values recognized for the assets acquired and the liabilities assumed are based on reasonable estimates and assumptions.

Property, plant, and equipment is mostly comprised of land, buildings, equipment (including machinery, furniture, and fixtures) and construction in process. The fair value of property, plant, and equipment was determined using a market participant approach.

Other intangibles relate to $235 million of definite-lived intangible assets. Definite-lived intangible assets consist primarily of developed product market authorization rights and customer relationships. The acquired definite-lived intangibles are being amortized over a weighted-average estimated useful life of approximately 13 years. The estimated fair value of intangibles was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of cash flows an asset would generate over its useful life.

The goodwill associated with NMP, recorded within the PDx segment, is non-deductible for tax purposes and is attributed to expected synergies with NMP’s existing assets and workforce that are expected to allow the Company greater access and growth in the Japan market.

Included in All other non-current liabilities are asset retirement obligations and decommissioning liabilities of $124 million, which were assumed in the transaction.

NMP has a defined benefit pension plan which has pension assets of $71 million and pension liabilities of $33 million, a net asset of $38 million, which we acquired in the transaction and is included in All other non-current assets.

Deferred income tax liabilities include the expected U.S. federal, state, and foreign tax consequences associated with temporary differences between the preliminary fair values of the assets acquired and liabilities assumed and the respective tax basis.

If the acquisition of NMP had taken place as of the beginning of 2024, consolidated revenues and earnings would not have been significantly different than reported amounts.

MIM Software

On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $259 million, net of cash acquired of $11 million, and potential contingent payments valued at $13 million pertaining to achievement of certain milestones, for a total purchase price of $283 million. The acquisition included up to $23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The purchase price allocation, which was finalized in the first quarter of 2025 without material adjustments, resulted in goodwill of $189 million, customer-related intangible assets of $52 million, developed technology intangible assets of $48 million, net deferred tax liabilities of $13 million, and other net assets of $7 million. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and AI solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide.

If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts.

GOODWILL.


	Imaging		AVS		PCS		PDx		Total
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936
Reallocation	(1,031)		1,031		—		—		—
Acquisitions(1)	194		42		—		—		236
Foreign currency exchange and other	(13)		(19)		(3)		(1)		(36)
Balance at December 31, 2024	3,581		4,987		2,035		2,533		13,136
Acquisitions(2)	81		—		—		220		301
Foreign currency exchange and other	20		33		6		(8)		51
Balance at December 31, 2025	$	3,682	$	5,020	$	2,041	$	2,745	$	13,489

(1) Includes the purchase of MIM Software recorded within our Imaging segment, as described above, and Intelligent Ultrasound Group PLC in our AVS segment.

The Company performs an impairment test of goodwill annually in the fourth quarter using either the quantitative or qualitative approach. In 2025 the impairment testing was conducted using the qualitative approach. Based on the results of the testing conducted, we concluded that no goodwill impairments existed for the years ended December 31, 2025, 2024 and 2023.

OTHER INTANGIBLE ASSETS.



	As of December 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	279	$	(43)	$	236	$	112	$	(24)	$	88
Patents and technology	2,698		(2,128)		570		2,593		(1,987)		606
Capitalized software	1,703		(1,470)		233		1,743		(1,437)		306
Trademarks and other	47		(31)		15		33		(29)		4
Total definite-lived assets	4,727		(3,672)		1,055		4,481		(3,477)		1,004
Indefinite-lived assets(1)	75		—		75		74		—		74
Total other intangible assets	$	4,802	$	(3,672)	$	1,130	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

The Company performs an impairment test of IPR&D in the third quarter. In 2025, 2024, and 2023, the Company performed qualitative testing for all IPR&D assets and quantitative testing when warranted. Based on the results of this testing, there were no material impairments of indefinite-lived intangible assets recognized in the years ended December 31, 2025, 2024, or 2023.

During the year ended December 31, 2025, we recorded additions to acquired intangible assets subject to amortization of $280 million, primarily related to patents and technology and customer-related intangibles, with a weighted-average useful life of ten years.

Amortization expense was $291 million, $312 million, and $362 million for the years ended December 31, 2025, 2024, and 2023, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2025, 2024, or 2023.

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2025 over the next five calendar years is as follows.


	2026		2027		2028		2029		2030
Estimated annual pre-tax amortization	$	259	$	178	$	127	$	108	$	93

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

PROPOSED ACQUISITION.

ACQUISITIONS.

icometrix

Nihon Medi-Physics

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	271
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	577

The preliminary fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Preliminary allocation
Receivables	$	53
Inventories	9
All other current assets(1)	35
Property, plant, and equipment	240
Goodwill	220
Other intangible assets	235
All other non-current assets	39
Deferred income taxes	(81)
All other non-current liabilities	(145)
Other(2)	(28)
Total net assets post acquisition	$	577

(1) All other current assets includes $35 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

Included in All other non-current liabilities are asset retirement obligations and decommissioning liabilities of $124 million, which were assumed in the transaction.

If the acquisition of NMP had taken place as of the beginning of 2024, consolidated revenues and earnings would not have been significantly different than reported amounts.

MIM Software

If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts.

GOODWILL.


	Imaging		AVS		PCS		PDx		Total
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936
Reallocation	(1,031)		1,031		—		—		—
Acquisitions(1)	194		42		—		—		236
Foreign currency exchange and other	(13)		(19)		(3)		(1)		(36)
Balance at December 31, 2024	3,581		4,987		2,035		2,533		13,136
Acquisitions(2)	81		—		—		220		301
Foreign currency exchange and other	20		33		6		(8)		51
Balance at December 31, 2025	$	3,682	$	5,020	$	2,041	$	2,745	$	13,489

(1) Includes the purchase of MIM Software recorded within our Imaging segment, as described above, and Intelligent Ultrasound Group PLC in our AVS segment.

OTHER INTANGIBLE ASSETS.



	As of December 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	279	$	(43)	$	236	$	112	$	(24)	$	88
Patents and technology	2,698		(2,128)		570		2,593		(1,987)		606
Capitalized software	1,703		(1,470)		233		1,743		(1,437)		306
Trademarks and other	47		(31)		15		33		(29)		4
Total definite-lived assets	4,727		(3,672)		1,055		4,481		(3,477)		1,004
Indefinite-lived assets(1)	75		—		75		74		—		74
Total other intangible assets	$	4,802	$	(3,672)	$	1,130	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2025 over the next five calendar years is as follows.


	2026		2027		2028		2029		2030
Estimated annual pre-tax amortization	$	259	$	178	$	127	$	108	$	93

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Dec. 31, 2025	Jun. 30, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Principal debt issued	$ 10,024		$ 9,036
Less: Unamortized debt issuance costs and discounts	49		33
Add: Cumulative basis adjustment for fair value hedges	27		(51)
Total borrowings	10,003		8,951
Less: Short-term borrowings	508		1,502
Long-term borrowings	9,495		7,449
Long-term borrowings, current	$ 502		1,500
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 0		1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750		1,750
Senior notes \| 4.150% senior notes due December 15, 2028
Debt Instrument [Line Items]
Stated interest rate	4.15%
Principal debt issued	$ 600		0
Senior notes \| 4.800% senior notes due August 14, 2029
Debt Instrument [Line Items]
Stated interest rate	4.80%
Principal debt issued	$ 1,000		1,000
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250		1,250
Senior notes \| 4.800% senior notes due January 15, 2031
Debt Instrument [Line Items]
Stated interest rate	4.80%	4.80%
Principal debt issued	$ 650		0
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750		1,750
Senior notes \| 5.500% senior notes due June 15, 2035
Debt Instrument [Line Items]
Stated interest rate	5.50%	5.50%
Principal debt issued	$ 850		0
Senior notes \| 4.950% senior notes due December 15, 2035
Debt Instrument [Line Items]
Stated interest rate	4.95%
Principal debt issued	$ 650		0
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000		1,000
Line of credit \| Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Principal debt issued	500		750
Other
Debt Instrument [Line Items]
Principal debt issued	$ 24		$ 36

SHARE-BASED COMPENSATION

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

We grant stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock.

Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted. The options become exercisable over the vesting period, typically becoming fully vested in three to three and a half years, and expire ten years from the grant date if not exercised. We value stock options using a Black-Scholes option pricing model.

RSUs provide an employee the right to shares of GE HealthCare stock when the restrictions lapse over the vesting period of three to three and a half years. Upon vesting, each RSU is converted into one share of GE HealthCare common stock. We value RSUs using the market price on the grant date.

PSUs provide an employee with the right to receive shares of GE HealthCare stock based upon achievement of certain performance metrics. PSUs are subject to an employee service period of three years. PSUs may include a relative total shareholder return (“TSR”) modifier to determine the number of shares earned at the end of the performance period. We engage third-party valuation specialists to assist with the fair value estimate of the PSUs that include the TSR modifier using a Monte Carlo simulation to model the probability of possible outcomes.

The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the years ended December 31, 2025, 2024, and 2023, and the related weighted average stock option valuation assumptions used in the Black-Scholes model.


Weighted Average Grant Date Fair Value	For the years ended December 31
(In dollars)	2025		2024		2023
Stock options	$	30	$	32	$	25
RSUs	83		89		73
PSUs	85		96		85


Key Assumptions in the Black-Scholes Valuation for Stock Options	For the years ended December 31
	2025		2024		2023
Risk-free rate	4.0	%	4.1	%	3.6	%
Dividend yield	0.16	%	0.13	%	0.01	%
Expected volatility	26.7	%	26.2	%	26.2	%
Expected term (in years)	6.2		6.2		6.2

For awards granted in 2023, 2024, and 2025, the expected volatility was derived from a peer group’s blended historical and implied volatility as GE HealthCare does not have sufficient historical volatility based on the expected term of the underlying options. The expected term of the stock options was determined using the simplified method. The risk-free interest rate was determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield assumption is based on the expected annualized dividend payment at the date of grant.


Stock Option Activity
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 1, 2025	4,246	$	82
Granted	666	85
Exercised/Vested	(606)	61
Forfeited	(208)	79
Expired	(339)	126
Outstanding as of December 31, 2025	3,760	$	82	6.0	$	28
Exercisable as of December 31, 2025	2,219	$	83	4.6	$	20
Expected to vest	3,634	$	82	5.9	$	28


RSU and PSU Activity
	RSUs						PSUs
	Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)
Outstanding as of January 1, 2025	2,860	$	78				778	$	91
Granted	1,478	83					492	85
Exercised/Vested	(1,484)	75					(72)	70
Forfeited	(313)	81					(122)	89
Expired	—	—					—	—
Outstanding as of December 31, 2025	2,542	$	82	2.0	$	208	1,076	$	88	2.0	$	88

Share-based compensation expense is recognized within Cost of products, Cost of services, SG&A, or R&D, as appropriate, in the Consolidated Statements of Income.


Share-based Compensation Expense	For the years ended December 31
	2025		2024		2023



Share-based compensation expense (pre-tax)	$	130	$	125	$	114
Income tax benefits	(24)		(23)		(23)
Share-based compensation expense (after-tax)	$	106	$	102	$	91


Other Share-based Compensation Data	For the years ended December 31
	2025		2024		2023

Cash received from stock options exercised	$	37	$	33	$	34
Intrinsic value of stock options exercised and RSUs/PSUs vested	141		251		106

Unrecognized compensation expense was $159 million as of December 31, 2025 and is expected to be recognized over a weighted-average period of approximately 2.0 years.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Supply Chain Finance Programs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Supplier Finance Program, Obligation [Roll Forward]
Confirmed obligations outstanding at beginning of period	$ 394	$ 365
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Invoices confirmed during the year	$ 818	$ 886
Confirmed invoices paid during the year	(853)	(855)
Foreign exchange and other	1	(2)
Confirmed obligations outstanding at end of period	$ 360	$ 394
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,002	$ 921
Work in process	95	92
Finished goods	1,137	926
Inventories	$ 2,234	$ 1,939

POSTRETIREMENT BENEFIT PLANS - Schedule of Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Pension Plans
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)			$ 305
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Cost (income) of postretirement benefit plans	$ (218)	$ (250)	(224)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	0	0	(1,791)
Plan amendments	0	0	53
Net loss (gain) – current year	294	348	695
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	0	0	(108)
Amortization of net (loss) gain	65	68	121
Amortization of prior service (cost) credit	11	(8)	(4)
Total changes in other comprehensive loss (income)	370	408	(1,034)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	152	158	(1,258)
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Cost (income) of postretirement benefit plans	37	(20)	(22)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	0	0	542
Plan amendments	0	(1)	0
Net loss (gain) – current year	16	98	198
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	1	0	0
Amortization of net (loss) gain	(21)	(14)	(6)
Amortization of prior service (cost) credit	2	2	3
Total changes in other comprehensive loss (income)	(2)	86	737
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	35	66	715
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Cost (income) of postretirement benefit plans	(86)	(87)	(86)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	0	0	(1,216)
Plan amendments	0	0	0
Net loss (gain) – current year	(45)	(48)	50
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	0	0	0
Amortization of net (loss) gain	64	61	64
Amortization of prior service (cost) credit	80	87	87
Total changes in other comprehensive loss (income)	98	100	(1,015)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$ 12	$ 13	$ (1,101)

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Equity Method Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Equity method investment balance	$ 28	$ 163
Equity method income (loss)	$ 3	8	$ 11
Nihon Medi-Physics Co., Ltd
Schedule of Equity Method Investments [Line Items]
Ownership Percentage	50.00%
Equity method investment balance	$ 0	139
Equity method income (loss)	2	10	10
Other
Schedule of Equity Method Investments [Line Items]
Equity method investment balance	28	24
Equity method income (loss)	$ 1	$ (2)	$ 1

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References + Details

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net financing income and investment income (loss)	$ 41	$ (1)	$ 26
Equity method income (loss)	3	8	11
Change in fair value of assumed obligations	(30)	(32)	(32)
Gain on remeasurement of NMP equity method investment	97	0	0
Other items, net	46	80	81
Total other income (expense) – net	$ 157	$ 55	$ 86

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References + Details

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Capitalized contract costs	$ 253	$ 217
Capitalized contract period	2 years
Contract liabilities, revenue recognized	$ 1,588	$ 1,585
Product \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	2 years
Service \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	5 years

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Schedule of Changes in AOCI

Changes in AOCI by component were as follows.


	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclassifications – net of taxes(2) of $22, $186, and $1	74		(601)		(5)		(532)
Reclassifications from AOCI – net of taxes(3) of $—, $97, and $6	—		(296)		(22)		(318)
Other comprehensive income (loss)	74		(897)		(27)		(850)
Spin-Off related adjustments – net of taxes(4) of $— $(509), and $—	28		1,972		—		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(37)		—		—		(37)
December 31, 2023	(1,706)		1,033		(18)		(691)
Other comprehensive income (loss) before reclassifications – net of taxes of $(19), $93, and $(11)	(271)		(306)		33		(545)
Reclassifications from AOCI – net of taxes(3) of $—, $44, and $(1)	—		(150)		3		(147)
Other comprehensive income (loss)	(271)		(456)		36		(691)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(4)		—		—		(4)
December 31, 2024	(1,973)		576		18		(1,379)
Other comprehensive income (loss) before reclassifications – net of taxes of $60, $74, and $5	354		(259)		5		101
Reclassifications from AOCI – net of taxes(3)(5) of $—, $50, and $2	63		(163)		(21)		(120)
Other comprehensive income (loss)	418		(422)		(16)		(19)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(7)		(3)		—		(10)
December 31, 2025	$	(1,548)	$	158	$	3	$	(1,388)

(1) The amount of CTA recognized in Other comprehensive income (loss) (“OCI”) included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”

(2) Includes pre-tax impact to Pension and Other Postretirement Plans of $(305) million for the pension plan amendment and related remeasurement of plan assets and benefit obligations. Refer to Note 10, “Postretirement Benefit Plans” for further information.

(3) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Consolidated Statements of Income.

(4) Refer to Note 10, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from the GE pension and other postretirement plans in connection with the Spin-Off.

(5) Includes net of tax impact of $63 million of gains to Currency translation adjustments and $8 million of losses to Pension and Other Postretirement Plans related to the derecognition of the prior NMP equity method investment. Refer to Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

FINANCING RECEIVABLES (Tables)

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

Schedule of Receivables


Current Receivables	As of
	December 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,719	$	3,382
Non-income based tax receivables	159		155
Other sundry receivables	180		133
Current sundry receivables	339		287
Allowance for credit losses	(103)		(103)
Total current receivables – net	$	3,955	$	3,566


Long-Term Receivables	As of
	December 31, 2025		December 31, 2024
Long-term customer receivables	$	73	$	59
Non-income based tax receivables	24		20
Other sundry receivables	100		68
Long-term sundry receivables	124		88

Allowance for credit losses	(7)		(5)
Total long-term receivables – net	$	190	$	142



	As of
	December 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	21	$	23
Investment in finance leases, net of deferred income	76		69
Allowance for credit losses	(2)		(2)
Current financing receivables – net	$	95	$	90

Loans receivable, at amortized cost	$	44	$	35
Investment in finance leases, net of deferred income	149		152
Allowance for credit losses	(3)		(4)
Non-current financing receivables – net	$	190	$	183

INCOME TAXES - Reconciliation of Federal Statutory Income Tax Rate to Actual Income Tax Rate - 2025 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Amount
Income from continuing operations before income taxes	$ 2,768	$ 2,581	$ 2,361
Tax expected at 21%	581	542	496
State and local income taxes, net of federal income tax effect	41	49	24
Foreign tax effects		38	63
Effect of cross-border tax laws
Foreign-derived deduction eligible income	(49)
Net CFC tested income	45
Other	5
Tax credits
R&D tax credits	(28)	(51)	(33)
Foreign tax credits	(81)
Changes in valuation allowances	9	(281)	19
Nontaxable or nondeductible items	22
Changes in unrecognized tax benefits	(24)	170	11
Other adjustments	8	0	(14)
Total	$ 614	$ 531	$ 743
Percent
Tax expected at 21%	21.00%
State and local income taxes, net of federal income tax effect	1.50%
Effect of cross-border tax laws
Foreign-derived deduction eligible income	(1.80%)
Net CFC tested income	1.60%
Other	0.20%
Tax credits
R&D tax credits	(1.00%)
Foreign tax credits	(2.90%)
Changes in valuation allowances	0.30%
Nontaxable or nondeductible items	0.80%
Changes in unrecognized tax benefits	(0.90%)
Other adjustments	0.30%
Effective income tax rate	22.20%	20.60%	31.50%
China
Amount
Foreign tax effects	$ 30
Percent
Foreign tax effects	1.10%
Other foreign jurisdictions
Amount
Foreign tax effects	$ 54
Percent
Foreign tax effects	2.00%

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Contract assets	$ 645	$ 589
Other deferred assets	428	385
Contract and other deferred assets	1,073	974
Non-current contract assets	91	103
Non-current other deferred assets	120	105
Total contract and other deferred assets	$ 1,285	$ 1,183

EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (“EPS”) is Net income attributable to GE HealthCare. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs, and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.


Earnings Per Share	For the years ended December 31
(In millions, except per share amounts)		2025		2024		2023
Numerator:
Net income from continuing operations		$	2,154	$	2,050	$	1,618
Net (income) loss attributable to noncontrolling interests		(70)		(57)		(46)
Net income from continuing operations attributable to GE HealthCare		2,084		1,993		1,572
Deemed preferred stock dividend of redeemable noncontrolling interest		—		—		(183)
Net income from continuing operations attributable to GE HealthCare common stockholders		2,084		1,993		1,389
Income (loss) from discontinued operations, net of taxes		—		—		(4)
Net income attributable to GE HealthCare common stockholders		$	2,084	$	1,993	$	1,385
Denominator:
Basic weighted-average shares outstanding		456		456		455
Dilutive effect of common stock equivalents		1		2		3
Diluted weighted-average shares outstanding		458		459		458
Basic Earnings Per Share:
Continuing operations		$	4.56	$	4.37	$	3.06
Discontinued operations		—		—		(0.01)
Attributable to GE HealthCare common stockholders		4.56		4.37		3.05
Diluted Earnings Per Share:
Continuing operations		$	4.55	$	4.34	$	3.04
Discontinued operations		—		—		(0.01)
Attributable to GE HealthCare common stockholders		4.55		4.34		3.03
Antidilutive securities(1)		3		3		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

BORROWINGS - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Maturities of Long-Term Debt [Abstract]
2026	$ 508
2027	1,767
2028	600
2029	1,000
2030	1,250
Thereafter	4,900
Total	$ 10,024	$ 9,036

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	December 31, 2025		December 31, 2024
Cash and cash equivalents(1)	$	4,492	$	2,874
Short-term restricted cash	20		16
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Financial Position	4,512		2,889
Long-term restricted cash(2)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Cash Flows	$	4,515	$	2,893

(1) The increase in Cash and cash equivalents was primarily due to proceeds from the issuance of senior unsecured notes by the Company in the fourth quarter of 2025. Refer to Note 9, “Borrowings” for further information.

(2) Long-term restricted cash is recognized within All other non-current assets in the Consolidated Statements of Financial Position.

Schedule of Restricted Cash and Cash Equivalents

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	December 31, 2025		December 31, 2024
Cash and cash equivalents(1)	$	4,492	$	2,874
Short-term restricted cash	20		16
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Financial Position	4,512		2,889
Long-term restricted cash(2)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Cash Flows	$	4,515	$	2,893

(2) Long-term restricted cash is recognized within All other non-current assets in the Consolidated Statements of Financial Position.

Schedule of Inventory

INVENTORIES.


	As of
	December 31, 2025		December 31, 2024
Raw materials	$	1,002	$	921
Work in process	95		92
Finished goods	1,137		926
Inventories	$	2,234	$	1,939

Summary of Property, Plant and Equipment

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	December 31, 2025		December 31, 2024
Land and improvements	$	144	$	66
Buildings, structures, and related equipment	2,140		1,943
Machinery and equipment	2,872		2,705
Leasehold improvements and manufacturing plants under construction	574		553
Total property, plant, and equipment, at original cost	5,731		5,267
Accumulated depreciation	(3,049)		(3,080)
Right-of-use operating lease assets, net of amortization(1)	410		364
Property, plant, and equipment – net	$	3,092	$	2,550

(1) See Note 7, “Leases” for further information.

Schedule of Other Current Assets


All Other Current Assets	As of
	December 31, 2025		December 31, 2024
Prepaid expenses and deferred costs	$	228	$	188
Financing receivables – net	95		90
Derivative instruments(1)	169		123
Tax receivables	154		115
Other(2)	81		16
All other current assets	$	726	$	532

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(2) As of December 31, 2025, Other primarily consists of indemnity assets associated with the NMP acquisition and separation agreements with GE. These amounts were not material as of December 31, 2024.

Schedule of Other Noncurrent Assets


All Other Non-Current Assets	As of
	December 31, 2025		December 31, 2024
Prepaid pension asset	$	742	$	657
Equity method and other investments	351		373
Financing receivables – net	190		183
Derivative instruments(1)	88		22
Long-term receivables – net	190		142
Inventories	121		139
Contract and other deferred assets	211		208
Capitalized cloud computing arrangement implementation costs(2)	200		84
Other(3)	112		142
All other non-current assets	$	2,205	$	1,950

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(2) See the supplemental table “Capitalized Cloud Computing Arrangement Implementation Costs” for further information.

(3) Other primarily consists of indemnity assets associated with separation agreements with GE, and tax receivables.

Schedule of Other Current Liabilities


All Other Current Liabilities	As of
	December 31, 2025		December 31, 2024
Sales allowances and related liabilities	$	256	$	242
Income and indirect tax liabilities including uncertain tax positions	324		279
Product warranties	169		168
Accrued logistics and utilities	197		163
Operating lease liabilities	134		115
Derivative instruments(1)	47		90
Interest payable on borrowings	100		92
Environmental and asset retirement obligations	11		17
Other(2)	348		386
All other current liabilities	$	1,587	$	1,552

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(2) Other primarily consists of miscellaneous accrued costs, dividends payable, and contingent consideration liabilities.

Schedule of Other Noncurrent Liabilities


All Other Non-Current Liabilities	As of
	December 31, 2025		December 31, 2024
Contract liabilities	$	803	$	686
Operating lease liabilities	284		270
Environmental and asset retirement obligations(1)	413		291
Income and indirect tax liabilities including uncertain tax positions	156		237
Derivative instruments(2)	160		64
Finance lease obligations	42		40
Sales allowances and related liabilities	23		23
Other(3)	178		184
All other non-current liabilities	$	2,061	$	1,796

(1) Refer to Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on the increase in Environmental and asset retirement obligations.

(2) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(3) Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

Schedule of Capitalized Cloud Computing Arrangement Implementation Costs


	As of
	December 31, 2025		December 31, 2024
Capitalized implementation costs	$	249	$	114
Accumulated amortization	(49)		(30)
Total Capitalized cloud computing arrangement implementation costs, net	$	200	$	84

Schedule of Equity Method Investments


		Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage	2025		2024		2025		2024		2023
Nihon Medi-Physics Co., Ltd.(1)	50%	$	—	$	139	$	2	$	10	$	10
Other		28		24		1		(2)		1
Total		$	28	$	163	$	3	$	8	$	11

(1) In the first quarter of 2025, the Company acquired its remaining interest in NMP. Refer to Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

Schedule of Supply Chain Finance Programs

A rollforward of our outstanding obligations confirmed and paid under the supply chain finance programs, which are included within Accounts payable in the Consolidated Statements of Financial Position, is presented below.


	For the years ended December 31
	2025		2024
Confirmed obligations outstanding at beginning of period	$	394	$	365
Invoices confirmed during the year	818		886
Confirmed invoices paid during the year	(853)		(855)
Foreign exchange and other	1		(2)
Confirmed obligations outstanding at end of period	$	360	$	394

Schedule of Redeemable Noncontrolling Interest

Activity attributable to redeemable noncontrolling interests is presented below.


	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	188	$	165	$	230
Net income attributable to redeemable noncontrolling interests	66		50		41
Redemption value adjustments(1)	—		—		183
Distributions to redeemable noncontrolling interests and other(2)	(45)		(28)		(289)
Balance at end of period	$	209	$	188	$	165

(1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to Retained earnings in the Consolidated Statements of Financial Position.

(2) In 2023, the redeemable noncontrolling interest holder exercised its option redemption provision and the Company paid a redemption amount of $211 million.

Schedule of Other Income (Expense), Net

OTHER INCOME (EXPENSE) – NET.


	For the years ended December 31
		2025		2024		2023
Net financing income and investment income (loss)		$	41	$	(1)	$	26
Equity method income (loss)		3		8		11
Change in fair value of assumed obligations		(30)		(32)		(32)
Gain on remeasurement of NMP equity method investment(1)		97		—		—
Other items, net(2)		46		80		81
Total other income (expense) – net		$	157	$	55	$	86

(1) During the year ended December 31, 2025, the Company acquired its remaining interest in NMP. Refer to Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

(2) Other items, net primarily consists of a mix of licensing and royalty income, government grants, lease income, change in tax indemnities, and gains and losses related to derivatives. Additionally, for the year ended December 31, 2025 it includes a realization of a gain contingency.

BORROWINGS - Narrative (Details)	3 Months Ended		12 Months Ended
BORROWINGS - Narrative (Details)	Dec. 31, 2025 USD ($) series	Mar. 31, 2025 USD ($)	Dec. 31, 2025 USD ($) series	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2025 USD ($)
Debt Instrument [Line Items]
Principal debt issued	$ 10,024,000,000		$ 10,024,000,000	$ 9,036,000,000
Interest expense, long-term debt			540,000,000	580,000,000	$ 616,000,000
Guarantee obligation, carrying value	3,000,000		3,000,000	3,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	1,149,000,000		1,149,000,000	784,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	22,000,000		22,000,000	25,000,000
Senior notes
Debt Instrument [Line Items]
Debt, principal amount	$ 9,500,000,000		$ 9,500,000,000
Debt repurchase price, percentage	101.00%		101.00%
Number of debt series \| series	9		9
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding	$ 0		$ 0	0
4.800% senior notes due January 15, 2031 \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount						$ 650,000,000
Stated interest rate	4.80%		4.80%			4.80%
Principal debt issued	$ 650,000,000		$ 650,000,000	0
5.500% senior notes due June 15, 2035 \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount						$ 850,000,000
Stated interest rate	5.50%		5.50%			5.50%
Principal debt issued	$ 850,000,000		$ 850,000,000	0
4.150% senior notes due December 15, 2028 \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount	$ 600,000,000		$ 600,000,000
Stated interest rate	4.15%		4.15%
Principal debt issued	$ 600,000,000		$ 600,000,000	0
4.950% senior notes due December 15, 2035 \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount	$ 650,000,000		$ 650,000,000
Stated interest rate	4.95%		4.95%
Principal debt issued	$ 650,000,000		$ 650,000,000	0
5.600% senior notes due November 15, 2025 \| Senior notes
Debt Instrument [Line Items]
Stated interest rate	5.60%		5.60%
Debt repayments	$ 1,500,000,000
Principal debt issued	0		$ 0	$ 1,500,000,000
5-Year Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term		5 years	5 years	5 years
Maximum borrowing capacity	3,000,000,000		$ 3,000,000,000
364-Day Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term		364 days	364 days	364 days
Maximum borrowing capacity	500,000,000		$ 500,000,000
3-Year Delayed Draw Term Loan Facility \| Line of credit \| Unsecured debt
Debt Instrument [Line Items]
Debt, term			3 years
Maximum borrowing capacity	750,000,000		$ 750,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit
Debt Instrument [Line Items]
Debt repayments		$ 250,000,000
Principal debt issued	500,000,000		$ 500,000,000	$ 750,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit \| Unsecured debt
Debt Instrument [Line Items]
Debt, term			3 years
Maximum borrowing capacity	$ 2,000,000,000		$ 2,000,000,000

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ 0	$ 0	$ 0
Effects of net investment hedges	0	0	0
Effects of fair value hedges	0	0	0
Effects of derivatives not designated as hedging instruments	5	8	10
SG&A \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0
Effects of derivatives not designated as hedging instruments	0	0	0
SG&A \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
SG&A \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
SG&A \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
SG&A \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
SG&A \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	5	8	10
Interest and other financial charges – net
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0
Effects of net investment hedges	59	42	37
Effects of fair value hedges	(15)	(27)	(1)
Effects of derivatives not designated as hedging instruments	0	0	0
Interest and other financial charges – net \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0
Effects of derivatives not designated as hedging instruments	0	0	0
Interest and other financial charges – net \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	38	31	34
Interest and other financial charges – net \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	21	11	3
Interest and other financial charges – net \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	63	(103)	24
Interest and other financial charges – net \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(78)	76	(25)
Interest and other financial charges – net \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0
Effects of net investment hedges	0	0	0
Effects of fair value hedges	0	0	0
Effects of derivatives not designated as hedging instruments	7	38	52
Other \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0
Effects of derivatives not designated as hedging instruments	(1)	1	5
Other \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Other \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Other \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Other \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Other \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	9	37	47
Interest expense \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(15)	(27)	(1)
Product \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	18	(4)	23
Effects of net investment hedges	0	0	0
Effects of fair value hedges	0	0	0
Effects of derivatives not designated as hedging instruments	28	(37)	3
Product \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	18	(4)	23
Effects of derivatives not designated as hedging instruments	28	(37)	3
Product \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Product \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Product \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Product \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Product \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0	0
Service \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	5	(1)	6
Effects of net investment hedges	0	0	0
Effects of fair value hedges	0	0	0
Effects of derivatives not designated as hedging instruments	7	(9)	2
Service \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	5	(1)	6
Effects of derivatives not designated as hedging instruments	7	(9)	2
Service \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Service \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0
Service \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Service \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0
Service \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	$ 0	$ 0	$ 0

INCOME TAXES - Summary of Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Balance at beginning of period	$ 231	$ 540	$ 272
Provision for income taxes	4	(279)	(12)
Foreign currency exchange and other	16	(31)	280
Balance at end of period	$ 251	$ 231	$ 540

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On January 2, 2026, we repaid $500 million of the remaining Term Loan Facility upon maturity.

RECEIVABLES - Allowance for Credit Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 103	$ 98	$ 91
Additions charged to costs and expenses	10	20	16
Write-offs	(15)	(12)	(11)
Foreign currency exchange and other	4	(2)	2
Ending balance	$ 103	$ 103	$ 98

POSTRETIREMENT BENEFIT PLANS - Plan Obligations in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Jan. 01, 2023
Retirement Benefits [Abstract]
Accumulated benefit obligation	$ 22,595	$ 22,185	$ 22,906
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	19,754	19,517
Fair value of plan assets	14,677	14,327
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	19,778	19,540
Fair value of plan assets	$ 14,677	$ 14,327

POSTRETIREMENT BENEFIT PLANS - Plan Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jan. 01, 2023
Change in plan assets
Funded status – surplus (deficit)				$ (4,045)
Pension Plans
Change in plan assets
Funded status – surplus (deficit)				(2,835)
Pension Plans \| U.S. Plans
Change in projected benefit obligations
Balance at January 1	$ 18,241	$ 19,363
Service cost	4	35	$ 35
Interest cost	996	970	1,022
Participant contributions	0	4
Actuarial loss (gain) – net	591	(799)
Benefits paid	(1,266)	(1,332)
Settlements	0	0
Special termination cost	3	0
Acquisitions/Divestitures/Mergers	0	0
Exchange rate adjustments	0	0
Balance at December 31	18,569	18,241	19,363
Change in plan assets
Balance at January 1	14,378	15,485
Actual gain (loss) on plan assets	1,443	49
Employer contributions	176	172
Participant contributions	0	4
Benefits paid	(1,266)	(1,332)
Acquisitions/Divestitures/Mergers	0	0
Exchange rate adjustments	0	0
Balance at December 31	14,731	14,378	15,485
Funded status – surplus (deficit)	(3,838)	(3,863)
Pension Plans \| International Plans
Change in projected benefit obligations
Balance at January 1	2,957	3,385
Service cost	21	20	20
Interest cost	151	141	139
Participant contributions	1	0
Actuarial loss (gain) – net	(122)	(357)
Benefits paid	(136)	(131)
Settlements	(8)	(4)
Special termination cost	0	0
Acquisitions/Divestitures/Mergers	33	0
Exchange rate adjustments	252	(96)
Balance at December 31	3,148	2,957	3,385
Change in plan assets
Balance at January 1	3,276	3,733
Actual gain (loss) on plan assets	14	(263)
Employer contributions	41	30
Participant contributions	1	0
Benefits paid	(144)	(136)
Acquisitions/Divestitures/Mergers	72	0
Exchange rate adjustments	269	(89)
Balance at December 31	3,528	3,276	3,733
Funded status – surplus (deficit)	380	319
Other Postretirement Benefits Plan
Change in projected benefit obligations
Balance at January 1	1,016	1,133
Service cost	6	7	6
Interest cost	50	54	59
Participant contributions	14	16
Actuarial loss (gain) – net	(45)	(48)
Benefits paid	(134)	(146)
Settlements	0	0
Special termination cost	1	0
Acquisitions/Divestitures/Mergers	0	0
Exchange rate adjustments	0	0
Balance at December 31	908	1,016	1,133
Change in plan assets
Balance at January 1	0	0
Actual gain (loss) on plan assets	0	0
Employer contributions	120	130
Participant contributions	14	16
Benefits paid	(134)	(146)
Acquisitions/Divestitures/Mergers	0	0
Exchange rate adjustments	0	0
Balance at December 31	0	0	$ 0
Funded status – surplus (deficit)	$ (908)	$ (1,016)		$ (1,210)

POSTRETIREMENT BENEFIT PLANS - Components of Expense (Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (288)	$ (406)	$ (382)
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Curtailment loss (gain)			17
Settlement loss (gain)			61
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	4	35	35
Interest cost	996	970	1,022
Expected return on plan assets	(1,145)	(1,196)	(1,242)
Amortization of net loss (gain)	(65)	(68)	(121)
Amortization of prior service cost (credit)	(11)	8	4
Curtailment loss (gain)	0	0	17
Settlement loss (gain)	0	0	61
Special termination cost	3	1	0
Non-operating	(222)	(285)	(259)
Net periodic expense (income)	(218)	(250)	(224)
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	21	20	20
Interest cost	151	141	139
Expected return on plan assets	(152)	(193)	(184)
Amortization of net loss (gain)	21	14	6
Amortization of prior service cost (credit)	(2)	(2)	(3)
Curtailment loss (gain)	0	0	0
Settlement loss (gain)	(1)	0	0
Special termination cost	0	0	0
Non-operating	17	(40)	(42)
Net periodic expense (income)	37	(20)	(22)
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	6	7	6
Interest cost	50	54	59
Expected return on plan assets	0	0	0
Amortization of net loss (gain)	(64)	(61)	(64)
Amortization of prior service cost (credit)	(80)	(87)	(87)
Curtailment loss (gain)	0	0	0
Settlement loss (gain)	0	0	0
Special termination cost	1	0	0
Non-operating	(92)	(94)	(92)
Net periodic expense (income)	$ (86)	$ (87)	$ (86)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2025
Accounting Policies [Abstract]
BASIS OF PRESENTATION	The consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for annual financial information and in accordance with the instructions to Form 10-K. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements.
RECLASSIFICATION	Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation. Amounts due from related parties and due to related parties, which were previously shown on separate lines on the Consolidated Statements of Financial Position and Consolidated Statements of Cash Flows, were reclassified to Receivables, All other current assets, Accounts Payable, All other current liabilities, and All other operating activities – net as applicable. Additionally, gain on fair value remeasurement of contingent consideration amounts, which was previously shown on a separate line on the Consolidated Statements of Cash Flows, was reclassified to All other operating activities – net.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Estimates are used for, but are not limited to, determining the following: revenue from contracts with customers; recoverability of long-lived assets and inventory; valuation of goodwill and intangible assets; useful lives used in depreciation and amortization; asset retirement obligations; income taxes and related valuation allowances; accruals for contingencies including legal and product warranties; actuarial assumptions used to determine costs of pension and other postretirement benefits; valuation of pension assets; valuation and recoverability of receivables; valuation of derivatives; and valuation of assets acquired, liabilities assumed, and contingent consideration as a result of acquisitions. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.
REVENUE RECOGNITION	REVENUE RECOGNITION. Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. The Company recognizes a contract with a customer when there is a legally enforceable agreement between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives, discounts, returns, chargebacks, group purchasing organization fees, rebates, or credits, as well as taxes collected from customers that are remitted to government authorities. Our estimates for these deductions, which are accounted for as variable consideration, are based on historical experience and consider current and forecasted market trends. We record these estimated amounts as a reduction to revenue when we recognize the related product or service sales. Payment terms are generally within 12 months. Payment terms within 12 months are not treated as significant financing components. Contracts for the sale of products and services often include multiple distinct performance obligations, usually involving an upfront deliverable of equipment and future performance obligations such as installation, training, or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors. Revenue is recognized in the period in which the customer obtains control of the underlying products or services, allowing them the ability to direct the use of, and obtain substantially all of, the remaining benefits of such product or service. This may occur at a point in time or over time. Shipping and handling costs to deliver products to customers are expensed as incurred and recognized within Cost of products or Cost of services in our Consolidated Statements of Income. For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time the revenue is recognized. The provision recorded reflects the estimated costs of replacement and free-of-charge services that will be incurred related to the products sold. Service-type warranties or extended warranties sold with products are considered separate performance obligations. As such, a portion of the overall transaction price is allocated to these performance obligations and recognized in revenue over time, as the performance obligations are satisfied. The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified within Contract and other deferred assets or All other non-current assets in the Consolidated Statements of Financial Position and are recognized within Selling, general, and administrative (“SG&A”) in the Consolidated Statements of Income based on the timing of when the Company expects to earn related revenues. Management assesses these costs for impairment based on periodic assessments of recoverability. Performance Obligations Satisfied at a Point in Time We primarily recognize revenue from sales of products at the point in time that the customer obtains control, which is generally no earlier than when the customer has physical possession. Our billing terms for these point-in-time product contracts generally coincide with delivery to the customer and customer acceptance; however, periodically, we transfer control of products in advance of billing or we receive customer advances and deposits from customers in advance of transfer of control of products which are recognized as contract assets or contract liabilities, respectively, in the Consolidated Statements of Financial Position. Any differences between the timing of our revenue recognition and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. Performance Obligations Satisfied Over Time We recognize revenue from the sale of certain service contracts, including preventative maintenance, corrective services, and extended warranties over time on a ratable basis consistent with the nature, timing, and extent of our services, which primarily relate to routine maintenance and as-needed product repairs. Our billing terms for these contracts vary and can occur in advance of or following the period of service; however, we generally invoice periodically as services are provided. The differences between the timing of our revenue recognized and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions.
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	CASH, CASH EQUIVALENTS, AND RESTRICTED CASH. Cash deposits, short-term investments, and high-liquidity mutual funds with original maturities of three months or less are included in Cash, cash equivalents, and restricted cash in the Consolidated Statements of Financial Position. Restricted cash primarily relates to funds restricted in connection with escrow accounts and other contractual and legal restrictions.
INVESTMENT SECURITIES	INVESTMENT SECURITIES. Publicly traded equity securities for which we do not have the ability to exercise significant influence are recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated Statements of Income. Certain private equity securities for which we do have the ability to exercise significant influence are also recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated Statements of Income based on an election made. Privately held equity securities for which we do not have the ability to exercise significant influence are accounted for using the measurement alternative approach and are recorded at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes in the measurement recognized through Other (income) expense – net in the Consolidated Statements of Income. Equity investments without readily determinable fair value as of December 31, 2025 and 2024 were $217 million and $176 million, respectively. Investment securities are recognized within All other non-current assets in the Consolidated Statements of Financial Position.
EQUITY METHOD INVESTMENTS	EQUITY METHOD INVESTMENTS. Investments in equity securities in which we do not have a controlling financial interest, but over which we have significant influence are accounted for using the equity method of accounting, or at fair value if we elect the fair value option. Equity method investments are assessed for other-than-temporary impairment when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. Equity method investments are recognized within All other non-current assets in the Consolidated Statements of Financial Position. Our share of the results of equity method investments is recognized within Other (income) expense – net in the Consolidated Statements of Income.
RECEIVABLES	RECEIVABLES. Amounts due from customers arising from the sales of products and services are recorded at the outstanding amount, less allowances for credit losses, chargebacks, and other credits. We regularly monitor the recoverability of our receivables.
FINANCING RECEIVABLES	FINANCING RECEIVABLES. Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance, non-homogeneous loans and leases, and smaller-balance homogeneous loans and leases. Loans Loans represent term loans that are collateralized by equipment and other assets. Loans are classified as either held for sale or held for investment (“HFI”) based on management’s intent and ability to hold the loans for the foreseeable future. Loans where the Company does not have the ability and intent to hold for investment purposes and those where the Company intends to hold for sale in the foreseeable future are accounted for as loans held for sale. Loans held for sale are recorded at the lower of cost or current fair value with any fair value write-down (or change to the write-down) recorded as a valuation allowance through current period earnings in the period in which the change occurs. Loans classified as HFI are recorded at amortized cost. Investment in Finance Leases Finance leases include mostly sales-type leases of equipment and represent net unpaid rentals and estimated unguaranteed residual values of leased equipment, less related deferred income and the allowance for credit losses. See Note 7, “Leases” for further information on our finance leases and “Allowance for credit losses” below for the Company’s policy regarding allowances for credit losses on financing receivables. Credit Quality Indicators We manage our financing receivables portfolio using delinquency and nonaccrual data as key performance indicators. We assess the overall quality of the portfolio based on a potential risk of loss measure. The metric incorporates both the borrower’s credit quality along with any related collateral protection. Financing receivables are considered past due if default on a contractual principal or interest payment exists for a period of 30 days or more. We stop accruing interest on financing receivables at the earlier of when collection of an account becomes doubtful or the account becomes 90 days past due. Although we stop accruing interest in advance of payments, we recognize income within Other (income) expense – net in the Consolidated Statements of Income when we determine that the account is returned to accrual status, provided that the amount does not exceed that which would have been earned at the historical effective interest rate.
ALLOWANCE FOR CREDIT LOSSES	ALLOWANCE FOR CREDIT LOSSES. When we record customer receivables, contract assets, and financing receivables, we maintain an allowance for credit losses for the current expected credit losses. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. The credit losses are recognized within SG&A in the Consolidated Statements of Income. For financing receivables, expected credit losses are calculated based on the gross carrying amount of the financial asset, multiplied by a factor reflecting the probability of default and the loss in the event of default. We routinely evaluate our entire portfolio for potential specific credit or collection issues that might indicate an impairment. We estimate expected credit losses based on relevant information from past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses.
INVENTORIES	INVENTORIES. Inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a first-in, first-out basis. Inventories are generally classified as current, however, based on consumption timelines, certain inventories are considered non-current and are recognized, net of related reserves, within All other non-current assets in the Consolidated Statements of Financial Position. As necessary, we record provisions and write-downs for excess, slow moving, and obsolete inventory. To determine these amounts, we regularly review inventory quantities on hand and compare them to historical utilization and estimates of future product demand, market conditions, and technological developments.
PROPERTY, PLANT, AND EQUIPMENT	PROPERTY, PLANT, AND EQUIPMENT. Property, plant, and equipment is stated at cost and is depreciated on a straight-line basis over its estimated useful life. Estimated useful lives generally range from 8 to 40 years for buildings, structures and related equipment, 3 to 20 years for machinery and equipment, and 1 to 16 years for leasehold improvements. Repair and maintenance costs are expensed as incurred. Property, plant and equipment is reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, assets are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values.
LEASES, Lessee Arrangements	Lessee Arrangements At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. ROU assets are recognized within Property, plant, and equipment – net and lease liabilities are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. Options to extend a lease are included as part of the ROU lease asset and liability at commencement when it is reasonably certain the Company will exercise the option. We have elected to combine lease and non-lease components in determining our lease liability, primarily for real estate leases. Non-lease components are generally related to services that the lessor performs for the Company associated with the leased asset. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using our incremental collateralized borrowing rate at lease commencement for leases that commenced post-Spin-Off and GE’s incremental collateralized borrowing rate at lease commencement for leases that commenced pre-Spin-Off. For leases with an initial term of 12 months or less, an ROU asset and lease liability are not recognized, and lease expense is recognized on a straight-line basis over the lease term. Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations, and usage-based amounts. The Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. We review ROU assets for impairment annually or when events occur or circumstances change that indicate that the asset may be impaired.
LEASES, Lessor Arrangements	Lessor Arrangements Equipment leased to others under operating leases is recognized within Property, plant, and equipment – net in the Consolidated Statements of Financial Position. Leases classified as sales-type leases or direct finance leases are recognized within All other current assets and All other non-current assets, respectively, in the Consolidated Statements of Financial Position. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term or purchase the underlying asset, vary by customer.
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS. Goodwill and Acquired Intangibles Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We test goodwill for impairment at the reporting unit level annually in the fourth quarter of each year as of October 1st, or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. When testing goodwill for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of a reporting unit is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that goodwill is impaired, an impairment charge is recognized based on the difference between the reporting unit’s carrying value and its fair value. When performing a quantitative test, the market approach is typically used for estimating the fair values for our reporting units. Under the market approach, we estimate the fair value based on market multiples of earnings derived from comparable publicly traded companies with operating and investment characteristics similar to the reporting unit. Depending on the specific reporting unit circumstances, we may also consider performing a valuation based on an income approach. It is reasonably possible that the judgments and estimates used could change in future periods. In-process research and development (“IPR&D”) acquired as part of a business acquisition is capitalized at fair value when acquired and is considered an indefinite-lived intangible asset. We test indefinite-lived intangible assets for impairment annually in the third quarter of each year or when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. When testing IPR&D for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of the IPR&D is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that the IPR&D is impaired, an impairment charge is recognized based on the difference between the IPR&D’s carrying value and its fair value. When the IPR&D project is complete, the asset is considered a finite-lived intangible asset and subject to an impairment test at that date. Thereafter, the resulting asset is amortized over its estimated useful life and is subject to impairment assessments in the same manner as all amortizing intangible assets. For other intangible assets that are not deemed indefinite-lived, the cost of the intangible asset is amortized on a straight-line basis over the asset’s estimated useful life. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, they are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values. Internal-use Software Internal-use software is software that is developed, purchased, or modified to meet internal needs and for which no substantive plan exists to sell, lease, or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begins after both of the following occur: (1) the preliminary project development stage is completed and (2) management authorizes and commits to funding the software project and it is probable that the project will be completed and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are recognized within Other intangible assets – net in the Consolidated Statements of Financial Position and are amortized on a straight-line basis over the asset’s estimated useful life. Capitalized cloud computing arrangement implementation costs For cloud computing arrangements that are considered a service contract, our capitalization of implementation costs is aligned with the internal-use software requirements. Capitalized amounts are recognized within All other non-current assets in the Consolidated Statements of Financial Position and are amortized on a straight-line basis over the expected term of the related service contract. External-use Software External-use software relates to software that is (1) intended to be sold, licensed, or marketed to our customers or (2) embedded and integral to our tangible products for which research and development (“R&D”) has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset and recognized within Other intangible assets – net in the Consolidated Statements of Financial Position. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated useful life of the product. The Company performs regular reviews to assess whether unamortized capitalized external use software program costs remain recoverable through future revenue.
DERIVATIVES AND HEDGING	DERIVATIVES AND HEDGING. We use derivative contracts to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. Our policy is to use derivatives solely for managing risks and not for speculative purposes. We employ the following hedge types: (1) cash flow hedges of foreign currency risk associated with third-party and intercompany foreign currency-denominated forecasted transactions and firm commitments, (2) net investment hedges of foreign currency risk associated with investments in foreign operations, (3) fair value hedges of interest rate risk associated with long-term borrowings, and (4) economic hedges not designated as qualifying hedging relationships of foreign currency risk associated with monetary assets and liabilities, including intercompany balances and equity price risk. For net investment hedges, changes in the fair value of the components of the hedging derivatives excluded from the assessment of hedge effectiveness are deferred and amortized to earnings in the Consolidated Statements of Income using a systematic and rational method over the life of the derivative transaction. Contracts that do not in their entirety meet the definition of a derivative instrument and are not measured at fair value may contain embedded features affecting some or all of the cash flows or value of other exchanges that would otherwise be considered derivatives when assessed separately from the host contract. Such embedded features are separated from the host contract and accounted for as a derivative measured at fair value if their economic characteristics and risks are not clearly and closely related to those of the host contract.
INCOME TAXES	INCOME TAXES. Uncertain tax positions that meet the more likely than not recognition threshold are included in the financial statements. Such uncertain tax positions are measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Our policy is to adjust these reserves when facts and circumstances change, such as the change in the technical merit of a position, an uncertain tax position is effectively settled with the relevant taxing authority, or the statute of limitations has expired. Penalties and interest related to income tax matters are recognized within Benefit (provision) for income taxes in the Consolidated Statements of Income. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax basis, as well as net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and credits considering all available positive and negative evidence, including the impact of the Tax Matters Agreement with GE, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, taxable income in prior carryback years, if applicable, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established to reduce its carrying value to the amount that is more likely than not to be realized. Deferred taxes are provided for the outside basis difference of certain investments in non-U.S. affiliates and associated companies based upon our evaluation of the undistributed earnings of such entities if the permanently reinvested assumption cannot be made.
POSTRETIREMENT BENEFIT PLANS	POSTRETIREMENT BENEFIT PLANS. We measure our plan assets at fair value and categorize plan assets for disclosure purposes in accordance with the fair value hierarchy. Certain assets for which the fair value is measured using the net asset value (“NAV”) per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The components of net periodic benefit costs, other than the service cost component, are recognized within Non-operating benefit (income) costs in the Consolidated Statements of Income for plans sponsored by the Company. We engage third-party actuaries to assist in the determination of benefit obligations and related net periodic benefit costs. We develop significant long-term assumptions, including discount rates and the expected rate of return on assets in connection with our pension accounting. In the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement, we recognize differences between expected long-term return on plan assets and actual returns, and net actuarial gains and losses for the pension plan liabilities within the Consolidated Statements of Comprehensive Income (Loss). We amortize gains and losses, as well as the effects of changes in actuarial assumptions and plan provisions, that exceed 10% of the greater of the market related value of plan assets or benefit obligations, determined as of the beginning of the year. The period over which gains and losses are amortized to earnings is generally over the average remaining life expectancy of plan participants.
LOSS CONTINGENCIES	LOSS CONTINGENCIES. Loss contingencies are uncertain and unresolved matters that arise in the ordinary course of business and result from events that have the potential to result in a future loss. Such contingencies include, but are not limited to, product warranties, claims, litigation, environmental obligations, regulatory investigations and proceedings, product quality, and losses resulting from other events and developments. When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the loss. When there appears to be a range of possible losses with equal likelihood, liabilities are based on the low end of such range. Disclosure is provided for material loss contingencies when a loss is probable and a reasonable estimate can be made, when a loss is probable but a reasonable estimate cannot be made, and when it is reasonably possible that a loss will be incurred or the amount of a loss will exceed the recorded provision. We regularly review contingencies to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. Legal costs incurred in connection with loss contingencies are expensed as incurred.
ASSET RETIREMENT OBLIGATIONS	ASSET RETIREMENT OBLIGATIONS. Our operations involve the use, disposal, and cleanup of substances regulated under nuclear decommissioning regulations that require asset retirement obligations. Liabilities for nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. We record asset retirement obligations associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives.
SUPPLY CHAIN FINANCE PROGRAMS	SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables to borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements.
FAIR VALUE MEASUEMENTS, RECURRING AND NON-RECURRING FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS. The following sections describe the valuation methodologies we use to measure financial and non-financial instruments at fair value including certain assets within our postretirement benefit plans. Observable inputs for fair value measurements reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. These inputs establish the following fair value hierarchy: •Level 1 — Quoted prices for identical instruments in active markets. •Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. •Level 3 — Significant inputs to the valuation model are unobservable. RECURRING FAIR VALUE MEASUREMENTS. For financial assets and liabilities measured at fair value on a recurring basis, primarily money market funds, investment securities, derivatives, and contingent consideration, fair value is the price we would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Money Market Funds Money market funds are valued using pricing information from the fund managers, quoted on a daily basis, and are considered Level 2 inputs. Investment Securities Publicly traded equity securities are valued using Level 1 quoted price inputs. Non-publicly traded equity securities for which the fair value option was elected are classified within Level 3 and are valued using unobservable inputs, primarily by discounting expected future cash flows. Derivatives The majority of our derivatives are valued using model-derived offers received from financial institutions for similar over-the-counter instruments without an active market or internal models. The models maximize observable inputs including interest rates and both forward and spot prices for currencies. As of December 31, 2025 and 2024, foreign currency contracts, interest rate contracts, embedded derivatives, and equity-linked total return swaps were valued using Level 2 inputs. Contingent Consideration When an acquisition involves a contingent consideration arrangement, we record on the date of acquisition a liability for the fair value of the estimated additional consideration we may be obligated to pay in the future. The fair value is based upon estimates of future financial projections under various potential scenarios using a probability-weighted expected payment model discounted to present value. The estimates used to determine the fair value are subject to significant judgment and as such are considered Level 3 inputs. We subsequently remeasure such liabilities at the end of each reporting period and record changes in the fair value within SG&A in the Consolidated Statements of Income. Investments in Annuity Contracts, Private Equity, Real Estate and Collective Funds held within our Postretirement Benefit Plans Investments are generally valued using the NAV per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. Investments that are measured at fair value using the NAV practical expedient are not required to be classified in the fair value hierarchy. Investments classified within Level 3 primarily relate to an annuity contract, real estate, and private equities which are valued using unobservable inputs, primarily by discounting expected future cash flows, using comparative market multiples, third-party pricing sources, or a combination of these approaches as appropriate. See Note 10, “Postretirement Benefit Plans” for further information. Debt Securities held within our Postretirement Benefit Plans When available, we use quoted market prices to determine the fair value of debt securities which are Level 1 inputs. For our remaining debt securities, we obtain pricing information from an independent pricing vendor. The inputs and assumptions to the pricing vendor’s models are derived from market observable sources including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. These investments are classified within Level 2. See Note 10, “Postretirement Benefit Plans” for further information. There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended December 31, 2025, 2024, and 2023. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. NON-RECURRING FAIR VALUE MEASUREMENTS. Certain assets and liabilities are measured at fair value on a non-recurring basis. These items may include financing receivables and long-lived assets reduced to fair value upon classification as held for sale and impaired equity method investments and long-lived assets, which, when written down to fair value upon an impairment, are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Company uses to measure these assets not measured on a recurring fair value basis. Equity Method Investments Equity method investments for which the fair value option was not elected are initially recorded at cost and are adjusted in each period for the Company’s share of the investee’s income or loss and dividends paid. In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using either a discounted cash flow model, comparative market multiples, third-party pricing sources, or a combination of these approaches, as appropriate. These investments are generally valued using Level 3 inputs. Equity Investments Without Readily Determinable Fair Value Equity investments without readily determinable fair value, subject to a policy choice on a transaction-by-transaction basis, are accounted for under the measurement alternative at cost less impairment and adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. In the instance of impairment, if any, equity investments are adjusted to fair value using market observable data if available. If market observable data is not available, fair values are estimated using discounted cash flow models, comparative market multiples, or a combination of these approaches using Level 3 inputs. Financing Receivables We generally use market data, including pricing on recently closed market transactions, to value financing receivables that are held for sale. Such financing receivables are valued using Level 2 inputs. When data is unobservable, we use valuation methodologies based on current market interest rate data adjusted for inherent credit risk. Such financing receivables are valued using Level 3 inputs. Long-Lived Assets Fair values of long-lived assets are primarily developed internally and are corroborated by available external appraisal information, as applicable. These assets are generally valued using Level 3 inputs.
FOREIGN CURRENCY	FOREIGN CURRENCY. We have determined that the functional currency for many of our international operations is the local currency, and for other international operations the functional currency is the USD. The basis of this determination is the currency in which each of the international operations primarily generates and expends cash. When the functional currency is not the USD, asset and liability accounts are translated at period-end exchange rates. The Company translates functional currency income and expense amounts to their USD equivalents using average exchange rates for the period. These translation gains and losses are recognized within Accumulated other comprehensive income (loss) – net (“AOCI”) in the Consolidated Statements of Financial Position. Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the non-functional currency and those resulting from remeasurements of monetary items, are included in Cost of products, Cost of services, SG&A, and R&D in the Consolidated Statements of Income, depending on the underlying nature of the item.
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS. Our financial statements include the operations of acquired businesses from the date of acquisition. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with U.S. GAAP, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. When we acquire the remaining equity ownership of a company in which we hold an equity interest, we remeasure our equity interest to fair value. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as Goodwill. Transaction costs are expensed as incurred. For those arrangements that involve potential future contingent consideration, on the date of acquisition we record a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future.
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS. Certain of our operations have been presented as discontinued. We present businesses whose disposal represents a strategic shift that has, or will have, a major effect on our operations and financial results as discontinued operations when the components meet the criteria for held for sale, are sold, or are spun-off. Presentation as discontinued operations is consistent for all periods presented.
RESTRUCTURING COSTS	RESTRUCTURING COSTS. We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT. The Company conducts R&D activities to create new products, develop new applications for existing products, and enhance existing products. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&D costs are expensed as incurred. In certain instances, R&D activities may be funded by third parties, including government entities. These R&D funding arrangements may include upfront payments, R&D cost sharing payments, and future milestone payments that may be based upon the occurrence of future R&D or commercialization events. Payments received as part of the R&D funding arrangements are generally presented as an offset to R&D expense.
COLLABORATIVE ARRANGEMENTS	COLLABORATIVE ARRANGEMENTS. We enter into collaborative arrangements primarily related to development of new products. A collaborative arrangement is a contractual arrangement that involves two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. The assessment for a collaborative arrangement is performed throughout the life of the arrangement based on changes in the responsibilities of all parties. Amounts that are owed by collaboration partners related to R&D activities are generally presented as an offset to R&D expense.
ACCOUNTING CHANGES	ACCOUNTING CHANGES. We evaluate Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not included in our disclosures were assessed and determined to either be not applicable or are not expected to have a significant impact on our financial statements. Recent Accounting Pronouncements Reflected in Our Consolidated Financial Statements In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the year ended December 31, 2025, prospectively applied to disclosures in our notes to the financial statements. See Note 11, “Income Taxes.” for further information. Other Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 addresses investor requests for more transparency about expense information through the disaggregation of relevant expense captions in the notes to the financial statements. The provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. We expect the adoption to increase disclosures in our notes to the financial statements. In September 2025, the FASB issued ASU No. 2025-06 (“ASU 2025-06”), Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. ASU 2025-06 updates the accounting for internal-use software by eliminating the concept of development stages. Under the updated guidance, software costs are capitalized once management has authorized and committed to funding the project, and it is probable the project will be completed and the software will be used to perform the function intended. The provisions of ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual periods. We are currently evaluating the effect that ASU 2025-06 will have on our financial statements.

SUPPLEMENTAL FINANCIAL INFORMATION

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	December 31, 2025		December 31, 2024
Cash and cash equivalents(1)	$	4,492	$	2,874
Short-term restricted cash	20		16
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Financial Position	4,512		2,889
Long-term restricted cash(2)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Consolidated Statements of Cash Flows	$	4,515	$	2,893

(2) Long-term restricted cash is recognized within All other non-current assets in the Consolidated Statements of Financial Position.

INVENTORIES.


	As of
	December 31, 2025		December 31, 2024
Raw materials	$	1,002	$	921
Work in process	95		92
Finished goods	1,137		926
Inventories	$	2,234	$	1,939

Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Consolidated Statements of Financial Position and are not reflected in the table above. See the supplemental table “All Other Non-Current Assets” for further information.

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	December 31, 2025		December 31, 2024
Land and improvements	$	144	$	66
Buildings, structures, and related equipment	2,140		1,943
Machinery and equipment	2,872		2,705
Leasehold improvements and manufacturing plants under construction	574		553
Total property, plant, and equipment, at original cost	5,731		5,267
Accumulated depreciation	(3,049)		(3,080)
Right-of-use operating lease assets, net of amortization(1)	410		364
Property, plant, and equipment – net	$	3,092	$	2,550

(1) See Note 7, “Leases” for further information.

Depreciation expense related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $287 million, $268 million, and $248 million for the years ended December 31, 2025, 2024, and 2023, respectively.

ALL OTHER ASSETS AND ALL OTHER LIABILITIES.


All Other Current Assets	As of
	December 31, 2025		December 31, 2024
Prepaid expenses and deferred costs	$	228	$	188
Financing receivables – net	95		90
Derivative instruments(1)	169		123
Tax receivables	154		115
Other(2)	81		16
All other current assets	$	726	$	532

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.


All Other Non-Current Assets	As of
	December 31, 2025		December 31, 2024
Prepaid pension asset	$	742	$	657
Equity method and other investments	351		373
Financing receivables – net	190		183
Derivative instruments(1)	88		22
Long-term receivables – net	190		142
Inventories	121		139
Contract and other deferred assets	211		208
Capitalized cloud computing arrangement implementation costs(2)	200		84
Other(3)	112		142
All other non-current assets	$	2,205	$	1,950

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(2) See the supplemental table “Capitalized Cloud Computing Arrangement Implementation Costs” for further information.

(3) Other primarily consists of indemnity assets associated with separation agreements with GE, and tax receivables.


All Other Current Liabilities	As of
	December 31, 2025		December 31, 2024
Sales allowances and related liabilities	$	256	$	242
Income and indirect tax liabilities including uncertain tax positions	324		279
Product warranties	169		168
Accrued logistics and utilities	197		163
Operating lease liabilities	134		115
Derivative instruments(1)	47		90
Interest payable on borrowings	100		92
Environmental and asset retirement obligations	11		17
Other(2)	348		386
All other current liabilities	$	1,587	$	1,552

(1) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(2) Other primarily consists of miscellaneous accrued costs, dividends payable, and contingent consideration liabilities.


All Other Non-Current Liabilities	As of
	December 31, 2025		December 31, 2024
Contract liabilities	$	803	$	686
Operating lease liabilities	284		270
Environmental and asset retirement obligations(1)	413		291
Income and indirect tax liabilities including uncertain tax positions	156		237
Derivative instruments(2)	160		64
Finance lease obligations	42		40
Sales allowances and related liabilities	23		23
Other(3)	178		184
All other non-current liabilities	$	2,061	$	1,796

(1) Refer to Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on the increase in Environmental and asset retirement obligations.

(2) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(3) Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

CAPITALIZED CLOUD COMPUTING ARRANGEMENT IMPLEMENTATION COSTS.


	As of
	December 31, 2025		December 31, 2024
Capitalized implementation costs	$	249	$	114
Accumulated amortization	(49)		(30)
Total Capitalized cloud computing arrangement implementation costs, net	$	200	$	84

Amortization expense related to capitalized cloud computing arrangement implementation costs was $19 million, $10 million, and $7 million for the years ended December 31, 2025, 2024, and 2023, respectively.

EQUITY METHOD INVESTMENTS.


		Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage	2025		2024		2025		2024		2023
Nihon Medi-Physics Co., Ltd.(1)	50%	$	—	$	139	$	2	$	10	$	10
Other		28		24		1		(2)		1
Total		$	28	$	163	$	3	$	8	$	11

As of December 31, 2025 and 2024, the fair value of investments over which we have significant influence and have elected the fair value option was $32 million and $6 million, respectively.

SUPPLY CHAIN FINANCE PROGRAMS.


	For the years ended December 31
	2025		2024
Confirmed obligations outstanding at beginning of period	$	394	$	365
Invoices confirmed during the year	818		886
Confirmed invoices paid during the year	(853)		(855)
Foreign exchange and other	1		(2)
Confirmed obligations outstanding at end of period	$	360	$	394

REDEEMABLE NONCONTROLLING INTERESTS.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value.

Activity attributable to redeemable noncontrolling interests is presented below.


	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	188	$	165	$	230
Net income attributable to redeemable noncontrolling interests	66		50		41
Redemption value adjustments(1)	—		—		183
Distributions to redeemable noncontrolling interests and other(2)	(45)		(28)		(289)
Balance at end of period	$	209	$	188	$	165

(2) In 2023, the redeemable noncontrolling interest holder exercised its option redemption provision and the Company paid a redemption amount of $211 million.

OTHER INCOME (EXPENSE) – NET.


	For the years ended December 31
		2025		2024		2023
Net financing income and investment income (loss)		$	41	$	(1)	$	26
Equity method income (loss)		3		8		11
Change in fair value of assumed obligations		(30)		(32)		(32)
Gain on remeasurement of NMP equity method investment(1)		97		—		—
Other items, net(2)		46		80		81
Total other income (expense) – net		$	157	$	55	$	86

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes.

The fair values of derivative contracts are recognized within All other current assets, All other non-current assets, All other current liabilities, and All other non-current liabilities in the Consolidated Statements of Financial Position based upon the contractual timing of settlements for these contracts. We designate certain derivative contracts as hedging instruments in cash flow, fair value, or net investment hedges. We evaluate the effectiveness of our derivative contracts designated as hedging instruments on a quarterly basis.

Cash Flow Hedges

We use foreign currency forward contracts to hedge the volatility of cash flows related to firm commitments and forecasted transactions, including intercompany transactions, denominated in foreign currencies other than a subsidiary’s functional currency. The maximum length of time over which we hedge forecasted transactions is five years. As of December 31, 2025, these contracts have a maximum remaining maturity of 51 months.

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of December 31, 2025, we expect to reclassify $7 million of pre-tax net deferred gains associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions.

The cash flows associated with derivatives designated as cash flow hedges are recorded in All other operating activities – net in the Consolidated Statements of Cash Flows.

Net Investment Hedges

We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of December 31, 2025, these contracts were designated as hedges of our net investment in foreign operations, primarily in Euro and Chinese Renminbi currencies.

We use the spot method to assess hedge effectiveness for our net investment hedges. Changes in the fair value of the designated hedging instruments attributable to fluctuations in foreign currency to USD spot exchange rates are initially recorded and held as a component of the CTA portion of AOCI until the hedged foreign operation is either sold or substantially liquidated. Changes in fair value of the portion of net investment hedging derivatives excluded from the assessment of effectiveness are recorded in CTA and then recognized within Interest and other financial charges – net in the Consolidated Statements of Income using a systematic and rational method over the life of the hedge. Excluded components on the cross-currency swaps designated as net investment hedges, in the form of accrued interest, are recorded within Interest and other financial charges – net in the Consolidated Statements of Income.

The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities – net in the Consolidated Statements of Cash Flows. For the years ended December 31, 2025 and 2024, All other investing activities – net includes $178 million and $94 million, respectively, of payments for the settlement of cross-currency swaps that were designated as net investment hedges. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities – net in the Consolidated Statements of Cash Flows.

Fair Value Hedges

We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges to hedge the changes in fair value due to benchmark interest rate risk of specific designated cash flows of our senior unsecured notes.

We record the changes in fair value on these swap contracts in Interest and other financial charges – net in our Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment.

Cash flows for the periodic interest settlements on the interest rate swaps are recorded in All other operating activities – net in the Consolidated Statements of Cash Flows.

Derivatives Not Designated as Hedging Instruments

We also execute derivative instruments, such as foreign currency forward contracts and equity-linked total return swaps, which are not designated as qualifying hedges. These derivatives serve as economic hedges of foreign currency exchange rate and equity price risks. We also identify and record foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of any substantive party to the contract as embedded derivatives.

The changes in fair value of derivatives not designated as qualifying hedge transactions are recorded in Cost of products, Cost of services, SG&A, and Other (income) expense – net in the Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Consolidated Statements of Income.

The cash flows associated with derivatives not designated but used as economic hedges are recorded, based on the nature of the underlying hedged transaction, in All other operating activities – net and All other investing activities – net in the Consolidated Statements of Cash Flows. The cash flows related to embedded derivatives are included in All other operating activities – net in the Consolidated Statements of Cash Flows.

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	December 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,508	$	52	$	23	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,508		52		23		1,210		43		11
Cross-currency swaps(1)	4,115		51		135		1,995		15		46
Foreign currency forward and options contracts	2,581		50		37		1,731		30		18
Derivatives accounted for as net investment hedges	6,697		101		172		3,726		45		64
Interest rate swaps(1)	2,700		28		—		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		28		—		2,700		—		51
Foreign currency forward contracts	4,761		20		7		3,925		11		29
Other derivatives(1)(2)	320		56		5		370		47		—



Derivatives not designated as hedging instruments	5,081		76		12		4,294		57		29
Total derivatives	$	15,986	$	256	$	207	$	11,930	$	145	$	155

(1) As of December 31, 2025, accrued interest is included in the above fair value and is not considered material. As of December 31, 2024, accrued interest is excluded from the above fair value and is not considered material.

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

The following table presents amounts recorded in Long-term borrowings in the Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	December 31, 2025				December 31, 2024
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated as fair value hedges	$	2,722	$	27	$	2,644	$	(51)

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis in our Consolidated Statements of Financial Position and in the table above.

As of December 31, 2025 and 2024, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $107 million and $77 million, respectively.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the years ended December 31
		2025		2024		2023
Cash flow hedges		$	—	$	44	$	(6)
Net investment hedges(1)		(263)		80		(97)

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity
	For the year ended December 31, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	18	$	5	$	—	$	—	$	—
Effects of cash flow hedges	18		5		—		—		—
Cross-currency swaps	—		—		—		38		—
Foreign currency forward and options contracts	—		—		—		21		—
Effects of net investment hedges(1)	—		—		—		59		—

Interest rate swaps(2)	—		—		—		63		—
Debt basis adjustment on Long-term borrowings	—		—		—		(78)		—

Effects of fair value hedges	—		—		—		(15)		—
Foreign currency forward contracts	28		7		—		—		(1)



Other derivatives(3)	—		—		5		—		9
Effects of derivatives not designated as hedging instruments	28		7		5		—		7























	For the year ended December 31, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(4)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(4)		(1)		—		—		—
Cross-currency swaps	—		—		—		31		—
Foreign currency forward and option contracts	—		—		—		11		—
Effects of net investment hedges(1)	—		—		—		42		—

Interest rate swaps(2)	—		—		—		(103)		—
Debt basis adjustment on Long-term borrowings	—		—		—		76		—

Effects of fair value hedges	—		—		—		(27)		—
Foreign currency forward contracts	(37)		(9)		—		—		1
Other derivatives(3)	—		—		8		—		37
Effects of derivatives not designated as hedging instruments	(37)		(9)		8		—		38


	For the year ended December 31, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	23	$	6	$	—	$	—	$	—
Effects of cash flow hedges	23		6		—		—		—
Cross-currency swaps	—		—		—		34		—
Foreign currency forward and option contracts	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		37		—

Interest rate swaps(2)	—		—		—		24		—
Debt basis adjustment on Long-term borrowings	—		—		—		(25)		—

Effects of fair value hedges	—		—		—		(1)		—
Foreign currency forward contracts	3		2		—		—		5



Other derivatives(3)	—		—		10		—		47
Effects of derivatives not designated as hedging instruments	3		2		10		—		52

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the years ended December 31, 2025, 2024, and 2023.

(2) Amount includes interest expense on interest rate derivatives of $(15) million, $(27) million, and $(1) million for the years ended December 31, 2025, 2024, and 2023 respectively.

(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Consolidated Statements of Income.

Counterparty Credit Risk

The Company would be exposed to credit-related losses in the event of non-performance by counterparties on executed derivative instruments. The credit exposure of derivative contracts is represented by the fair value of contracts as of the reporting date. The fair value of the Company’s derivatives can change significantly from period to period based on, among other factors, market movements, and changes in our positions.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, by limiting the amount of credit exposure to individual counterparties, and by actively monitoring counterparty credit ratings and the amount of individual credit exposure.

We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. None of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

FAIR VALUE MEASUREMENTS.

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of December 31, 2025								As of December 31, 2024
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	399	$	—	$	399	$	—	$	312	$	—	$	312
Investment securities	47		—		30		77		32		—		—		32
Derivatives	—		256		—		256		—		145		—		145
Liabilities:
Derivatives	—		207		—		207		—		155		—		155
Contingent consideration	—		—		30		30		—		—		34		34

Cash equivalents

As of December 31, 2025 and 2024, Cash, cash equivalents, and restricted cash of $4,512 million and $2,889 million, respectively, included money market funds of $399 million and $312 million, and other cash equivalents of $3,046 million and $1,573 million, respectively. The carrying values of the other cash equivalents approximates the fair value due to their short maturities and are valued using Level 1 or Level 2 inputs. Refer to Note 18, “Supplemental Financial Information” for further information.

Derivatives

Derivatives are measured at fair value using a discounted cash flow method or option models using interest rates, foreign exchange spot and forward rates and yield curves observable at commonly quoted intervals, implied volatilities, and credit spreads as key inputs. Unobservable inputs relate to our own credit risk which is not significant to the overall measurement of fair value.

Contingent consideration

Contingent consideration is recorded at fair value based on estimates of future cash flows in connection with business acquisitions. As the valuation of these liabilities is based on inputs that are less observable or not observable in the market, the determination of fair value is classified within Level 3 of the fair value hierarchy.

Non-recurring fair value measurements

Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the years ended December 31, 2025, 2024, and 2023, with the exception of the gain on fair value measurement of the NMP equity method investment as described in Note 8, “Acquisitions, Goodwill, and Other Intangible Assets.”

Fair value of other financial instruments

The estimated fair value of borrowings as of December 31, 2025 and 2024 was $10,545 million and $9,374 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $10,003 million and $8,951 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information.

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Contingency [Line Items]
State taxes, net of federal benefit, revaluation of deferred tax assets	$ 10	$ 35	$ 59
Additions for tax positions of prior years, foreign currency translation	37
Reduction for tax positions of prior years, expired tax attributes	102
Additions for tax positions of prior years, ongoing audit reserves		172
Net operating loss deferred tax asset, audit reserves		142
Reductions for tax positions of prior years, CTA		14
Reductions for tax positions of prior years, tax audits closed		19
Additions for tax positions of prior years	43	181	156
Reductions for tax positions of prior years	108	33	203
Decrease in valuation allowance		310
Increase in valuation allowance related to spin-off activities			269
Operating loss carryforwards	5,987
Deferred tax asset, net operating loss carryforward, gross	1,170
Unrecognized tax benefits, net operating loss	300
Unrecognized tax benefits, US foreign tax credits	407
Deferred tax liabilities, undistributed foreign earnings			21
Unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries	$ 8,000
France
Income Tax Contingency [Line Items]
Decrease in valuation allowance		$ 295
GE
Income Tax Contingency [Line Items]
Additions for tax positions of prior years			134
Reductions for tax positions of prior years			$ 183

POSTRETIREMENT BENEFIT PLANS - Schedule of Defined Benefit Plans (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jan. 01, 2023
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligation	$ 22,595	$ 22,185		$ 22,906
Unrecognized gain recorded in AOCI				2,481
Net Benefit Liability
Projected benefit obligations				22,953
Fair value of plan assets				18,908
Net liability				4,045
Pension Plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligation				21,696
Unrecognized gain recorded in AOCI				1,258
Net Benefit Liability
Projected benefit obligations				21,743
Fair value of plan assets				18,908
Net liability				2,835
Other Postretirement Benefits Plan
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligation				1,210
Unrecognized gain recorded in AOCI				1,223
Net Benefit Liability
Projected benefit obligations	908	1,016	$ 1,133	1,210
Fair value of plan assets	0	0	$ 0	0
Net liability	$ 908	$ 1,016		$ 1,210

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

POSTRETIREMENT BENEFIT PLANS - Weighted Average Asset Allocation (Details) - Pension Plans	Dec. 31, 2025
Global equity securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation	22.00%
Actual allocation	26.00%
Debt securities, cash, and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Target allocation	49.00%
Actual allocation	46.00%
Real estate
Defined Benefit Plan Disclosure [Line Items]
Target allocation	5.00%
Actual allocation	4.00%
Private equities and other investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation	12.00%
Actual allocation	12.00%
Annuity contract
Defined Benefit Plan Disclosure [Line Items]
Target allocation	12.00%
Actual allocation	12.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) payment_installment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) benefit_plan	Jan. 01, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Plan asset or obligation reporting threshold	$ 50
Defined benefit plan, number of annual installments upon retirement \| payment_installment	10
Projected benefit obligations				$ 22,953
Fair value of plan assets				18,908
Defined benefit plan, expected future employer contributions, next fiscal year	$ 350
Expected amortization of net actuarial gain, next fiscal year	108
Expected amortization of prior service credit, next fiscal year	$ 93
Number of plans with employee termination payment \| benefit_plan			2
Weighted average health care cost trend rate assumed, initial rate	8.40%
Weighted average health care cost trend rate assumed, ultimate rate	4.50%
Defined contribution plan, employer contribution amount	$ 154	$ 130	$ 122
Level 3 \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,564	692
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations				21,743
Fair value of plan assets				$ 18,908
Curtailment loss (gain)			17
Benefit obligation, increase for curtailment			23
AOCI, decrease due to remeasurement			305
Settlement loss (gain)			61
Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18,259	17,654
Pension Plans \| Level 3 \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,564	692
Pension Plans \| GE HealthCare Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations	15,519
Fair value of plan assets	$ 13,988
Funded percentage	90.00%
Pension Plans \| GE HealthCare Supplemental Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations	$ 1,672
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations	18,569	18,241	19,363
Fair value of plan assets	14,731	14,378	15,485
Curtailment loss (gain)	0	0	17
AOCI, decrease due to remeasurement	0	0	(108)
Settlement loss (gain)	0	0	61
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations	3,148	2,957	3,385
Fair value of plan assets	3,528	3,276	3,733
Curtailment loss (gain)	0	0	0
AOCI, decrease due to remeasurement	1	0	0
Settlement loss (gain)	$ (1)	$ 0	$ 0

RESTRUCTURING ACTIVITIES

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

RESTRUCTURING ACTIVITIES

Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring charges (gains) primarily include employee-related termination benefits associated with workforce reductions, facility exit costs, asset write-downs, and cease-use costs. For segment reporting, restructuring activities are not allocated.

Net expenses for restructuring initiatives committed to by management through December 31, 2025 are included in the table below.


	For the years ended December 31
		2025		2024		2023
Employee termination costs		$	100	$	85	$	38
Facility and other exit costs		8		18		3
Asset write-downs		12		17		13
Total restructuring activities – net		$	120	$	120	$	54

These restructuring initiatives are expected to result in additional expenses of approximately $53 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated Statements of Income.

Liabilities related to restructuring are recognized within Current compensation and benefits, All other current liabilities, Non-current compensation and benefits, and All other non-current liabilities in the Consolidated Statements of Financial Position. The activity related to our restructuring liabilities follows.


	Employee termination costs		Facility and other exit costs		Total
Balance at December 31, 2023	$	43	$	25	$	68

Charges	85		8		93
Payments and other adjustments	(60)		(15)		(75)
Balance at December 31, 2024	67		18		86
Charges	95		7		102
Payments and other adjustments	(81)		(15)		(96)
Balance at December 31, 2025	$	82	$	11	$	92

Consolidated Statements of Financial Position (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 103	$ 103
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	458,844,209	457,246,971
Treasury stock (in shares)	3,107,626	291,053

LEASES - Schedule of Maturity of Operating Leases (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Operating Lease
2026	$ 153
2027	116
2028	73
2029	42
2030	20
Thereafter	56
Total	460
Less: imputed interest	41
Operating lease liabilities	$ 419	$ 385

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Total revenues	$ 20,625	$ 19,672	$ 19,552
Gross profit	8,248	8,205	7,922
Selling, general, and administrative	4,225	4,269	4,282
Research and development	1,260	1,311	1,205
Total operating expenses	5,485	5,580	5,487
Operating income	2,763	2,625	2,435
Interest and other financial charges – net	440	504	542
Non-operating benefit (income) costs	(288)	(406)	(382)
Other (income) expense – net	(157)	(55)	(86)
Income from continuing operations before income taxes	2,768	2,581	2,361
Benefit (provision) for income taxes	(614)	(531)	(743)
Net income from continuing operations	2,154	2,050	1,618
Income (loss) from discontinued operations, net of taxes	0	0	(4)
Net income	2,154	2,050	1,614
Net (income) loss attributable to noncontrolling interests	(70)	(57)	(46)
Net income attributable to GE HealthCare	2,084	1,993	1,568
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)
Net income attributable to GE HealthCare common stockholders	$ 2,084	$ 1,993	$ 1,385
Earnings per share from continuing operations attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	$ 4.56	$ 4.37	$ 3.06
Diluted (in dollars per share)	4.55	4.34	3.04
Earnings per share attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	4.56	4.37	3.05
Diluted (in dollars per share)	$ 4.55	$ 4.34	$ 3.03
Weighted-average number of shares outstanding:
Basic (in shares)	456	456	455
Diluted (in shares)	458	459	458
Product
Total revenues	$ 13,661	$ 13,075	$ 13,127
Cost of sales	8,942	8,271	8,465
Service
Total revenues	6,964	6,597	6,425
Cost of sales	$ 3,436	$ 3,196	$ 3,165

POSTRETIREMENT BENEFIT PLANS

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

POSTRETIREMENT BENEFIT PLANS

In connection with the Spin-Off, on January 1, 2023, GE HealthCare assumed a portion of former GE pension and other postretirement obligations and assets. The pension and other postretirement obligations assumed relate to benefits owed to current GE HealthCare employees, former GE HealthCare employees, and certain GE legacy plan participants. As of January 1, 2023, GE HealthCare established the assumed pension plans as single-employer plans, but continued to participate in legacy GE multiple-employer other postretirement benefit (“OPEB”) plans sponsored by GE. On January 1, 2024, we transitioned from the legacy GE multiple-employer OPEB plans to a GE HealthCare sponsored single-employer OPEB plan. This change did not have an impact on our results of operations or financial position.

The total assets and liabilities for all plans assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of plan assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

(1) Defined benefit plans are comprised of both U.S. Plans and International Plans, as described below.
(2) OPEB Plans are comprised of benefits, as described below.

DESCRIPTION OF OUR PLANS.

We disclose in the following tables postretirement plans with assets or obligations that exceed $50 million. We use a December 31st measurement date for these plans and all tables presented below are for the years ended December 31st.

The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $15,519 million, plan assets of $13,988 million, and is 90% funded per U.S. GAAP as of December 31, 2025. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $1,672 million as of December 31, 2025, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below.

Our International Pension Plans include all other plans that cover non-U.S. participants. These plans include obligations that existed prior to the Spin-Off and obligations transferred to GE HealthCare from GE in connection with the Spin-Off. In certain countries, benefit accruals have ceased and/or have been closed to new hires as of various dates.

The OPEB Plans include unfunded postretirement health and life insurance defined benefit obligations to U.S. participants. GE HealthCare assumed the obligations associated with these plans in connection with the Spin-Off. Participants share in the cost of the healthcare and life insurance benefits. With the exception of production employees, subsidized benefits are generally only available to closed groups of employees and retirees.

Funding

The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand. In 2026, the Company expects to make total cash contributions of approximately $350 million to these plans.


Plan Funded Status	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
Change in projected benefit obligations
Balance at January 1	$	18,241	$	19,363	$	2,957	$	3,385	$	1,016	$	1,133
Service cost	4		35		21		20		6		7
Interest cost	996		970		151		141		50		54
Participant contributions	—		4		1		—		14		16

Actuarial loss (gain) – net	591		(799)		(122)		(357)		(45)		(48)
Benefits paid	(1,266)		(1,332)		(136)		(131)		(134)		(146)

Settlements	—		—		(8)		(4)		—		—
Special termination cost	3		—		—		—		1		—
Acquisitions/Divestitures/Mergers	—		—		33		—		—		—
Exchange rate adjustments	—		—		252		(96)		—		—
Balance at December 31	$	18,569	$	18,241	$	3,148	$	2,957	$	908	$	1,016
Change in plan assets
Balance at January 1	$	14,378	$	15,485	$	3,276	$	3,733	$	—	$	—
Actual gain (loss) on plan assets	1,443		49		14		(263)		—		—
Employer contributions	176		172		41		30		120		130
Participant contributions	—		4		1		—		14		16
Benefits paid	(1,266)		(1,332)		(144)		(136)		(134)		(146)
Acquisitions/Divestitures/Mergers	—		—		72		—		—		—
Exchange rate adjustments	—		—		269		(89)		—		—
Balance at December 31	$	14,731	$	14,378	$	3,528	$	3,276	$	—	$	—
Funded status – surplus (deficit)	$	(3,838)	$	(3,863)	$	380	$	319	$	(908)	$	(1,016)

Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). Actuarial losses in 2025 and gains in 2024 related to projected benefit obligations were primarily the result of changes in discount rates.


Amounts Recorded in Consolidated Statements of Financial Position
	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
All other non-current assets	$	13	$	11	$	723	$	642	$	—	$	—
Current compensation and benefits	(178)		(172)		(23)		(18)		(118)		(135)
Non-current compensation and benefits	(3,673)		(3,702)		(319)		(305)		(790)		(881)
Net amount recorded	$	(3,838)	$	(3,863)	$	380	$	319	$	(908)	$	(1,016)

The projected benefit obligation balance at December 31 represents the actuarial present value of benefits based on employee service and compensation as of the measurement date and incorporates assumptions relating to future compensation levels and other demographic and financial assumptions. The accumulated benefit obligation represents the same actuarial obligations, excluding an assumption about future compensation levels.


Plan Obligations in Excess of Plan Assets	As of
	December 31, 2025		December 31, 2024
Accumulated benefit obligation	$	22,595	$	22,185
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	19,754	$	19,517
Fair value of plan assets	14,677		14,327
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	19,778	$	19,540
Fair value of plan assets	14,677		14,327


Pre-Tax Amounts Recorded in AOCI
	U.S. Plans				International Plans				OPEB Plans
	2025		2024		2025		2024		2025		2024
Net loss (gain)	$	(147)	$	(506)	$	909	$	849	$	(450)	$	(469)
Prior service cost (credit)	(40)		(51)		(15)		(16)		(367)		(447)
Total recorded in AOCI	$	(187)	$	(557)	$	893	$	833	$	(818)	$	(916)


Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Cost (income) of postretirement benefit plans	$	(218)	$	(250)	$	(224)	$	37	$	(20)	$	(22)	$	(86)	$	(87)	$	(86)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	—		—		(1,791)		—		—		542		—		—		(1,216)
Plan amendments	—		—		53		—		(1)		—		—		—		—
Net loss (gain) – current year	294		348		695		16		98		198		(45)		(48)		50
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	—		—		(108)		1		—		—		—		—		—

Amortization of net (loss) gain	65		68		121		(21)		(14)		(6)		64		61		64
Amortization of prior service (cost) credit	11		(8)		(4)		2		2		3		80		87		87
Total changes in other comprehensive loss (income)	$	370	$	408	$	(1,034)	$	(2)	$	86	$	737	$	98	$	100	$	(1,015)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$	152	$	158	$	(1,258)	$	35	$	66	$	715	$	12	$	13	$	(1,101)

With respect to the retirement benefit balances included on our Consolidated Statement of Financial Position as of December 31, 2025, we estimate that we will amortize $108 million of net actuarial gain and $93 million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2026.


Components of Expense (Income)
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Service cost – Operating	$	4	$	35	$	35	$	21	$	20	$	20	$	6	$	7	$	6
Interest cost	996		970		1,022		151		141		139		50		54		59
Expected return on plan assets	(1,145)		(1,196)		(1,242)		(152)		(193)		(184)		—		—		—
Amortization of net loss (gain)	(65)		(68)		(121)		21		14		6		(64)		(61)		(64)
Amortization of prior service cost (credit)	(11)		8		4		(2)		(2)		(3)		(80)		(87)		(87)
Curtailment loss (gain)	—		—		17		—		—		—		—		—		—
Settlement loss (gain)	—		—		61		(1)		—		—		—		—		—
Special termination cost	3		1		—		—		—		—		1		—		—
Non-operating	$	(222)	$	(285)	$	(259)	$	17	$	(40)	$	(42)	$	(92)	$	(94)	$	(92)
Net periodic expense (income)	$	(218)	$	(250)	$	(224)	$	37	$	(20)	$	(22)	$	(86)	$	(87)	$	(86)

In 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $17 million as non-operating benefit costs and an increase to our pension liability of $23 million in the year ended December 31, 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $305 million as of December 31, 2023.

Also in 2023, management approved and paid a one-time lump sum payment for certain terminated employees in two plans who were vested in their benefits. These lump sum settlements reduce our future cash requirements. As a result of the partial settlement of the pension liability, we recognized a non-cash pre-tax settlement charge in the year ended December 31, 2023. The settlement charge of $61 million represents a pro rata portion of unrecognized net loss recorded in AOCI and is recorded in Non-operating benefit (income) costs in the Consolidated Statement of Income.


Assumptions
	U.S. Plans						International Plans						OPEB Plans
	2025		2024		2023		2025		2024		2023		2025		2024		2023
Weighted-average benefit obligations assumptions
Discount rate	5.4	%	5.7	%	5.2	%	5.1	%	4.9	%	4.2	%	5.0	%	5.5	%	5.1	%
Compensation increases	3.5	%	3.5	%	3.7	%	2.7	%	2.8	%	3.1	%	3.6	%	3.6	%	3.6	%
Weighted-average benefit cost assumptions
Discount rate	5.7	%	5.2	%	5.5	%	4.9	%	4.2	%	4.6	%	5.5	%	5.1	%	5.4	%
Expected rate of return on plan assets	7.0	%	7.0	%	7.0	%	4.7	%	5.3	%	5.2	%	—	%	—	%	—	%

For the December 31, 2025 postretirement health care obligations remeasurement, the Company assumed a 8.4% initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 4.5% in 2038 and remain at that level thereafter.

Assumptions Used in Calculations

Accounting requirements necessitate the use of assumptions to reflect the uncertainties and the length of time over which the pension obligations will be paid. The actual amount of future benefit payments will depend upon when participants retire, the amount of their benefit at retirement, and how long they live. To reflect the obligation in today’s U.S. dollars, we discount the future payments using a rate that matches the time frame over which the payments are expected to be made. We also assume a long-term rate of return that will be earned on investments used to fund these payments.

GE HealthCare engages third-party actuaries to assist in the determination of the pension and other postretirement defined benefit plan assumptions. We evaluate these assumptions annually. We periodically evaluate other assumptions, such as retirement age, mortality, and turnover, and update them as necessary to reflect our actual experience and expectations for the future.

We determine the discount rate using the weighted average yields on high-quality fixed-income securities that have maturities consistent with the expected timing of benefit payments.

The expected return on plan assets is the estimated long-term rate of return that will be earned on the investments used to fund the pension obligations. To determine this rate, we consider the current and target composition of plan investments, our historical returns earned, and our expectations about the future.

The compensation assumption is used to estimate the annual rate at which compensation of active plan participants will grow. If the rate of growth assumed increases, the size of the pension obligations will increase, as will the amount recorded in AOCI in our Consolidated Statements of Financial Position and amortized to earnings in subsequent periods.


Expected Future Benefit Payments of Our Benefit Plans
	U.S. Plans		International Plans		OPEB Plans
2026	$	1,397	$	157	$	118
2027	1,403		158		116
2028	1,408		167		112
2029	1,409		172		110
2030	1,404		179		105
2031-2035	6,797		980		436

PENSION PLAN ASSETS.

The GE HealthCare Employee Benefits Investment Committee (the “Investment Committee”) and various country pension boards oversee and monitor the investment decisions related to the assets of our U.S. funded pension plans and other international pension assets, respectively. The Investment Committee retains independent investment managers and advisors and uses documented policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, the funded status of the plans, and other relevant factors and considerations.

The assets of our U.S. funded pension plans are invested in a portfolio that includes U.S. and international equity securities; U.S. government and corporate debt securities; asset-backed debt securities; private equity; real estate and other alternative investments; as well as cash and cash equivalents and derivatives contracts. This combination of assets and derivatives is utilized to implement the investment strategies as well as for hedging asset and liability risks. The Investment Committee sets target allocation percentages at an asset class level, including permitted ranges above or below the target allocation percentages.

In October 2025, the Trustee of the Company’s United Kingdom (“U.K.”) defined benefit pension plan entered into an agreement with a third-party insurance company to execute a full bulk annuity purchase (“buy-in”) for the plan. The agreement does not relieve the Company of the primary responsibility to fund the pension obligations. The buy-in was undertaken to reduce pension risk, including investment, longevity, interest rate and inflation risk, by closely aligning plan assets with the plan’s long-term benefit obligations. The annuity contract is reported within the fair value of plan assets and is intended to provide payments to the plan in amounts equivalent to the benefits owed to members in accordance with the plan rules.

The plan assets for international plans are managed and allocated by the country pension boards in each country.


Composition of Plan Assets			Basis of fair value measurement
	Balance as of December 31, 2025		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	4,832	$	2,292	$	108	$	—	$	2,432
Debt securities, cash, and cash equivalents	8,412		2,042		5,330		—		1,040
Real estate	793		—		—		299		494
Private equities and other investments	1,990		(75)		46		161		1,858
Annuity contract	2,104		—		—		2,104		—
Other	128		—		—		—		—
Fair value of plan assets	$	18,259	$	4,258	$	5,484	$	2,564	$	5,825

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


			Basis of fair value measurement
	Balance as of December 31, 2024		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	4,084	$	944	$	38	$	—	$	3,101
Debt securities, cash, and cash equivalents	10,593		1,307		8,000		—		1,285
Real estate	1,100		—		—		476		623
Private equities and other investments	1,877		7		53		216		1,602

Fair value of plan assets	$	17,654	$	2,258	$	8,091	$	692	$	6,612

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.

As of December 31, 2025 and 2024, the fair value of plan assets that used significant unobservable inputs (Level 3) was $2,564 million and $692 million, respectively. These assets primarily relate to an annuity contract, real estate, and private equity investments. The changes to the balances of Level 3 plan assets during 2025 were primarily driven by the buy-in transaction for the U.K. defined benefit pension plan described above. The changes to the balances of Level 3 plan assets during 2024 were not significant.


Weighted Average Asset Allocation of Pension Plans	2025 Target		2025 Actual

Global equity securities	22	%	26	%
Debt securities, cash, and cash equivalents	49	%	46	%
Real estate	5	%	4	%
Private equities and other instruments	12	%	12	%
Annuity contract	12	%	12	%

DEFINED CONTRIBUTION PLAN.

GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan were $154 million, $130 million, and $122 million for the years ended December 31, 2025, 2024, and 2023, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Cumulative Basis Adjustment for Fair value Hedges (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Long-term borrowings designated as fair value hedges	$ 2,722	$ 2,644
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term borrowings	Long-term borrowings
Cumulative basis adjustment included in the carrying amount	$ 27	$ (51)

SHARE-BASED COMPENSATION - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares shares
Stock options, shares
Outstanding at beginning of period (in shares) \| shares	4,246
Granted (in shares) \| shares	666
Exercised (in shares) \| shares	(606)
Forfeited (in shares) \| shares	(208)
Expired (in shares) \| shares	(339)
Outstanding at end of period (in shares) \| shares	3,760
Exercisable (in shares) \| shares	2,219
Expected to vest (in shares) \| shares	3,634
Stock options, weighted average exercise price
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 82
Granted (in dollars per share) \| $ / shares	85
Exercised (in dollars per share) \| $ / shares	61
Forfeited (in dollars per share) \| $ / shares	79
Expired (in dollars per share) \| $ / shares	126
Outstanding at end of period (in dollars per share) \| $ / shares	82
Exercisable (in dollars per share) \| $ / shares	83
Expected to vest (in dollars per share) \| $ / shares	$ 82
Stock options, weighted average contractual term (in years)
Stock options, weighted average remaining contractual term, outstanding	6 years
Stock options, weighted average remaining contractual term, exercisable	4 years 7 months 6 days
Stock options, weighted average remaining contractual term, expected to vest	5 years 10 months 24 days
Stock options, intrinsic value
Stock options, intrinsic value, outstanding \| $	$ 28
Stock options, intrinsic value, exercisable \| $	20
Stock options, intrinsic value, expected to vest \| $	$ 28

POSTRETIREMENT BENEFIT PLANS - Schedule of Expected Benefit Payments (Details) $ in Millions	Dec. 31, 2025 USD ($)
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
2026	$ 1,397
2027	1,403
2028	1,408
2029	1,409
2030	1,404
2031-2035	6,797
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
2026	157
2027	158
2028	167
2029	172
2030	179
2031-2035	980
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
2026	118
2027	116
2028	112
2029	110
2030	105
2031-2035	$ 436

SHAREHOLDERS' EQUITY - Schedule of Changes in AOCI (Details) - USD ($) $ in Millions		12 Months Ended
	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		$ 8,464	$ 7,145	$ 9,362
Other comprehensive income (loss) before reclassifications – net of taxes		101	(545)	(532)
Reclassifications from AOCI – net of taxes		(120)	(147)	(318)
Other comprehensive income (loss)		(19)	(691)	(850)
Equity, ending balance		10,390	8,464	7,145
Pension Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
AOCI, decrease due to remeasurement				(305)
Nihon Medi-Physics
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Foreign currency translation gain, reclassification adjustment	$ 63
Defined benefit pension plan loss, reclassification adjustment	$ 8
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,379)	(691)	(1,878)
Spin-Off related adjustments – net of taxes				2,000
Equity, ending balance		(1,388)	(1,379)	(691)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,973)	(1,706)	(1,845)
Equity, ending balance		(1,548)	(1,973)	(1,706)
Currency translation adjustments, including noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications – net of taxes		354	(271)	74
Reclassifications from AOCI – net of taxes		63	0	0
Other comprehensive income (loss)		418	(271)	74
Spin-Off related adjustments – net of taxes				28
Other comprehensive income (loss) before reclass, tax		60	(19)	22
Reclass from AOCI, tax		0	0	0
Spin-Off related adjustments, tax				0
Currency translation adjustments, attributable to noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss)		(7)	(4)	(37)
Pension and Other Postretirement Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		576	1,033	(42)
Equity, ending balance		158	576	1,033
Pension and Other Postretirement Plans, including to noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications – net of taxes		(259)	(306)	(601)
Reclassifications from AOCI – net of taxes		(163)	(150)	(296)
Other comprehensive income (loss)		(422)	(456)	(897)
Spin-Off related adjustments – net of taxes				1,972
Other comprehensive income (loss) before reclass, tax		74	93	186
Reclass from AOCI, tax		50	44	97
Spin-Off related adjustments, tax				(509)
Pension and Other Postretirement Plans, attributable to noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss)		(3)	0	0
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		18	(18)	9
Equity, ending balance		3	18	(18)
Cash flow hedges, including noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications – net of taxes		5	33	(5)
Reclassifications from AOCI – net of taxes		(21)	3	(22)
Other comprehensive income (loss)		(16)	36	(27)
Spin-Off related adjustments – net of taxes				0
Other comprehensive income (loss) before reclass, tax		5	(11)	1
Reclass from AOCI, tax		2	(1)	6
Spin-Off related adjustments, tax				0
Cash flow hedges, attributable to noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss)		0	0	0
Equity attributable to noncontrolling interests
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		18	12	5
Other comprehensive income (loss)		(10)	(4)	(37)
Equity, ending balance		$ 11	$ 18	$ 12

FINANCING RECEIVABLES

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

FINANCING RECEIVABLES

Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Consolidated Statements of Financial Position.



	As of
	December 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	21	$	23
Investment in finance leases, net of deferred income	76		69
Allowance for credit losses	(2)		(2)
Current financing receivables – net	$	95	$	90

Loans receivable, at amortized cost	$	44	$	35
Investment in finance leases, net of deferred income	149		152
Allowance for credit losses	(3)		(4)
Non-current financing receivables – net	$	190	$	183

As of December 31, 2025, 1%, 1%, and 1% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2024, 4%, 4%, and 3% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Audit Information [Abstract]
Auditor Location	Chicago, Illinois
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Finance lease income	$ 14	$ 14	$ 13

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Supplier Finance Program [Line Items]
Equity investments without readily determinable fair value	$ 217	$ 176
Foreign currency transactions gain (loss)	$ (149)	$ 16	$ 16
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Minimum \| Buildings, structures, and related equipment
Supplier Finance Program [Line Items]
Estimated useful lives	8 years
Minimum \| Machinery and equipment
Supplier Finance Program [Line Items]
Estimated useful lives	3 years
Minimum \| Leasehold improvements and manufacturing plants under construction
Supplier Finance Program [Line Items]
Estimated useful lives	1 year
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	180 days
Maximum \| Buildings, structures, and related equipment
Supplier Finance Program [Line Items]
Estimated useful lives	40 years
Maximum \| Machinery and equipment
Supplier Finance Program [Line Items]
Estimated useful lives	20 years
Maximum \| Leasehold improvements and manufacturing plants under construction
Supplier Finance Program [Line Items]
Estimated useful lives	16 years

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Revenues by Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 20,625	$ 19,672	$ 19,552
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Total revenues	9,245	8,855	8,944
Operating segments \| AVS
Segment Reporting Information [Line Items]
Total revenues	5,354	5,131	5,094
Operating segments \| AVS \| Procedural Guidance
Segment Reporting Information [Line Items]
Total revenues	2,752	2,711	2,666
Operating segments \| AVS \| Specialized Ultrasound
Segment Reporting Information [Line Items]
Total revenues	2,601	2,420	2,428
Operating segments \| PCS
Segment Reporting Information [Line Items]
Total revenues	3,086	3,125	3,142
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Total revenues	2,256	2,194	2,283
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Total revenues	831	931	859
Operating segments \| PDx
Segment Reporting Information [Line Items]
Total revenues	2,900	2,508	2,306
Other
Segment Reporting Information [Line Items]
Total revenues	$ 40	$ 52	$ 66

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Assets:
Money market funds	$ 4,512	$ 2,889
Recurring
Assets:
Investment securities	77	32
Derivatives	256	145
Liabilities:
Derivatives	207	155
Contingent consideration	30	34
Recurring \| Money market funds
Assets:
Money market funds	399	312
Level 1 \| Recurring
Assets:
Investment securities	47	32
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	0	0
Level 1 \| Recurring \| Money market funds
Assets:
Money market funds	0	0
Level 2 \| Recurring
Assets:
Investment securities	0	0
Derivatives	256	145
Liabilities:
Derivatives	207	155
Contingent consideration	0	0
Level 2 \| Recurring \| Money market funds
Assets:
Money market funds	399	312
Level 3 \| Recurring
Assets:
Investment securities	30	0
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	30	34
Level 3 \| Recurring \| Money market funds
Assets:
Money market funds	$ 0	$ 0

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	$ 4,727	$ 4,481
Accumulated Amortization	(3,672)	(3,477)
Finite-lived assets, net	1,055	1,004
Indefinite-lived assets	75	74
Gross Carrying Amount	4,802	4,555
Net	1,130	1,078
Customer-related
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	279	112
Accumulated Amortization	(43)	(24)
Finite-lived assets, net	236	88
Patents and technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	2,698	2,593
Accumulated Amortization	(2,128)	(1,987)
Finite-lived assets, net	570	606
Capitalized software
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	1,703	1,743
Accumulated Amortization	(1,470)	(1,437)
Finite-lived assets, net	233	306
Trademarks and other
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	47	33
Accumulated Amortization	(31)	(29)
Finite-lived assets, net	$ 15	$ 4

RESTRUCTURING ACTIVITIES (Tables)

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Activities

Net expenses for restructuring initiatives committed to by management through December 31, 2025 are included in the table below.


	For the years ended December 31
		2025		2024		2023
Employee termination costs		$	100	$	85	$	38
Facility and other exit costs		8		18		3
Asset write-downs		12		17		13
Total restructuring activities – net		$	120	$	120	$	54

The activity related to our restructuring liabilities follows.


	Employee termination costs		Facility and other exit costs		Total
Balance at December 31, 2023	$	43	$	25	$	68

Charges	85		8		93
Payments and other adjustments	(60)		(15)		(75)
Balance at December 31, 2024	67		18		86
Charges	95		7		102
Payments and other adjustments	(81)		(15)		(96)
Balance at December 31, 2025	$	82	$	11	$	92

REVENUE RECOGNITION

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

CONTRACT AND OTHER DEFERRED ASSETS.

Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.


	As of
	December 31, 2025		December 31, 2024
Contract assets	$	645	$	589
Other deferred assets	428		385
Contract and other deferred assets	1,073		974
Non-current contract assets(1)	91		103
Non-current other deferred assets(1)	120		105
Total contract and other deferred assets	$	1,285	$	1,183

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Consolidated Statements of Financial Position.

Capitalized costs to obtain a contract were $253 million and $217 million as of December 31, 2025 and 2024, respectively. Generally, these costs are recognized within two years of being capitalized. When recognized, the costs to obtain a contract are recorded within SG&A in the Consolidated Statements of Income.

CONTRACT LIABILITIES.

Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which these remaining performance obligations are expected to be satisfied with our customers.


	As of
	December 31, 2025		December 31, 2024
Contract liabilities	$	2,095	$	1,943
Non-current contract liabilities(1)	803		686
Total contract liabilities	$	2,899	$	2,629

(1)Non-current contract liabilities are recognized within All other non-current liabilities in the Consolidated Statements of Financial Position.

Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,588 million and $1,585 million for the years ended December 31, 2025 and 2024, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations (“RPO”) represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty. RPO also excludes estimated revenue from arrangements where we lease equipment manufactured by the Company to customers.


	As of
	December 31, 2025		December 31, 2024
Products	$	5,001	$	4,755
Services	10,728		9,737
Total RPO	$	15,729	$	14,491

We expect to recognize substantially all of the revenue for our product-related RPO within two years and services-related RPO within five years.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows - operating activities
Net income	$ 2,154	$ 2,050	$ 1,614
Less: Income (loss) from discontinued operations, net of taxes	0	0	(4)
Net income from continuing operations	2,154	2,050	1,618
Adjustments to reconcile Net income to Cash from (used for) operating activities – continuing operations:
Depreciation of property, plant, and equipment	287	268	248
Amortization of intangible assets	291	312	362
Gain on remeasurement of Nihon Medi-Physics equity method investment	(97)	0	0
Net periodic postretirement benefit plan (income) expense	(267)	(357)	(332)
Postretirement plan contributions	(338)	(332)	(357)
Share-based compensation	130	125	114
Provision for income taxes	614	531	743
Cash paid during the year for income taxes	(429)	(491)	(474)
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	(216)	(157)	(173)
Inventories	(142)	(81)	111
Contract and other deferred assets	(60)	3	10
Accounts payable	90	60	(100)
Contract liabilities	81	68	26
Current compensation and benefits	94	39	153
All other operating activities – net	(204)	(83)	151
Cash from (used for) operating activities – continuing operations	1,987	1,955	2,101
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(482)	(401)	(387)
Dispositions of property, plant, and equipment	0	0	1
Purchases of businesses, net of cash acquired	(378)	(313)	(147)
Purchases of investments	(118)	(40)	(48)
All other investing activities – net	(69)	(160)	23
Cash from (used for) investing activities – continuing operations	(1,047)	(914)	(558)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	1	0	(12)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,734	995	2,006
Repayments and other reductions (maturities longer than 90 days)	(1,767)	(1,418)	(855)
Dividends paid to stockholders	(64)	(55)	(41)
Repurchase of common stock	(200)	0	0
Redemption of noncontrolling interests	0	0	(211)
Net transfers (to) from GE	0	0	(1,317)
Proceeds from stock issued under employee benefit plans	37	33	34
Taxes paid related to net share settlement of equity awards	(42)	(93)	(33)
All other financing activities – net	(81)	(34)	(49)
Cash from (used for) financing activities – continuing operations	617	(573)	(478)
Cash from (used for) operating activities – discontinued operations	0	(4)	0
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	66	(77)	(10)
Increase (decrease) in cash, cash equivalents, and restricted cash	1,623	387	1,055
Cash, cash equivalents, and restricted cash at beginning of year	2,893	2,506	1,451
Cash, cash equivalents, and restricted cash at end of year	4,515	2,893	2,506
Supplemental disclosure of cash flows information
Cash paid during the year for interest	(522)	(550)	(570)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$ 164	$ 143	$ 140

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Goodwill [Roll Forward]
Beginning balance	$ 13,136	$ 12,936
Reallocation		0
Acquisitions	301	236
Foreign currency exchange and other	51	(36)
Ending balance	13,489	13,136
Imaging
Goodwill [Roll Forward]
Beginning balance	3,581	4,431
Reallocation		(1,031)
Acquisitions	81	194
Foreign currency exchange and other	20	(13)
Ending balance	3,682	3,581
AVS
Goodwill [Roll Forward]
Beginning balance	4,987	3,933
Reallocation		1,031
Acquisitions	0	42
Foreign currency exchange and other	33	(19)
Ending balance	5,020	4,987
PCS
Goodwill [Roll Forward]
Beginning balance	2,035	2,038
Reallocation		0
Acquisitions	0	0
Foreign currency exchange and other	6	(3)
Ending balance	2,041	2,035
PDx
Goodwill [Roll Forward]
Beginning balance	2,533	2,534
Reallocation		0
Acquisitions	220	0
Foreign currency exchange and other	(8)	(1)
Ending balance	$ 2,745	$ 2,533

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

SHAREHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

SHAREHOLDERS' EQUITY

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET.

Changes in AOCI by component were as follows.


	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclassifications – net of taxes(2) of $22, $186, and $1	74		(601)		(5)		(532)
Reclassifications from AOCI – net of taxes(3) of $—, $97, and $6	—		(296)		(22)		(318)
Other comprehensive income (loss)	74		(897)		(27)		(850)
Spin-Off related adjustments – net of taxes(4) of $— $(509), and $—	28		1,972		—		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(37)		—		—		(37)
December 31, 2023	(1,706)		1,033		(18)		(691)
Other comprehensive income (loss) before reclassifications – net of taxes of $(19), $93, and $(11)	(271)		(306)		33		(545)
Reclassifications from AOCI – net of taxes(3) of $—, $44, and $(1)	—		(150)		3		(147)
Other comprehensive income (loss)	(271)		(456)		36		(691)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(4)		—		—		(4)
December 31, 2024	(1,973)		576		18		(1,379)
Other comprehensive income (loss) before reclassifications – net of taxes of $60, $74, and $5	354		(259)		5		101
Reclassifications from AOCI – net of taxes(3)(5) of $—, $50, and $2	63		(163)		(21)		(120)
Other comprehensive income (loss)	418		(422)		(16)		(19)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(7)		(3)		—		(10)
December 31, 2025	$	(1,548)	$	158	$	3	$	(1,388)

SHARE REPURCHASES.

On April 30, 2025, our Board of Directors authorized a share repurchase program (the “repurchase program”) for up to $1,000 million of our common stock. The repurchase program does not have an expiration date, does not obligate the Company to acquire any particular amount of common stock, and may be suspended or terminated at any time at the Company's discretion. During the year ended December 31, 2025, we repurchased 2.8 million shares under the repurchase program for total consideration of approximately $200 million.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Derivative Assets at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	December 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,508	$	52	$	23	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,508		52		23		1,210		43		11
Cross-currency swaps(1)	4,115		51		135		1,995		15		46
Foreign currency forward and options contracts	2,581		50		37		1,731		30		18
Derivatives accounted for as net investment hedges	6,697		101		172		3,726		45		64
Interest rate swaps(1)	2,700		28		—		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		28		—		2,700		—		51
Foreign currency forward contracts	4,761		20		7		3,925		11		29
Other derivatives(1)(2)	320		56		5		370		47		—



Derivatives not designated as hedging instruments	5,081		76		12		4,294		57		29
Total derivatives	$	15,986	$	256	$	207	$	11,930	$	145	$	155

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

Schedule of Derivative Liabilities at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	December 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,508	$	52	$	23	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,508		52		23		1,210		43		11
Cross-currency swaps(1)	4,115		51		135		1,995		15		46
Foreign currency forward and options contracts	2,581		50		37		1,731		30		18
Derivatives accounted for as net investment hedges	6,697		101		172		3,726		45		64
Interest rate swaps(1)	2,700		28		—		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		28		—		2,700		—		51
Foreign currency forward contracts	4,761		20		7		3,925		11		29
Other derivatives(1)(2)	320		56		5		370		47		—



Derivatives not designated as hedging instruments	5,081		76		12		4,294		57		29
Total derivatives	$	15,986	$	256	$	207	$	11,930	$	145	$	155

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

Schedule of Effect of Derivatives Instruments on Statement of Financial Position and Statement of Income

The following table presents amounts recorded in Long-term borrowings in the Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	December 31, 2025				December 31, 2024
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated as fair value hedges	$	2,722	$	27	$	2,644	$	(51)

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity
	For the year ended December 31, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	18	$	5	$	—	$	—	$	—
Effects of cash flow hedges	18		5		—		—		—
Cross-currency swaps	—		—		—		38		—
Foreign currency forward and options contracts	—		—		—		21		—
Effects of net investment hedges(1)	—		—		—		59		—

Interest rate swaps(2)	—		—		—		63		—
Debt basis adjustment on Long-term borrowings	—		—		—		(78)		—

Effects of fair value hedges	—		—		—		(15)		—
Foreign currency forward contracts	28		7		—		—		(1)



Other derivatives(3)	—		—		5		—		9
Effects of derivatives not designated as hedging instruments	28		7		5		—		7























	For the year ended December 31, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(4)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(4)		(1)		—		—		—
Cross-currency swaps	—		—		—		31		—
Foreign currency forward and option contracts	—		—		—		11		—
Effects of net investment hedges(1)	—		—		—		42		—

Interest rate swaps(2)	—		—		—		(103)		—
Debt basis adjustment on Long-term borrowings	—		—		—		76		—

Effects of fair value hedges	—		—		—		(27)		—
Foreign currency forward contracts	(37)		(9)		—		—		1
Other derivatives(3)	—		—		8		—		37
Effects of derivatives not designated as hedging instruments	(37)		(9)		8		—		38


	For the year ended December 31, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	23	$	6	$	—	$	—	$	—
Effects of cash flow hedges	23		6		—		—		—
Cross-currency swaps	—		—		—		34		—
Foreign currency forward and option contracts	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		37		—

Interest rate swaps(2)	—		—		—		24		—
Debt basis adjustment on Long-term borrowings	—		—		—		(25)		—

Effects of fair value hedges	—		—		—		(1)		—
Foreign currency forward contracts	3		2		—		—		5



Other derivatives(3)	—		—		10		—		47
Effects of derivatives not designated as hedging instruments	3		2		10		—		52

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the years ended December 31, 2025, 2024, and 2023.

(2) Amount includes interest expense on interest rate derivatives of $(15) million, $(27) million, and $(1) million for the years ended December 31, 2025, 2024, and 2023 respectively.

(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Consolidated Statements of Income.

Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the years ended December 31
		2025		2024		2023
Cash flow hedges		$	—	$	44	$	(6)
Net investment hedges(1)		(263)		80		(97)

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of December 31, 2025								As of December 31, 2024
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	399	$	—	$	399	$	—	$	312	$	—	$	312
Investment securities	47		—		30		77		32		—		—		32
Derivatives	—		256		—		256		—		145		—		145
Liabilities:
Derivatives	—		207		—		207		—		155		—		155
Contingent consideration	—		—		30		30		—		—		34		34

SHARE-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Summary of Weighted Average Grant Date Fair Value and Share-Based Compensation Activity


Weighted Average Grant Date Fair Value	For the years ended December 31
(In dollars)	2025		2024		2023
Stock options	$	30	$	32	$	25
RSUs	83		89		73
PSUs	85		96		85


Stock Option Activity
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 1, 2025	4,246	$	82
Granted	666	85
Exercised/Vested	(606)	61
Forfeited	(208)	79
Expired	(339)	126
Outstanding as of December 31, 2025	3,760	$	82	6.0	$	28
Exercisable as of December 31, 2025	2,219	$	83	4.6	$	20
Expected to vest	3,634	$	82	5.9	$	28

Schedule of Stock Options Valuation Assumptions


Key Assumptions in the Black-Scholes Valuation for Stock Options	For the years ended December 31
	2025		2024		2023
Risk-free rate	4.0	%	4.1	%	3.6	%
Dividend yield	0.16	%	0.13	%	0.01	%
Expected volatility	26.7	%	26.2	%	26.2	%
Expected term (in years)	6.2		6.2		6.2

Schedule of RSU and PSU Activity


RSU and PSU Activity
	RSUs						PSUs
	Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)
Outstanding as of January 1, 2025	2,860	$	78				778	$	91
Granted	1,478	83					492	85
Exercised/Vested	(1,484)	75					(72)	70
Forfeited	(313)	81					(122)	89
Expired	—	—					—	—
Outstanding as of December 31, 2025	2,542	$	82	2.0	$	208	1,076	$	88	2.0	$	88

Summary of Share-Based Compensation Expense and Other Share-Based Compensation Data


Share-based Compensation Expense	For the years ended December 31
	2025		2024		2023



Share-based compensation expense (pre-tax)	$	130	$	125	$	114
Income tax benefits	(24)		(23)		(23)
Share-based compensation expense (after-tax)	$	106	$	102	$	91


Other Share-based Compensation Data	For the years ended December 31
	2025		2024		2023

Cash received from stock options exercised	$	37	$	33	$	34
Intrinsic value of stock options exercised and RSUs/PSUs vested	141		251		106

LEASES - Net Investment in Finance Leases (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
Minimum lease payments receivable	$ 243	$ 242
Less: deferred income	(30)	(31)
Discounted lease receivable	213	211
Estimated unguaranteed residual value of leased assets, net of deferred income	12	10
Investment in finance leases, net of deferred income	$ 225	$ 221

INCOME TAXES - Schedule of Income from Continuing Operations Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
U.S. income	$ 1,028	$ 593	$ 816
Non-U.S. income	1,740	1,988	1,545
Income from continuing operations before income taxes	$ 2,768	$ 2,581	$ 2,361

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Consolidated Statements of Changes in Equity - USD ($) $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2022		0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0	$ 0	$ 0	$ 0	$ 11,235	$ (1,878)	$ 5
Treasury stock, beginning balance (in shares) at Dec. 31, 2022			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from GE, including Spin-Off-related adjustments	(2,849)					(4,851)	2,000	2
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5		6,379		(6,384)
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		1,000,000
Net income attributable to GE HealthCare	1,568				1,568
Dividends declared	(55)				(55)
Other comprehensive income (loss) attributable to GE HealthCare	(813)						(813)
Changes in equity attributable to noncontrolling interests	5							5
Share-based compensation	114			114
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	(187)				(187)
Equity, ending balance (in shares) at Dec. 31, 2023		455,000,000
Equity, ending balance at Dec. 31, 2023	7,145	$ 5	$ 0	6,493	1,326	0	(691)	12
Treasury stock, ending balance (in shares) at Dec. 31, 2023			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		2,000,000
Issuance of shares under equity awards, net of shares withheld for taxes and other	(60)		$ (25)	(35)
Net income attributable to GE HealthCare	1,993				1,993
Dividends declared	(58)				(58)
Other comprehensive income (loss) attributable to GE HealthCare	(688)						(688)
Changes in equity attributable to noncontrolling interests	7							7
Share-based compensation	$ 125			125
Equity, ending balance (in shares) at Dec. 31, 2024	457,246,971	457,000,000
Equity, ending balance at Dec. 31, 2024	$ 8,464	$ 5	$ (25)	6,583	3,262	0	(1,379)	18
Treasury stock, ending balance (in shares) at Dec. 31, 2024	291,053		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		2,000,000
Issuance of shares under equity awards, net of shares withheld for taxes and other	$ (5)			(5)
Repurchase of common stock (in shares)	2,800,000		3,000,000
Repurchase of common stock	$ (200)		$ (200)
Net income attributable to GE HealthCare	2,084				2,084
Dividends declared	(64)				(64)
Other comprehensive income (loss) attributable to GE HealthCare	(9)						(9)
Changes in equity attributable to noncontrolling interests	(8)							(8)
Share-based compensation	$ 129			129
Equity, ending balance (in shares) at Dec. 31, 2025	458,844,209	459,000,000
Equity, ending balance at Dec. 31, 2025	$ 10,390	$ 5	$ (225)	$ 6,707	$ 5,281	$ 0	$ (1,388)	$ 11
Treasury stock, ending balance (in shares) at Dec. 31, 2025	3,107,626		3,000,000

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Total assets	$ 4,491	$ 4,474
Total liabilities	(193)	(56)
Net deferred income tax asset (liability)	4,298	4,418
Deferred tax assets:
Employee benefits	1,247	1,340
Reserves and accruals	481	413
Operating loss carryforwards	463	447
Lease liabilities	48	57
Tax credit carryforwards	119	80
U.S. interest restriction carryforwards	135	156
Goodwill and other intangible assets	1,184	1,355
Property, plant, and equipment	181	223
Capitalized R&D	834	689
Other deferred tax assets	100	55
Total deferred income tax asset	4,793	4,817
Valuation allowances	(251)	(231)	$ (540)	$ (272)
Total deferred income tax asset after valuation allowance	4,542	4,586
Deferred tax liabilities:
ROU assets	(47)	(42)
Other deferred tax liabilities	(198)	(126)
Total deferred income tax liability	$ (244)	$ (168)

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Sales allowances and related liabilities	$ 256	$ 242
Income and indirect tax liabilities including uncertain tax positions	324	279
Product warranties	169	168
Accrued logistics and utilities	197	163
Operating lease liabilities	134	115
Derivative instruments	47	90
Interest payable on borrowings	100	92
Environmental and asset retirement obligations	11	17
Other	348	386
All other current liabilities	$ 1,587	$ 1,552

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2025	Mar. 31, 2025	Dec. 31, 2024
Business Combination [Line Items]
Environmental remediation liabilities	$ 15		$ 16
Asset retirement obligations	$ 409		$ 292
Nihon Medi-Physics
Business Combination [Line Items]
Asset retirement obligations and decommissioning liabilities assumed		$ 124

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-47

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Long-Lived Assets by Geographic Areas (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	$ 3,092	$ 2,550
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	962	908
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	439	392
Norway
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	368	296
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	296	62
All other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	$ 1,027	$ 893

INCOME TAXES - Schedule of Income Taxes Paid (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Paid, by Individual Jurisdiction [Line Items]
U.S. Federal	$ 38
U.S. State	17
Cash paid during the year for income taxes	429	$ 491	$ 474
Norway
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	69
China
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	66
India
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	41
Japan
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	23
United Kingdom
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	23
Other
Income Tax Paid, by Individual Jurisdiction [Line Items]
Foreign	$ 151

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Segment EBIT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
EBIT	$ 3,155	$ 3,211	$ 2,956
Restructuring costs	(120)	(120)	(54)
Acquisition and disposition-related benefits (charges)	(39)	(3)	15
Gain (loss) on business and asset dispositions	5	0	0
Spin-Off and separation costs	(38)	(251)	(270)
Amortization of acquisition-related intangible assets	(156)	(137)	(127)
Investment revaluation gain (loss)	112	(22)	1
Interest and other financial charges – net	(440)	(504)	(542)
Non-operating benefit income (costs)	288	406	382
Income from continuing operations before income taxes	2,768	2,581	2,361
Operating segments \| Imaging
Segment Reporting Information [Line Items]
EBIT	891	962	821
Operating segments \| AVS
Segment Reporting Information [Line Items]
EBIT	1,175	1,118	1,124
Operating segments \| PCS
Segment Reporting Information [Line Items]
EBIT	209	347	383
Operating segments \| PDx
Segment Reporting Information [Line Items]
EBIT	872	783	617
Other
Segment Reporting Information [Line Items]
EBIT	$ 7	$ 2	$ 11

INCOME TAXES

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

INCOME TAXES

The Company is subject to income taxes in the U.S. (both federal and state) and in numerous foreign jurisdictions. Changes in the tax laws or regulations in these jurisdictions, or in positions by the relevant authorities regarding their application, administration, or interpretation, may affect our tax liability, return on investments, and business operations.

The Tax Cuts and Jobs Act imposes tax on the Company for net controlled foreign corporation (“CFC”) tested income earned by certain non-U.S. subsidiaries (previously referred to as global intangible low-taxed income or “GILTI”). We have elected to account for net CFC tested income as a period cost. On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into U.S. law, which includes significant changes to the federal income tax system. The Company has recorded the OBBBA tax impacts in its provision for income taxes for the year ended December 31, 2025, none of which are material to our financial statements.


Income From Continuing Operations Before Income Taxes
	For the years ended December 31
	2025		2024		2023
U.S. income	$	1,028	$	593	$	816
Non-U.S. income	1,740		1,988		1,545
Total	$	2,768	$	2,581	$	2,361


Provision for Income Taxes	For the years ended December 31
	2025		2024		2023
Current
U.S. Federal	$	4	$	62	$	171
Non-U.S.	317		412		345
U.S. State	8		8		42
Deferred
U.S. Federal	110		3		—
Non-U.S.	131		(12)		103
U.S. State	44		58		82
Total	$	614	$	531	$	743

The effective income tax rate for the year ended December 31, 2025 differs from the statutory federal income tax rate as follows.


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the year ended December 31, 2025
	Amount		Percent
Income from continuing operations before income taxes	$	2,768
Tax expected at 21%	581		21.0	%
State and local income taxes, net of federal income tax effect(1)	41		1.5	%
Foreign tax effects
China	30		1.1	%
Other foreign jurisdictions	54		2.0	%
Effect of cross-border tax laws

Foreign-derived deduction eligible income	(49)		(1.8)	%
Net CFC tested income	45		1.6	%
Other	5		0.2	%
Tax credits
R&D tax credits	(28)		(1.0)	%
Foreign tax credits	(81)		(2.9)	%
Changes in valuation allowances	9		0.3	%
Nontaxable or nondeductible items(2)	22		0.8	%
Changes in unrecognized tax benefits	(24)		(0.9)	%
Other adjustments	8		0.3	%
Effective tax rate	$	614	22.2	%

(2) The tax impact of any share-based compensation items are included in this category.

For the years ended December 31, 2024 and 2023, the effective income tax rate differs from the statutory federal income tax rate as follows.


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the years ended December 31
	2024		2023
Income from continuing operations before income taxes	$	2,581	$	2,361
Tax expected at 21%	542		496
Foreign operations	38		63
Withholding taxes	34		28
U.S. tax on foreign operations	(43)		(35)
Uncertain tax positions	170		11
R&D benefits	(51)		(33)
State and local income taxes, net of federal income tax effect	49		24
Valuation allowance	(281)		19
Spin-Off and separation costs	72		184
Other	—		(14)
Provision for income taxes	$	531	$	743
Effective income tax rate	20.6%		31.5%

For the years ended December 31, 2025 and 2024, included in State and local income taxes, net of federal income tax effect is $10 million and $35 million of expense related to revaluation of deferred tax assets as a result of changes in future apportionment and state tax rates based on the 2024 and 2023 as-filed tax returns. For the year ended December 31, 2023, the Spin-Off and separation costs line includes $59 million of expense related to revaluation of state deferred tax assets associated with the Spin-Off.

UNRECOGNIZED TAX BENEFITS.

The Company is subject to periodic tax audits by tax authorities in the U.S. (both federal and state) and the numerous countries in which we operate. While the Company currently is being audited, or remains subject to audit, in a number of jurisdictions for tax years 2004-2024, including China, France, Germany, India, Japan, Norway, the U.K., and the United States, we believe that there are no jurisdictions in which the ultimate outcome of unresolved issues or claims is likely to be material to the results of operations, financial position, or cash flows. We believe that we have made adequate provisions for all unrecognized tax benefits.

The balance of unrecognized tax benefits, the amount of related interest and penalties, and the portion that, if recognized, would reduce tax expense and effective tax rate are as follows.


	2025		2024		2023
Balance at beginning of period	$	551	$	409	$	465
Additions for tax positions of the current year	5		4		—
Additions for tax positions of prior years	43		181		156
Reductions for tax positions of prior years	(108)		(33)		(203)
Settlements with tax authorities	(7)		(4)		(6)
Expiration of the statute of limitations	(21)		(6)		(3)
Balance at end of period	$	463	$	551	$	409

For the year ended December 31, 2025, the Additions for tax positions of prior years line includes $37 million of currency translation adjustments (“CTA”), and the Reductions for tax positions of prior years line includes $102 million related to a tax attribute that expired in 2025.

For the year ended December 31, 2024, the Additions for tax positions of prior years line includes $172 million of reserves established due to ongoing audits, of which $142 million was established against a net operating loss deferred tax asset. Also for the year ended December 31, 2024, the Reductions for tax positions of prior years includes CTA of $14 million and a reversal of $19 million related to various tax audits that were closed during the year.

For the year ended December 31, 2023, the Additions for tax positions of prior years line in the table above includes $134 million related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above.


Unrecognized Tax Benefits	For the years ended December 31
	2025		2024		2023
Unrecognized tax benefits	$	463	$	551	$	409
Accrued interest on unrecognized tax benefits	65		81		72

Portion that, if recognized, would reduce tax expense and effective tax rate	158		182		157

Interest and penalties on unrecognized tax benefits recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income were not material during the years ended December 31, 2025, 2024, and 2023.

DEFERRED INCOME TAXES.

We regularly evaluate the recoverability of our deferred tax assets and establish a valuation allowance, if necessary, to reduce the deferred tax assets to an amount that is more likely than not to be realized (a likelihood of more than 50%). Significant judgment is required in determining whether a valuation allowance is necessary and the amount of such valuation allowance. In assessing the recoverability of our deferred tax assets at December 31, 2025, we considered all available evidence, including the nature of financial statement losses, reversing taxable temporary differences, estimated future operating profits, and tax planning actions and strategies.


	As of
	December 31, 2025		December 31, 2024
Total assets	$	4,491	$	4,474
Total liabilities	(193)		(56)
Net deferred income tax asset (liability)	$	4,298	$	4,418


Components of the Net Deferred Income Tax Asset (Liability)	As of
	December 31, 2025		December 31, 2024
Deferred tax assets:
Employee benefits	$	1,247	$	1,340
Reserves and accruals	481		413
Operating loss carryforwards	463		447
Lease liabilities	48		57
Tax credit carryforwards	119		80
U.S. interest restriction carryforwards	135		156
Goodwill and other intangible assets	1,184		1,355
Property, plant, and equipment	181		223
Capitalized R&D	834		689
Other deferred tax assets	100		55
Total deferred income tax asset	4,793		4,817
Valuation allowances	(251)		(231)
Total deferred income tax asset after valuation allowance	4,542		4,586
Deferred tax liabilities:
ROU assets	(47)		(42)
Other deferred tax liabilities	(198)		(126)
Total deferred income tax liability	(244)		(168)
Net deferred income tax asset (liability)	$	4,298	$	4,418

Valuation allowances primarily relate to non-U.S. deferred taxes where there were historical losses and U.S. federal and state credit carryforwards. Activity in the valuation allowance consists of the following:


Valuation Allowances	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	231	$	540	$	272
Provision for income taxes	4		(279)		(12)
Foreign currency exchange and other	16		(31)		280
Balance at end of period	$	251	$	231	$	540

For the year ended December 31, 2024, our valuation allowance decreased by $310 million, which included a release of a valuation allowance in France of $295 million reflected in the Provision for income taxes line. Based on our analysis of all positive and negative evidence during the year ended December 31, 2024, we concluded that it is more likely than not that France deferred tax assets will be realizable based on our profitability in France as a stand-alone company post Spin-Off and our expectation for the continued generation of prospective positive income in the jurisdiction. In making these judgments, we considered various business and structural factors as a stand-alone company, which support our conclusion of the realization of the deferred tax assets. As a result of the Spin-Off, there was an increase in the valuation allowance of $269 million in 2023, which is included in the Foreign currency exchange and other line of the table above.

NET OPERATING LOSSES.

As of December 31, 2025, the Company had net operating loss carryforwards of $5,987 million primarily related to Ireland, France, Brazil, Germany, and the Netherlands, which can be carried forward indefinitely. The gross net operating loss carryforwards resulted in a deferred tax asset of $1,170 million as of December 31, 2025. This amount excludes accruals of $300 million for unrecognized tax benefits the Company has recorded related to the underlying tax positions which generated the net operating losses and expected impacts to U.S. foreign tax credits of $407 million.

UNDISTRIBUTED EARNINGS.

Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $8 billion to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable.

CASH TAXES PAID.

The amounts of cash paid for income taxes by GE HealthCare are as follows.


	For the year ended December 31, 2025
U.S. Federal	$	38
U.S. State	17
Foreign
Norway	69
China	66
India	41
Japan	23
United Kingdom	23
Other	151
Cash paid during the year for income taxes	$	429

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Significant Expenses by Segment (Details) - Operating segments - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Imaging
Segment Reporting Information [Line Items]
Cost of sales	$ 6,099	$ 5,623	$ 5,901
Other segment items	2,255	2,270	2,222
Total expenses	8,353	7,893	8,123
AVS
Segment Reporting Information [Line Items]
Cost of sales	2,629	2,485	2,485
Other segment items	1,550	1,528	1,485
Total expenses	4,178	4,014	3,970
PCS
Segment Reporting Information [Line Items]
Cost of sales	2,028	1,930	1,890
Other segment items	849	848	869
Total expenses	2,877	2,778	2,759
PDx
Segment Reporting Information [Line Items]
Cost of sales	1,450	1,236	1,192
Other segment items	579	490	497
Total expenses	$ 2,028	$ 1,725	$ 1,689

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

+ Details

LEASES (Tables)

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Schedule of Operating Lease Assets and Liabilities


Operating Lease Assets and Liabilities	As of
	December 31, 2025		December 31, 2024
Operating lease ROU assets	$	410	$	364
Current operating lease liabilities	134		115
Non-current operating lease liabilities	284		270
Total operating lease liabilities	$	419	$	385

Schedule of Lease Expense and Supplemental Information


Operating Lease Expense	For the years ended December 31
	2025		2024		2023
Long-term (fixed)	$	136	$	134	$	121
Long-term (variable)	101		120		106
Short-term	12		4		2
Total operating lease expense	$	249	$	258	$	229


Supplemental Information Related to Operating Leases	For the years ended December 31
	2025			2024			2023
Cash paid for amounts included in the measurement of operating lease liabilities	$	151		$	138		$	130
Right-of-use assets obtained in exchange for new lease liabilities	162			147			154
Weighted-average remaining lease term (in years)	4.6			4.4			4.7
Weighted-average discount rate	4.4		%	4.5		%	4.4		%

Schedule of Maturity of Lease Liabilities


Maturity of Lease Liabilities
	2026		2027		2028		2029		2030		Thereafter		Total
Undiscounted lease payments	$	153	$	116	$	73	$	42	$	20	$	56	$	460
Less: imputed interest													41
Total lease liability as of December 31, 2025													$	419

Schedule of Net Investment in Finance Leases


Net Investment in Finance Leases	As of
	December 31, 2025		December 31, 2024
Minimum lease payments receivable	$	243	$	242
Less: deferred income	(30)		(31)
Discounted lease receivable	213		211
Estimated unguaranteed residual value of leased assets, net of deferred income	12		10
Investment in finance leases, net of deferred income	$	225	$	221

Schedule of Contractual Maturities


Contractual Maturities

Due In	2026		2027		2028		2029		2030		Thereafter		Total
Minimum lease payments receivable	$	86	$	56	$	39	$	26	$	16	$	19	$	243

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Current customer receivables	$ 3,719	$ 3,382
Non-income based tax receivables	159	155
Other sundry receivables	180	133
Current sundry receivables	339	287
Allowance for credit losses	(103)	(103)	$ (98)	$ (91)
Total current receivables – net	3,955	3,566
Chargebacks	$ 148	$ 153

LEASES - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
Operating lease ROU assets	$ 410	$ 364
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant, and equipment – net	Property, plant, and equipment – net
Current operating lease liabilities	$ 134	$ 115
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	All other current liabilities	All other current liabilities
Non-current operating lease liabilities	$ 284	$ 270
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Total operating lease liabilities	$ 419	$ 385

RECEIVABLES (Tables)

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

Schedule of Receivables


Current Receivables	As of
	December 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,719	$	3,382
Non-income based tax receivables	159		155
Other sundry receivables	180		133
Current sundry receivables	339		287
Allowance for credit losses	(103)		(103)
Total current receivables – net	$	3,955	$	3,566


Long-Term Receivables	As of
	December 31, 2025		December 31, 2024
Long-term customer receivables	$	73	$	59
Non-income based tax receivables	24		20
Other sundry receivables	100		68
Long-term sundry receivables	124		88

Allowance for credit losses	(7)		(5)
Total long-term receivables – net	$	190	$	142



	As of
	December 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	21	$	23
Investment in finance leases, net of deferred income	76		69
Allowance for credit losses	(2)		(2)
Current financing receivables – net	$	95	$	90

Loans receivable, at amortized cost	$	44	$	35
Investment in finance leases, net of deferred income	149		152
Allowance for credit losses	(3)		(4)
Non-current financing receivables – net	$	190	$	183

Schedule of Allowance for Credit Losses Related to Current Receivables

Activity in the allowance for credit losses related to current receivables consisted of the following:


	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	103	$	98	$	91
Additions charged to costs and expenses	10		20		16
Write-offs	(15)		(12)		(11)
Foreign currency exchange and other	4		(2)		2
Balance at end of period	$	103	$	103	$	98

INCOME TAXES - Reconciliation of Federal Statutory Income Tax Rate to Actual Income Tax Rate - 2024 and 2023 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income from continuing operations before income taxes	$ 2,768	$ 2,581	$ 2,361
Tax expected at 21%	581	542	496
Foreign tax effects		38	63
Withholding taxes		34	28
U.S. tax on foreign operations		(43)	(35)
Changes in unrecognized tax benefits	(24)	170	11
R&D tax credits	(28)	(51)	(33)
State and local income taxes, net of federal income tax effect	41	49	24
Changes in valuation allowances	9	(281)	19
Spin-Off and separation costs		72	184
Other adjustments	8	0	(14)
Total	$ 614	$ 531	$ 743
Effective income tax rate	22.20%	20.60%	31.50%

LEASES - Supplemental Information Related to Operating Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 151	$ 138	$ 130
Right-of-use assets obtained in exchange for new lease liabilities	$ 162	$ 147	$ 154
Weighted-average remaining lease term (in years)	4 years 7 months 6 days	4 years 4 months 24 days	4 years 8 months 12 days
Weighted-average discount rate	4.40%	4.50%	4.40%

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Business Acquisitions (Details) - USD ($) $ in Millions		12 Months Ended
	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Purchase consideration
Cash consideration, net of cash acquired		$ 378	$ 313	$ 147
Preliminary allocation
Goodwill		$ 13,489	$ 13,136	$ 12,936
Nihon Medi-Physics
Purchase consideration
Cash consideration, net of cash acquired	$ 271
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	577
Preliminary allocation
Receivables	53
Inventories	9
All other current assets	35
Property, plant, and equipment	240
Goodwill	220
Other intangible assets	235
All other non-current assets	39
Deferred income taxes	(81)
All other non-current liabilities	(145)
Other	(28)
Total net assets post acquisition	577
Indemnification assets	$ 35

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 188	$ 165	$ 230
Net income attributable to redeemable noncontrolling interests	66	50	41
Redemption value adjustments	0	0	183
Distributions to redeemable noncontrolling interests and other	(45)	(28)	(289)
Balance at end of period	209	188	165
Redemption of noncontrolling interests	$ 0	$ 0	$ 211

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,731	$ 5,267
Accumulated depreciation	(3,049)	(3,080)
Right-of-use operating lease assets, net of amortization	410	364
Property, plant, and equipment – net	3,092	2,550
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	144	66
Buildings, structures, and related equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,140	1,943
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,872	2,705
Leasehold improvements and manufacturing plants under construction
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 574	$ 553

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Cash flow hedges	$ 0	$ 44	$ (6)
Net investment hedges	$ (263)	$ 80	$ (97)

REVENUE RECOGNITION - Summary of Contract Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Contract liabilities	$ 2,095	$ 1,943
Non-current contract liabilities	803	686
Total contract liabilities	$ 2,899	$ 2,629

REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Summary of Contract and Other Deferred Assets and Contract Liabilities


	As of
	December 31, 2025		December 31, 2024
Contract assets	$	645	$	589
Other deferred assets	428		385
Contract and other deferred assets	1,073		974
Non-current contract assets(1)	91		103
Non-current other deferred assets(1)	120		105
Total contract and other deferred assets	$	1,285	$	1,183

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Consolidated Statements of Financial Position.


	As of
	December 31, 2025		December 31, 2024
Contract liabilities	$	2,095	$	1,943
Non-current contract liabilities(1)	803		686
Total contract liabilities	$	2,899	$	2,629

(1)Non-current contract liabilities are recognized within All other non-current liabilities in the Consolidated Statements of Financial Position.

Schedule of Remaining Performance Obligations


	As of
	December 31, 2025		December 31, 2024
Products	$	5,001	$	4,755
Services	10,728		9,737
Total RPO	$	15,729	$	14,491

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranties

An analysis of changes in the liability for product warranties follows.



	For the years ended December 31
	2025		2024		2023
Balance at beginning of period	$	168	$	192	$	193
Current-year provisions	208		202		216
Expenditures	(214)		(220)		(218)
Foreign currency exchange and other	6		(6)		1
Balance at end of period	$	169	$	168	$	192

Schedule of Unrecognized Contractual Obligations

As of December 31, 2025, these future purchase obligations are as follows.


	2026		2027		2028		2029		2030		Thereafter		Total
Other Unrecognized Contractual Obligations	$	468	$	188	$	171	$	155	$	77	$	89	$	1,149